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Colorectal cancer is the 2nd most common cause of death by cancer in the UK, but it is 
treatable if diagnosed early. In order to increase the likelihood of early diagnosis, more 
must be understood about the early stages of colorectal tumourigenesis. It is known 
that intestinal stem cells (ISCs) are the cells of origin of colorectal tumourigenesis, and 
that an expansion of undifferentiated cell types, akin to ISCs, is one of the earliest events 
in mouse models of tumourigenesis. This indicates the importance of the relationship 
between the ISC compartment and tumourigenesis. 
In order to understand how changes in the ISC compartment may be contributing to 
tumourigenesis, the ability to accurately quantify this compartment is essential. 
Currently, analysis of the ISC compartment relies on the analysis of gene expression 
levels of ISC markers. However, there is a great deal of controversy surrounding the 
majority of these markers and there is no evidence that alterations in expression levels 
of these markers results in a functional change in the ISC compartment. 
Here I present a novel method for assessing the ISC compartment based on a functional 
capacity of ISCs; the ability to form intestinal organoids in culture. This new method 
uses organoid formation efficiency as a readout of changes in the ISC compartment, and 
can be used in conjunction with traditional methods of ISC marker expression to 
understand the relationship between expression of ISC markers and ISC functionality. I 
have used this method to further analyse the intestinal phenotype of a range of mouse 
models of colorectal cancer based on gene deletion of Apc, Cited1, Apc2, Pten and Pml. 
These experiments have shown that organoid formation efficiency can be a useful 
method for assessing the ISC compartment, although changes within this compartment 
may not be accurately predictive of tumourigenesis. 
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1 General Introduction 
 Intestinal anatomy and function 1.1
The intestine is a tube which runs from the stomach to the anus, which ingested food 
passes through for the absorption of nutrients and water. The small intestine can be 
divided into three parts; the duodenum, the jejunum and the ileum. The luminal surface 
of the small intestine consists of a sheet of epithelial cells which are organized into 
invaginations called the crypts of Lieberkuhn and finger-like projections called villi (see 
Figure 1.1) which maximize surface area for increased absorption efficiency. These 
epithelial cells are polarized, with microvilli on the luminal side which further increase 
surface area. Beneath the single-cell epithelial sheet are stromal fibroblasts which 
surround the crypts and extend into the villi (the stromal component of which is 
referred to as the lamina propria) encasing a blood supply to these cells. Beneath both 
the epithelial and stromal compartments is the smooth muscle layer, which is 
responsible for the peristaltic action essential for the movement of food along the 
intestine. 
1.1.1 Intestinal histology 
Structurally, the intestinal epithelium is a highly regulated tissue, with up to nine crypts 
feeding cells into each villus. The proliferative zone of the intestinal epithelium is 
located within the crypt. Transit amplifying cells within the crypt divide 4-5 times, with 
each cycle taking about 12 hours whilst migrating up the crypt-villus axis towards the 
crypt-villus junction where they terminally differentiate (Marshman et al. 2002). There 
are four main types of differentiated cells found within the intestine; the absorptive 
enterocytes and the secretory lineages of goblet cells, enteroendocrine cells and Paneth 
cells, Figure 1.1. Differentiated cells (apart from Paneth cells) continue to migrate up the 
villus eventually being sloughed off into the lumen at the villus apex and replaced by the 
continual stream of new cells migrating upwards from the crypt. This rapid turnover of 
cells is maintained by an intestinal stem cell (ISC) population at the base of the crypt, 
the daughter cells of which are capable of becoming any of the epithelial lineages within 
the intestine.  
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The majority of differentiated cells found in the villi are enterocytes, which are the 
absorptive cells responsible for nutrient uptake. Cells from this differentiated cell 
lineage are tightly packed together, with close cell-to-cell adhesions forming an 
epithelial barrier which helps to prevent microbes from entering the bloodstream. 
Enterocytes can be identified by their expression of the enzyme alkaline phosphatase. 
Goblet cells are responsible for the secretion of mucins which aid the lubrication of the 
epithelium and protect it from the high level of mechanical stress which occurs as a 
result of food movement through the intestine. Goblet cells also secrete trefoil proteins 
which facilitate tissue repair (Mashimo et al. 1996). Goblet cells are found throughout 
the villus, often at the crypt-villus junction. The mucins secreted by the goblet cells can 
be stained using Alcian Blue, and this staining technique is used to identify the number 
and position of intestinal goblet cells. 
Enteroendocrine cells are scarce in comparison to the other differentiated cell types but 
are found throughout the whole of the crypt-villus axis. These function to secrete 
hormones which control many gut functions such as regulating glucose levels and 
signalling to empty food from the stomach. They can be identified by their ability to 
reduce silver ions, marking them with black deposits when stained with Grimelius silver 
stain. 
Finally, Paneth cells are long-lived cells (6-8 weeks), found exclusively at the base of the 
intestinal crypt.  In contrast to the other cell types, they migrate back down the crypt-
villus axis as they differentiate (Bjerknes and Cheng 1981, 2006). The Paneth cells 
secrete a variety of anti-microbials and as such they are responsible for immunity and 
protection within the intestinal crypt. The Paneth cells also secrete a range of other 
factors which have a less well understood role in tissue maintenance, such as TGF-α, 
Wnt3 and the Notch ligand Dll4 (Bevins and Salzman 2011; Sato et al. 2010). These 
factors are thought to be important in maintaining the ISC population by regulating the 




Figure 1.1 A; Haemotoxylin and Eosin stain of a normal mouse small intestine. Black bar 
indicates 100μm. B; Cartoon representation of a normal intestinal crypt and villus showing the 





 Signalling pathways involved in intestinal homeostasis 1.2
The delicate balance of cell proliferation, migration and apoptosis within the intestine 
must be carefully regulated in order to maintain intestinal structure and function. This 
is achieved by controlling gene expression through a number of important signalling 
pathways, the most important of which are discussed here.  
1.2.1 Canonical Wnt signalling Pathway 
Canonical Wnt signalling is a signalling pathway which is essential during embryonic 
development due to its role in establishing the basic body pattern. This signalling 
pathway relies on the binding of a secreted ligand to a receptor, and the Wnt signalling 
molecules are highly conserved throughout the animal kingdom. 
In the absence of a Wnt signal, the intracellular proteins adenomatous polyposis coli 
(APC) and axin are phosphorylated by glycogen synthase kinase-3ß (GSK3) which 
increases their ability to bind to ß-catenin. When ß-catenin binds to these proteins it is 
also phosphorylated by GSK3, a process which results in the breakdown of ß-catenin, 
Figure 1.2. 
When a Wnt ligand binds to a Wnt receptor (a Frizzled (Fz)/low density lipoprotein 
(LDL) receptor-related protein (LRP) complex), a signal is transduced to the 
intracellular proteins stimulating interaction between Dishevelled (Dsh) and Axin, 
making it unavailable for binding to ß-catenin and initiating its breakdown (Logan and 
Nusse 2004). This results in an accumulation of ß-catenin in the cytoplasm and the 
nucleus, where it interacts with any member of the lymphoid enhancer-binding factor 1 
or T cell-specific transcription factor (LEF/TCF) to enhance transcription of a number of 
Wnt target genes (Behrens et al. 1996; Clevers and Van de Wetering 1997).  
Many Wnt target genes are associated with cell proliferation, migration and adhesion, 
processes which are all essential for the maintenance of the intestine. Indeed, the 
appropriate regulation of Wnt signalling is vital for the maintenance of the intestinal 
stem cell (ISC) population. The ISC population is found at the base of the intestinal 
crypt, and throughout the crypt-villus axis there is a gradient of Wnt agonists, with 
higher levels found near the ISC population (Gregorieff et al. 2005).  
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The importance of Wnt signalling within intestinal homeostasis has been demonstrated 
using a range of experimental formats. Ireland et al. showed that conditional 
homozygous deletion of β-catenin in the mouse resulted in catastrophic disruption of 
normal intestinal homeostasis, with crypt ablation, reduced numbers of goblet cells, 
increased apoptosis and detachment of sheets of enterocytes (Ireland et al. 2004). 
Likewise, transgenic ectopic expression of the Wnt inhibitor Dickkopf1 (Dkk1) resulted 
in reduced numbers of secretary cells, reduced proliferation and loss of crypts (Pinto et 
al. 2003), while deletion of the important Wnt-target gene C-myc was lethal to intestinal 
cells, resulting in a complete loss of all C-myc-/- crypts (Muncan et al. 2006). 
1.2.2 Notch Signalling pathway 
Notch signalling is a cell-to-cell signalling pathway, meaning that signalling can only 
occur via direct cell-to-cell contact of adjacent cells. Notch ligands (such as Jagged or 
Delta) interact with the Notch receptor and this causes two proteolytic cleavage events. 
The first, mediated by the tumour necrosis factor-α-converting enzyme (TACE), involves 
the cleavage of the extracellular domain from the Notch receptor. Once this has 
occurred, the second cleavage event takes place, releasing the Notch intracellular 
domain (NICD) which can then enter the nucleus and activate the transcription factor 
CSL, resulting in expression of Notch target genes, Figure 1.2. Like Wnt target genes, 
Notch target genes have a variety of functions which influence tissue homeostasis via 
roles in controlling apoptosis, proliferation, spatial patterning and cell fate 
determination (Artavanis-Tsakonas et al. 1999). 
Conditional inactivation of CSL within the mouse intestine (which effectively prevents 
Notch signalling), results in the conversion of proliferative cells within the intestine into 
post-mitotic goblet cells (Van Es et al. 2005). Not only does this demonstrate the 
importance of the Notch signalling pathway in homeostasis, but crucially it highlights 
that the maintenance of the undifferentiated cells, the ISCs, within the crypt is essential 
for intestinal homeostasis. Therefore the importance of Notch signalling is due to its 
role as a regulator of the ISC compartment, supported by the high levels of Notch 
ligands found at the base of the crypt in comparison to the rest of the crypt-villus axis.  
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1.2.3 TGFβ, BMP signalling pathway 
Both the TGF-β pathway and the BMP signalling pathway are activated by the binding of 
a ligand to the membrane-bound type II receptor which enables the type II receptor to 
dimerise with type I receptors, and phosphorylate its cytoplasmic domain. Once 
phosphorylated, the type I receptor can then recruit and phosphorylate either the 
SMAD2/3 proteins (TGF-β), or the SMAD1/5/8 proteins (BMP) which, once 
phosphorylated are collectively known as receptor regulated SMADS (R-SMADS). The R-
SMADS can then disassociate from the receptor and form a complex with SMAD4, 
thereby enabling its translocation into the nucleus. Once in the nucleus, SMAD4 can 
interact with regulatory proteins and regulate a range of gene transcription events 
(Figure 1.2). Target genes of the TGF-β/BMP signalling pathway have a range of 
functions, but are most commonly associated with inhibition of cellular growth and 
proliferation. 
Within the intestine, expression of TGF-β ligands is highest at the villus tip, concomitant 
with absence of cellular growth and proliferation, in accordance with its role within 
intestinal homeostasis (Barnard et al. 1993).  
1.2.4 The Hedgehog Pathway 
The Hedgehog signalling pathway is controlled by two cell membrane spanning proteins 
called Patched and Smoothened. When no ligand is bound, Patched inhibits 
Smoothened, which enables protein kinase A (PKA) to phosphorylate the transcription 
factors Gli2/3 resulting in the targeting of Gli2 for degradation. This leaves the 
truncated Gli3 protein free to enter the nucleus and act as a transcriptional repressor of 
Hedgehog target genes.  
When a Hedgehog ligand (either Sonic Hedgehog, Shh, Indian Hedgehog, Ihh or Desert 
Hedgehog, Dhh in vertebrates) binds to Patched, the inhibition of Smoothened is 
prevented, and active Smoothened prevents the phosphorylation and degradation of 
Gli2/3. This enables Gli2/3 to enter the nucleus and act as a transcription factor for a 
number of Hedgehog target genes. One of these target genes is FoxL1 (Madison et al. 
2009), which has been shown by Kaestner et al. to be a regulator of BMP and Wnt 
signalling (Kaestner et al. 1997). Loss of the Hedgehog target FoxL1 results in increased 
proliferation in the intestinal epithelium and a distorted crypt-villus architecture 
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(Kaestner et al. 1997). A similar effect is caused by the loss of the Hedgehog ligand (and 
therefore activator) Ihh in the intestinal epithelium, which results in increased 
proliferation, crypt fission, and expanded ISC compartment (Kosinski et al. 2010). Most 
importantly, as Hedgehog is a paracrine signalling pathway with ligands being 
expressed in the epithelium and secreted, the pathway is activated in the stromal cells 
and so loss of Ihh in the epithelium resulted in disruption of the mesenchymal 
architecture and deterioration of the extracellular matrix. This highlights the 





Figure 1.2 The four main signalling pathways involved in intestinal homeostasis; WNT, Notch,TGF/BMP and Hegdgehog signalling, which all control 
the expression of genes associated with homeostatic processes such as proliferation, apoptosis, differentiation, growth and migration.  
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 Adult intestinal stem cells 1.3
The least well understood cells within the intestine are the undifferentiated cells found 
at the base of the crypt, referred to as intestinal stem cells (ISCs). These stem cells 
persist throughout the lifetime of an individual, and their progeny are capable of 
differentiating into any of the intestinal epithelial cell lineages. Both the location and the 
gene expression patterns seen within the ISC population are controversial. It has 
previously been reported that ISCs can be subcategorized into two distinct populations; 
the crypt base columnar cells (CBC cells) which are responsible for intestinal 
homeostasis and a quiescent population found at the +4 position within the intestinal 
epithelia which is only active after intestinal trauma (Tian et al. 2011; Yan et al. 2012). 
However, the data produced from extensive studies on the matter has been interpreted 
in a number of different ways. 
1.3.1 Identifying the ISC: location and markers 
Traditionally, an adult stem cell is described as a long-lived, slowly dividing cell, multi-
potent and asymmetrically dividing. This does not appear to be the case for ISCs which 
despite being long-lived and multi-potent, are relatively very rapidly dividing cells, 
dividing every 24 hours (Barker et al. 2007) and appear to divide symmetrically (see 
section 1.3.2) (Escobar et al. 2011). However, this is relatively new knowledge and the 
quest to find ISC markers that match this dogma has hindered the identification of ISCs 
to date.  However, this has not been the only problem encountered when studying ISCs. 
Due to the small number of ISCs (predicted to be 4-6 per intestinal crypt) (Booth and 
Potten 2000) expression levels of any markers are low, thereby making 
immunohistochemistry difficult. As a result, most ISC identification methods rely on 
FAC sorting or in situ hybridisation, both of which make it difficult to determine the 
exact location of cells expressing the markers (Gregorieff et al. 2005). Thus a number of 
stem cell markers have been proposed and later refuted making this is a very dynamic 
and evolving area of research. 
For many years, DNA label retaining experiments were used to identify the “label 
retaining cell”, assumed to be the ISC. Cells at the +4 position within the intestinal crypt 
were shown to retain thymidine DNA labels long term despite continued cell division 
(Potten et al. 1974). Later, studies reported that the +4 cells specifically express the 
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marker Bmi1, and that these cells were proliferative and capable of self-renewal, and so 
Bmi1 expression has been widely used as a marker of ISCs (Sangiorgi and Capecchi 
2008).  
CBC cells are rapidly dividing (rapid in terms of stem cells) elongated cells at the base of 
the crypt which are interspersed with Paneth cells.  In 2007, it was reported that CBC 
cells are specifically positive for the expression of Lgr5. Lgr5 was at the time classified 
as an orphan receptor, but it is now known to interact with R-spondins, Wnt activators 
found at the base of the crypt (Zhao et al. 2007). Despite their rapid cell division, Lgr5+ 
cells were shown, using lineage tracing experiments, to be capable of generating all the 
cell lineages of the intestinal epithelium (Barker et al. 2007; Zhu et al. 2008). More 
recently, the Lgr5+ cells were shown to be specifically capable of forming intestinal 
organoids in culture (Sato et al. 2009), see section 1.3.4. By analysing the differential 
gene expression profiles of Lgr5hi and Lgr5low intestinal epithelial cells, it has been 
possible to identify other proteins which are specifically expressed in CBCs, and it was 
through this method that expression Olfm4 and Ascl2 was identified as a potential 
marker of the ISC compartment (van der Flier et al. 2009a; van der Flier et al. 2009b). 
Olfm4 encodes an anti-apoptotic factor that promotes tumour growth and facilitates cell 
adhesion, whereas Ascl2 is an imprinted gene that encodes a basic helix loop helix 
transcription factor. Interestingly, of these three markers of CBC cells, only Olfm4 is not 
a Wnt target gene, and so can be used to differentiate between changes in Wnt signalling 
and changes in the ISC population (Barker et al. 2007; Jubb et al. 2006; van der Flier et 
al. 2009a). 
Other ISC markers have been proposed over the last decade, including Hes1 and Msi1 
(Kayahara et al. 2003; Potten et al. 2003) due to the localisation of expression within 
normal and post-irradiated intestinal crypts, as well as increased expression in tumours 
derived from mouse models of intestinal tumourigenesis. The authors of these papers 
are careful that they only tentatively propose these genes as potential markers of the 
ISC population as a result of their localisation of expression, but much research has 
since been conducted which does not take this into account. This misunderstanding has 
resulted in new ISC markers being proposed as a result of their co-localisation with 
these genes. For example, Dckl1 was proposed as an ISC marker due to its co-
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localisation with Msi1 (May et al. 2007), but was later reported to be in fact a marker of 
a rare intestinal epithelium secretory lineage called “tuft” cells (Saqui-Salces et al. 
2011). 
The ISC markers which seem to have been most successfully used, are those which were 
determined by comparing the gene expression pattern of Lgr5+ cells to Lgr5- intestinal 
cells such as Prominin1/Cd133, Ascl2 and Olfm4 (Snippert et al. 2009; van der Flier et al. 
2009a; van der Flier et al. 2009b) all of which specifically mark the CBC cells. 
Over recent years it has been proposed that ISCs should be sub-categorised into rapidly 
dividing CBC cells which are responsible for intestinal homeostasis (identified by 
expression of Lgr5), and the more slowly dividing, label retaining +4 cells, which are 
thought of as “quiescent” stem cells and are activated in response to injury or cell death 
(identified by expression of Bmi1) (Tian et al. 2011; Yan et al. 2012). However, a recent 
paper from Hans Clever’s laboratory has disputed this, by using both single transcript in 
situ hybridisation and transcriptional profiling of sorted Lgr5hi expressing cells to show 
that all of the current ISC markers overlap in their expression, although there appears to 
be a gradient of expression of many of the markers between the CBCs and the +4 cells 
(Muñoz et al. 2012). Other proposed markers for the +4 population of stem cells are 
HopX, mTERT and Lrig1 (Montgomery et al. 2011; Powell et al. 2012; Takeda et al. 
2011), however, evidence contradicting the ability of each of these proteins to act as a 
marker for the +4 cell has been published by Barker et al., and so the controversy 
continues (Barker et al. 2012). 
The controversy surrounding the idea of two distinct ISC populations has been more 
recently explored by Buczacki et al, who showed that the quiescent label retaining stem 
cells are in fact committed to the secretory lineage and will invariably mature into 
Paneth and enteroendocrine cells. This seems to be the case during homeostasis, 
however, after injury these previously quiescent cells can undergo rapid proliferation 
and produce all of the main epithelial lineages, indicating that they can be pulled back 
from committed quiescent cells into active stem cells (Buczacki et al. 2013). This was 
achieved through pulse-chase experiments showing that the label retaining cells can 
only form clonally populated crypts after injury by radiation, hydroxyurea or 
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doxorubicin. This seminal work shows not only the complexity and fluidity of the 
system, but the utility of lineage tracing experiments in dissecting this complex system. 
All of the contradictory information published makes it very difficult to produce a 
definitive list of ISC markers. Much of the current literature is anchored around genes 
specifically expressed at the base of the crypt, although there is a growing consensus 
that Lgr5, Ascl2 and Olfm4 are key markers of an ISC population, but potentially not the 
only ISC population. 
1.3.2 ISC division 
The +4 stem cell is often referred to as the “quiescent” stem cell, due to its ability to 
retain a thymidine DNA label despite division (Potten et al. 1997). This assumed 
quiescence however, is not the conclusion arrived at by the research group who 
conducted the label-retaining experiment. This group presented a hypothesis known as 
the immortal strand hypothesis (Potten et al. 1978; Potten et al. 2002; Smith 2005). It 
was thought that the only way in which ISCs were able to protect their genome from a 
lifetime’s build-up of mutations was by some form of strand selection, whereby the 
original DNA template strand is retained within the daughter stem-cell. This argument 
has since been refuted by studying DNA segregation within the CBCs as opposed to the 
+4 ISCs and clearly demonstrates unbiased segregation of the DNA strands at division 
(Escobar et al. 2011). 
The retention of DNA labels lead to the assumption for many years that the intestinal 
stem cells divide asymmetrically to produce one intestinal stem cell, and one transit 
amplifying cell. (Potten et al. 2002; Smith 2005). This form of division is referred to as 
“invariant asymmetry”. However, it was observed that intestinal crypts tend to drive 
towards monoclonality whereby, after a given period of time, the entire crypt is 
descended from one ISC (Loeffler et al. 1993). This does not correspond with the idea of 
invariant asymmetry which fails to provide an adequate explanation for crypt 
monoclonality.  
Recently, another explanation has been proposed, whereby ISCs divide symmetrically 
either to produce two transit amplifying (TA) or two stem cells (SC) in an entirely 
stochastic manner (Figure 1.3), meaning that any of the ISCs within the crypt have an 
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equal likelihood of becoming the dominant clone. This hypothesis, termed “neutral 
drift” has been supported by mathematical modelling as well as some beautiful lineage 
tracing experiments from Hans Clever’s laboratory whereby each ISC is individually 
labelled and the development of clonality can be seen (Fletcher et al. 2012; Lopez-
Garcia et al. 2010; Snippert et al. 2010).  
Interestingly, as ISCs provide both homeostatic and regenerative functions, it should be 
considered that there may be some kind of “choice” as to whether an ISC divides 
asymmetrically, or symmetrically to produce 2 stem cells or 2 transit amplifying cells. It 
could be argued that stochastic symmetrical or asymmetrical division is required for 
homeostasis, and during times when the stem cell is required for regeneration, the rate 
of stem cell division is increased in order to replace lost cells. However, there is also a 
case for the idea that gross intestinal cell damage drives a regenerative stem cell 
division pathway, with more cells dividing symmetrically to produce 2 TA cells. This 
would enable the regeneration of the intestine without exposing the stem cell to the 
damage which results from an increased number of divisions, however a mechanism 
which could drive this division choice remains unclear. 
 
Figure 1.3 Diagrammatic representation of the three division “choices” which stem cells face. 
SC= Stem cell, TA= transit amplifying cell. 
1.3.3 Stem cell niche 
The ISC niche is described as the microenvironment in which the ISCs reside. It is 
thought that the niche may help establish or maintain stem cells by providing them with 
a range of signals. Paneth cells have long been thought of as the main constituent of the 
ISC niche due to their expression of  TGF-α, Wnt3, the Notch ligand Dll4 as well as a 
range of antimicrobial factors, which are necessary in both the establishment and 
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maintenance of in vitro culture of ISCs (Bevins and Salzman 2011; Sato et al. 2010). This 
was supported by a study which showed that organoid growth efficiency (see section 
1.3.4) was increased by the co-culture of Lgr5+ cells with Paneth cells (Sato et al. 2010).  
Due to the importance of Notch signalling in the maintenance of the ISC population, 
coupled with the fact that Notch receptors and delta ligands are membrane bound 
requiring cell contact with the Lgr5+ in order to activate Notch in the ICS, it is thought 
that the main role of Paneth cells within the ISC niche is the ability to activate the Notch 
signalling pathway (Fre et al. 2005).  
If the Paneth cells are essential for the maintenance of the ISC niche then it would be 
assumed that loss of Paneth cells would result in complete crypt ablation. This 
experiment was attempted in two ways; by expressing the diphtheria toxin gene within 
Paneth cells (Garabedian et al. 1997) and by conditional knockout of Sox9 (Bastide et al. 
2007), both of which resulted in some crypt dysplasia, but failed to result in complete 
breakdown in crypt villus structure which would be expected from a loss of the ISC 
population. This was explained as being the result of incomplete loss of Paneth cells, 
and the ability of the intestine to repair itself after even major damage. Furthermore, at 
the time of the experiment there were few ISC markers available resulting in an 
incomplete analysis of the effects on the ISC compartment. 
More recently, complete ablation of Paneth cells from the mouse intestine was achieved 
through the use of the Math1-/- mouse with the surprising result that Lgr5-expressing 
cells are in fact capable of survival, renewal and performance of all normal functions in 
the absence of Paneth cells (Kim et al. 2012). Math1 is described as a Notch-repressed 
target gene since inhibition of the Notch pathway activates its expression. It is a driver 
of differentiation by pushing cells into the secretory lineage and inhibiting proliferation. 
An explanation for the surprising result from the study by Kim et al. is offered by the 
proposition that loss of the important differentiation factor Math1, may render ISCs 
independent of Notch signalling, thereby removing their dependency on neighbouring 
Paneth cells (Schuijers and Clevers 2012; Van Es et al. 2010).  
A newly acquired self-sufficiency of Lgr5 stem cells due to the loss of Math1 could 
explain why no change in intestinal homeostasis was seen in the absence of Paneth cells 
and could be tested by culturing Lgr5+ cells from Math1-/- mice to assess if they are 
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capable of forming organoids in the absence of the Notch ligand Jagged which is 
required for the growth of organoids from single wildtype Lgr5+ cells (section 1.3.4). 
However, it does not explain the observation by Kim et al. that Lgr5+ cells are present at 
an earlier stage of intestinal development than the Paneth cells in normal mice (Kim et 
al. 2012), which would require the culturing of Lgr5+ cells from an early developmental 
stage to assess if Notch dependency increases throughout development. 
Despite the evidence discussed indicating that ISCs do not rely on the presence of 
Paneth cells for capacity to maintain intestinal homeostasis, recently we showed that 
Paneth cells are required for the ability of ISCs to repair the gut after trauma. By 
inducing loss of expression of β-catenin within the intestinal epithelium using either 
Villin-Cre (which recombines within the ISC and the Paneth cell as well as the other 
epithelial lineages) or AH-Cre (which recombines in the ISC and epithelia but not the 
Paneth cell) we were able to show that surviving ISCs were able to repopulate the 
intestine and retain function when the Paneth cell was unharmed, but were unable to in 
the absence of Paneth cells, thereby resulting in loss of crypt-villus architecture (Parry 
et al. 2013). This indicates that if there are indeed two distinct populations of ISCs, with 
one population responsible for homeostasis and the other responsible for damage 
repair, Paneth cells are an essential niche component only for the +4 cells, or they are 
required for interconversion between the two subsets of stem cells. 
Despite the contradictory evidence, it is clear from these studies that Paneth cells play 
an important role in the maintenance of the Lgr5+ ISCs, but their exact role is still far 
from clear, and the contribution of extraepithelial factors should not be underestimated. 
For example, it has been shown that the loss of Wnt3 from the intestinal epithelium in 
vivo causes no effect on intestinal morphology and function. However, the loss of Wnt3 
in organoid cultures (where the extraepithelia compartment of the intestine is absent) 
results in organoid death, an effect rescued when the organoids are in co-culture with 
mesenchymal cells (Farin et al. 2012). This indicates that Wnt3 from sources other than 
the Paneth cell and the epithelial compartment plays an essential role in the 
maintenance of the ISC niche.   
As previously mentioned, the importance of components contributing to the ISC niche 
can be assessed by their presence/absence during the time of development of the ISC 
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compartment. The establishment of the crypt-villus architecture with an ISC population 
occurs during perinatal development. Interestingly, during this stage of development 
thyroid hormone (T3) levels are particularly high. It is also known that loss of functional 
thyroid hormone receptor α results in deregulated intestinal morphology (Plateroti et 
al. 2001). This knowledge led to the recent study by Hasebe et al, in which T3 levels 
were manipulated during intestinal remodelling in amphibian metamorphosis to show 
that T3 is required by both the intestinal epithelium and the non-epithelial intestine 
(stroma and myofibroblasts) for the formation of ISCs (Hasebe et al. 2013). It has been 
shown that T3 regulates Hedgehog and BMP signalling (both important pathways 
involved in homeostasis of the ISC compartment) within the intestinal connective tissue, 
but not the epithelium, indicating the important role of cell-cell interactions and extra-
epithelial factors in the maintenance of the ISC niche. 
The complexity of the stem cell niche lies in its self-regulation. Potentially, the ISCs may 
be regulating their own niche by manipulating their microenvironment to suit their own 
requirements. The Kim et al. study in which Paneth cells were totally ablated from the 
intestinal epithelium without affecting homeostasis highlighted quite how fluid the 
system could be, with signals feeding both ways. This fluidity of the ISC niche is perhaps 
unsurprising, due to the importance of protecting the intestinal stem cell, and a highly 
regulated system has undoubtedly evolved to meet this requirement (Kim et al. 2012) . 
1.3.4 In vitro culture of ISCs 
In 2009 Sato et al. published a method which enabled the growth of intestinal organoids 
in culture. These organoids were grown from single mouse intestinal crypts and 
consisted of multiple crypt-like structures formed by crypt fission (Figure 1.4). 
Organoids can also be grown from single Lgr5+ cells, thereby cementing the use of Lgr5 
expression as a marker of the ISC population (Sato et al. 2009). The culture conditions 
artificially mimic those found within the intestine; they are seeded in Matrigel, which 
not only enables 3-dimensional growth, but is laminin-rich, as laminin has been found 
to prevent cell anoikis when in culture (Sato et al. 2009). Epidermal Growth factor 
(EGF) is also used in intestinal organoid culture as it is associated with intestinal 
proliferation. Inhibition of the BMP signalling pathway is achieved by the addition of 
Noggin in order to prevent the inhibition of intestinal self-renewal caused by BMP 
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signalling (Haramis et al. 2004; He et al. 2004). Importantly, the growth factor R-
spondin1 (Rspo1) is also required for intestinal organoid culture. R-spondins  are only 
capable of enhancing the Wnt-signal within cells in the presence of canonical Wnt 
ligands, indicating that Rspo1 only enhances the Wnt-signal in cells which are already 
Wnt-activated, and within cells expressing an Rspo1 receptor, such as Lgr5 (Kim et al. 
2008).  
When growing these organoids from single cells sorted for their expression of Lgr5, 
there are additional growth factor requirements, as the “stem cell niche” is no longer 
present. These growth factors are Jagged, a Notch ligand which activates the Notch 
signalling pathway within the Lgr5+ cells (a function normally carried out by Paneth 
cells) and the Rho kinase inhibitor Y27632. Rho kinase normally stimulates the activity 
of the tumour suppressor protein PTEN, and so it can be assumed that the addition of a 
Rho kinase inhibitor will result in higher levels of the oncogenic factor phosphorylated 
Akt (pAkt) (see Figure 1.6) which promotes cell survival (Li et al. 2005). 
The organoid structures produced contained all the differentiated epithelial cell types 
found within the intestine and are structurally very similar to intestinal tissue.  
This method represents not only a highly useful tool by which to test drugs, but also a 
way in which to understand the ISC niche. By altering the growth factor which enables 
single Lgr5+ cells to form organoids, it could greatly help the understanding of what is 
required for an ISC to function as an ISC.  
 
Figure 1.4 Organoid grown from a single intestinal crypt. Black bar represents 100µm. Black 




 Colorectal cancer  1.4
Colorectal cancer (CRC) is the third most common cancer in the UK, with 37,500 people 
being diagnosed every year. Although CRC survival rates have doubled in the last 30 
years, over half of all sufferers do not survive for longer than 5 years after diagnosis, 
despite it being curable if diagnosed early.  
There are a number of reasons why the incidence of CRC is so high. The high rate of cell 
division required to maintain the rapid turnover of cells within the intestinal epithelia, 
results in a high incidence of DNA replication errors and so a build-up of DNA mutations 
in these cells makes oncogenic mutations likely. Also, the direct exposure of intestinal 
cells to potential carcinogens via ingested food further increases the mutation rate. 
The development of sporadic CRC is a multistep process in which an accumulation of 
genetic mutations leads to the progression from normal intestinal epithelium to 
dysplastic tissue to benign adenoma through to metastatic carcinoma. Based on studies 
of the frequency of gene mutations at various stages of progression in human tumours, 
Fearon and Vogelstein proposed a model whereby loss of function of Adenomatous 
polyposis coli (APC) initiates the formation of a benign lesion, followed by an activating 
mutation in KRAS, allelic loss of the 18q locus and mutation of p53, which all contribute 
to the progression to malignant disease (Fearon and Vogelstein 1990), (Figure 1.5). 
The reason that the levels of mortality associated with this disease are so high is mainly 
due to late detection, as a patient usually only presents with symptoms once the disease 
has reached late stages and metastasised. It has been shown that one round of faecal 
occult blood screening (which examines a patients stool for non-visible traces of blood) 
reduces the relative risk of mortality associated with CRC  by 25% as a consequence of 
earlier detection (Hewitson et al. 2007; Mandel et al. 1993). In order to develop more 
screens for early detection of CRC it is essential that the early stages of colorectal 










1.4.1 Signalling Pathways associated with CRC 
As cancer is simply unregulated cell division it is unsurprising that most of the 
signalling pathways which are implicated as playing a role in CRC are pathways which 
play an important role in intestinal homeostasis. 
 PI3K pathway 1.4.1.1
Mutations which cause the constitutive activation of the phosphoinositide-3-kinase 
pathway (PI3K pathway) are found in 40% of all CRC tumours (Parsons et al. 2005). 
Activation of this pathway is normally the result of upstream receptor tyrosine kinases 
(RTKs) which cause phosphorylation of phosphatidylinositol-4-5-biphosphate (PIP2) 
which generates phosphatidylinositol-3-4-5-biphosphate (PIP3). PIP3 recruits AKT to 
the cell membrane where it is phosphorylated by phosphoinositide dependent kinases, 
converting it into its active form (pAKT) which can initiate translation, transcription, 
cell cycle progression as well as inhibit apoptosis through its kinase activity, see Figure 
1.6. PTEN (phosphatase homolog of tensin) is a lipid phosphatase and an important 
negative regulator of the PI3K pathway. It is therefore a tumour suppressor, which acts 
by converting PIP3 into PIP2. Reduction of PIP3 via PTEN results in the prevention of Akt 
recruitment to the membrane and its subsequent activation. Mutations which result in 
constitutive activation of this pathway can be either activating mutations of RTKs or 
inactivating mutations of downstream negative regulators of the pathway, such as 
PTEN. Interestingly, pAKT is responsible for the activation of GSK3 (Voskas et al. 2010), 
an important negative regulator of the Wnt pathway, and so there is a great deal of cross 
talk between the two pathways. 
Knowledge of the PI3K pathway has led to the development of a number of targeted 
therapies such as Trastuzumab, an antibody which targets human epidermal growth 
factor receptor 2 (HER2), a potent activator of the PI3K pathway. This therapy has been 
shown in phase III trials to significantly increase survival in patients with gastric 
tumours which express HER2 when used in conjunction with chemotherapy (Roukos 
2010). However, this treatment only increases survival for a couple of months as 
tumours become resistant via downstream activation of the pathway. Because of this, 
more targeted therapies are being sought from the range of proteins downstream in the 




Figure 1.6 The PI3Kinase pathway. Activation of the pathway by receptor binding results in the 
conversion of PIP2 to PIP3 which translocates AKT to the plasma membrane where it is phosphorylated by 
phosphoinositide dependent kinases (PDKs) into its active form, pAKT. 
  Wnt and cancer 1.4.1.2
As Wnt-target genes have been shown to control a number of regulatory processes 
associated with tumourigenesis, such as cell proliferation and adhesion (Staal et al. 
2004), it is unsurprising that abnormalities within this pathway are closely associated 
with cancer, particularly CRC (Bienz and Clevers 2000; Polakis 2000).  
Wnt signalling has also been linked to cell migration within the colon, and so may also 
be involved in the ability of early tumourigenic cells to metastasise. There seems to be a 
great deal of potential to target the Wnt pathway therapeutically to control 
tumourigenesis and metastasis and much work is ongoing to develop Wnt inhibitors as 
a potential therapeutic treatment to colorectal cancer (Dihlmann and von Knebel 
Doeberitz 2005). In order to do this effectively the Wnt signalling pathway needs to be 
fully elucidated with gene interactions and their effect on the tumourigenic properties 
of the cells and organism understood.  
Mutations in the important negative regulator of the Wnt signalling pathway, APC, are 
an early initiating step in the formation of spontaneous CRC, with loss of heterozygosity 
(LOH) of the APC gene occuring at an early stage of colorectal tumour progression. It has 
also been shown that APC mutations which result in activated Wnt-signalling are 
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present in over 80% of human colorectal tumours (Powell et al. 1992). Loss of 
functional APC leads to an increase in nuclear β-catenin, where it can act, along with 
TCF as a transcription factor to drive expression of a range of Wnt target genes.  
 Modelling CRC in the mouse 1.5
The importance of the Wnt signalling pathway, particularly during development, means 
that many of the molecular interactions and signalling strategies used within the Wnt 
pathway are highly conserved between species. As such, the pathways are extremely 
comparable between humans and mice. Mouse models are useful not only because 
genetically engineered mice can be generated in a relatively short space of time, but 
because they also enable the long term study of tumourigenesis, as well as investigating 
the roles that diet and environment play in tumourigenesis, which is not possible when 
using cancer cell lines. 
1.5.1 Mouse models of FAP 
APC was originally identified as the gene that is mutated in cases of familial 
adenomatous polyposis (FAP). FAP is an inherited autosomal disorder, sufferers of 
which develop multiple colonic polyps at a young age. Although the polyps are benign, 
there is a high risk that some will progress into malignant adenocarcinomas if left 
untreated (Groden et al. 1991).   
In 1990 a mouse which modelled FAP was identified within a colony of mice following 
random mutagenesis. Termed the Multiple Intestinal Neoplasia mouse (MIN), it carries 
a truncation mutation at codon 850 in one allele of the mouse homologue of APC and 
was reported to develop multiple adenomas throughout the entire intestinal tract from 
an early age (Moser et al. 1990). The development of the Apcmin model was a turning 
point in the study of CRC, and it was soon followed by a variety of different Apc+/- 
mutants, which shared the same phenotype of development of multiple adenomas, but 
interestingly differed in the number, size and location of the adenomas depending on 
the type of Apc mutation (Fodde et al. 1994; Su et al. 1992).   
Apc+/- mutants proved exceptionally useful in the study of modulators of Wnt-
dependent tumourigenesis. Using these model mice, it was possible to perform 
microarrays at various stages of tumour development, and establish a list of genes 
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which are expressed abnormally from the earliest stages of tumourigenesis, as these 
genes potentially play an important role in tumour initiation (Young et al. 2013).  It was 
through such a study that the importance of the COX-2 (PTGS2) gene was determined. 
Cox-2 was shown to be expressed from a very early stage of polyp formation, and so 
Cox-2 knockout mice were crossed with Apc+/- mice and it was shown that COX-2 
deficiency drastically reduced adenoma formation in these mice, and that chemical 
inhibitors of COX-2 could achieve the same effect (Oshima et al. 1996). Drug trials 
showed that the effect seen in Apc-deficient mouse models was also true for humans 
and although prescription must be carefully regulated due to cardiovascular side effects, 
the COX-2 inhibitor can significantly lower the number of colorectal polyps formed in 
FAP patients (Steinbach et al. 2000). 
1.5.2 Cre-lox technology  
Despite the utility of the Apcmin mouse in studying intestinal tumourigenesis, it has 
limited use when trying to study the earliest stages of disease. One of the earliest stages 
of disease onset is the inactivation of both alleles of APC (Gryfe et al. 1997) and in the 
min mouse the time of LOH is unknown, so a model whereby both Apc alleles could be 
deleted at a known time point was essential. Use of the Cre-loxP recombination system 
(Figure 1.7) has enabled the initial stages of intestinal tumourigenesis to be studied in 
detail. By inducing conditional loss of both alleles of Apc within the intestinal epithelium 
it has been shown that functional Apc is essential to maintain normal intestinal 
homeostasis, and loss of Apc immediately deregulates the tissue morphology by 
affecting migration, differentiation, proliferation and apoptosis (Sansom et al. 2004). 
Interestingly, this paper observed that the intestinal cells took on the appearance of 
“crypt progenitor cells”, supporting the evidence that Wnt signalling controls the 




Figure 1.7 Cre-Lox Technology.  When tamoxifen is administrated to mice which possess both the 
essential exon of the gene of interest flanked by LoxP sites and an oestrogen bound Cre-
recombinase, the tamoxifen frees the Cre-recombinase and enables recombination between 
LoxP sites resulting in the excision of the essential exon. This method is used to temporally 
control gene loss. 
 
When expressed, Cre-recombinase will recombine DNA between any two loxP sites in 
the same orientation. In this example, Cre-expression is linked to the tissue-specific 
promoter villin, which will express in the intestinal epithelia, including the ISCs. The 
transgene encodes a Cre-recombinase estrogen-receptor (ER) linked protein, which is 
inactive until an injection of tamoxifen binds the ER, freeing the Cre-Recombinase. This 
results in a tissue specific conditional knock out, induced by tamoxifen injection. One of 
the main advantages of this model is the ability to use different promoters to drive 
expression of the Cre-recombinase, and thereby drive recombination of the floxed gene 
in any number of specific cell compartments, for example using a Cre-recombinase 
linked to expression of the ISC marker Lgr5 results in recombination specifically within 
the ISC compartment. The utility of this extends beyond providing the ability to 
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determine the importance of mutation location on tumourigenesis, but also enables cell 
lineage tracing experiments using a lacZ reporter gene which once recombined 
expresses β-galactosidase which can easily be stained blue by performing an X-gal stain. 
Daughter cells of the recombined cells will also stain blue, as can be seen from Figure 
1.8 where recombination within ISC compartment enables visualisation of all daughter 
cells of single ISCs as they migrate up the crypt-villus. 
 
 
Figure 1.8 LacZ stain of mouse small intestinal villi. Each stripe of blue represents all of the 
progeny of a single recombined ISC using Cre-recombinase linked to Lgr5 expression.  
 
Cre-lox technology not only enables the study of the early stages of tumourigenesis via 
Apc deletion, but also enables the study of loss of genes which are embryonic lethal. For 
example, Cre-Lox technology has been used to study the effects of the loss of expression 
of the important tumour suppressor Pten, which is embryonic lethal. Loss of Pten 
results in increased levels of PiP3 which recruits Akt to the membrane, thereby 
increasing the levels of activated Akt. This effectively models the effects of constitutive 
PI3K pathway activation which is seen in many human CRC tumours. This method was 
used by Marsh et al., and showed that Pten loss in the adult mouse has no effect on the 
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homeostasis of normal intestine, but does cause accelerated tumourigenesis when 
coupled with defiency of Apc (Marsh et al. 2008).  
1.5.3 β-catenin mutant mouse models 
Another method of modelling Wnt-dependent CRC is via the expression of a mutant 
form of β-catenin which is far more stable in the cell and therefore resistant to 
proteasomal degradation. Mutations which result in a stabilised form of β-catenin are 
found in a subset of human colon tumours which do not carry the APC mutation. When 
modelled in the mouse, conditional stabilisation of β-catenin results in the formation of 
multiple tumours. Interestingly, the work was originally performed with expression of 
Cre-recombinase being driven by the calbindin promoter (which is not expressed in the 
proliferative zone of the intestine) and resulted in few tumours (Romagnolo et al. 
1999). Subsequently Cre-expression driven by a fatty acid binding protein gene 
promoter (which is expressed in the proliferative zone) was shown to result in many 
thousands of adenoma (Harada et al. 1999). These mouse models of CRC lead to the idea 
that oncogenic mutations in cells at the base of the crypt play a more important role in 
CRC than mutations in the differentiated cells along the crypt-villus axis. 
 Intestinal stem cells as the cells of origin of CRC 1.6
A study in 2008 used an Lgr5-promoter driven Cre to show that when Apc is deleted 
specifically within the Lgr5+ cell population, microadenomas form within the intestine 
within 3-5 weeks and develop rapidly to adenomas, whereas when Apc is deleted 
specifically from the transit-amplifying region, microadenomas are rare (Barker et al. 
2008). The loss of Apc in differentiating cells is thought to have so little effect because 
the cells are so rapidly lost from the villi. However, Apc mutations in Lgr5+ cells, as the 
ISCs, results in the population the whole crypt and villus with Apc-/- cells, thereby 
causing tumourigenesis. This result shows the importance of the relationship between 
the ISCs and tumourigenesis, and that expansions in the ISC compartment would 
provide the intestine with a higher number of cells of potential cancer origin.  
Despite the ISC being described as the cell of origin of intestinal cancer, other epithelial 
cells are capable of driving tumourigenesis, but it has been presented that ISC derived 
tumours are more aggressive (Barker et al. 2008). 
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 Cancer stem cells 1.7
Cells within a tumour often maintain a high degree of similarity to the cells of the tissue 
from which they originated, with similar interactions with the environment, and 
responses to molecular control mechanisms. This similarity with normal tissue could be 
taken forward to suggest that, like their tissue of origin, tumour cells are also organised 
into a hierarchy, with less and more potent cells present. The cancer stem cell 
hypothesis maintains that only a sub-population of cancer cells are capable of 
populating and maintaining the tumour, and it is only these cells which are capable of 
metastasising to form new tumours. As such it is essential that these cells are targeted 
by treatment.  
This idea is now supported with a great deal of data, which show that in both 
Leukaemia (Bonnet and Dick 1997; Lapidot et al. 1994) and a variety of solid tumours 
such as breast (Al-Hajj et al. 2003), brain (Singh et al. 2004) and colon (O’Brien et al. 
2006) there is a sub-population of cells which can form a new tumour when 
transplanted into an immune deficient mouse, but that the bulk of tumour cells are 
incapable of this. This insight has led to the cancer stem cell hypothesis.  
In the field of CRC, analysing the heterogeneity of tumour cells taken from solid primary 
tumours of CRC patients enabled the sorting of tumour cells according to the expression 
of various cell surface makers. It was found that of all the different expression patterns 
of these tumour cells, a small subpopulation of epithelial cells which expressed a high 
level of epithelial cell adhesion molecule (EpCAM) as well as CD44 (which is a reported 
breast cancer stem cell marker) were the only population of tumour cells capable of 
engraftment into immune-deficient mice (Dalerba et al. 2007). Interestingly, the 
tumours that they formed in these xenograft experiments re-acquired the same 
heterogeneity of expression patterns and phenotype seen in the parental tumour. This 
indicates that the EpCAMhigh/CD44+ tumour cells represent a subpopulation of CRC cells 
capable of populating and expanding a tumour, therefore potentially represent the 
cancer stem cell population.   
The ability of tumour cells to form tumours upon transplantation and serial 
transplantation into immune deficient animal models is seen as the gold standard for 
identification of cancer stem cells, however many argue that xenotransplantation is an 
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inappropriate method for identification of such cells. This controversy is based on the 
idea that xenotransplantation does not model a physiologically relevant environment of 
tumour growth, and that these assays are simply isolating a subpopulation of cells that 
have an increased fitness for survival in abnormal conditions. Interestingly, it was 
shown by Quintana et al. that the frequency of melanoma cells with tumourigenic ability 
is dramatically altered by the level of immune deficiency of the host animal into which 
they are transplanted (Quintana et al. 2008). This work indicates that the 
xenotransplantation assay may not be the most appropriate method for identifying 
CSCs. 
The recent drive to expand the knowledge base surrounding the cancer stem cell 
hypothesis has resulted in new, convincing supporting evidence using lineage tracing in 
models of sporadic tumourigenesis. Schepers et al. used the confetti mouse (previously 
used to elucidate monoclonality within the crypt) in order to demonstrate that 
intestinal adenoma growth is fuelled by a subpopulation of adenoma cells which 
express the ISC marker Lgr5 (Schepers et al. 2012). This important study also showed 
that the Lgr5+ adenoma cells are intermingled with Paneth cells, indicating that they 
may require a similar sort of niche environment to normal ISCs. It should be noted that 
sorted Lgr5+ intestinal tumour cells have not yet been able to form tumours when 
transplanted into immune deficient mice and so despite being multipotent, they have 
not yet been shown to possess self-renewal capacity. 
This work highlights the importance of choice of approach when attempting to identify 
CSC markers, and hints that despite the attractiveness of the CSC hypothesis, many of 
the markers which have already been published do not necessarily represent a true CSC 
population. 
1.7.1 Cancer stem cells and chemotherapy 
Most currently used chemotherapeutics target rapidly dividing cells which make up the 
bulk of the tumour, however it is thought that they are not as effective against the 
slowly dividing cancer stem cells. This results in the relapse of disease as cancer stem 
cells can repopulate the tumour after treatment (Figure 1.9). This knowledge has led to 
an increase in the number of studies aimed at understanding the drug sensitivity of 
CSCs to compounds used to treat the cancer, and it has been found in a number of 
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studies that less differentiated cell types within a tumour are often less sensitive to 
drugs (Ho et al. 2007; Levina et al. 2008).  
Interestingly, it has recently been shown that a number of ABC transporter proteins 
(which have been associated with drug efflux) are associated with stem cells, and if this 
is the case in CSCs then potentially this sub-population of tumour cells may be markedly 
more resistant to chemotherapeutics than the bulk of the tumour (Al-Hajj et al. 2004). 
 
 
Figure 1.9 Cancer stem cells and chemotherapeutics. Current chemotherapeutics target rapidly 
dividing cells, thereby reducing tumour size (tumour bulk shown as blue cells) but can leave the 
less rapidly dividing cancer stem cells (represented in red) unaffected, enabling them to re-
establish the tumour and cause relapse. By targeting the cancer stem cells, it may be possible to 
cause tumour regression as well as prevent metastasis. 
 
 It is evident that some method of targeting cancer stem cells is necessary in order to 
permanently treat the disease, however, this presents a number of difficulties. What we 
know about normal adult stem cells indicates that there is likely to be some sort of 
cancer stem cell niche, whereby the direct environment of the cancer stem cell 
promotes its existence. What is unknown is whether the niche regulates the stem cells 
or if the stem cells regulate their own niche. If it is the former then simply killing the 
cancer stem cells will not have any effect as whichever cell finds itself in the niche will 
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be driven to become a cancer stem cell. For this reason a greater understanding of the 
relationship between cancer stem cells and their niches is required in order for this 
hypothesis to be put to therapeutic use.  
Another difficulty commonly encountered when attempting to produce a therapy which 
specifically targets CSCs, is the similarities between normal ISCs and CSCs. Any 
treatment which does not distinguish between the two types of cells could cause severe 
damage to normal intestinal tissue. One recent attempt to expand the differences 
between the two populations of cells showed that expression of Dclk1 can differentiated 
between ISCs and CSCs. Using Cre-induced lineage tracing experiments, this study 
showed that normal intestinal cells which express Dclk1 do not represent the ISC 
population, whereas tumour cells which express Dclk1 represented a proliferative 
population of cells at the base of the polyp (Nakanishi et al. 2012). Developing this 
theme, this study then explored how the knowledge of these differences between CSCs 
and ISCs could be of use to therapy.  By specifically ablating Dclk1 positive cells in Min 
mice, it was shown that normal intestinal epithelium was undamaged, but there were 
high levels of tumour regression. This example represents how increased 
understanding of both normal ISCs and CSCs, as well as the relationship between the 
two, can result in the uncovering of potential therapeutic targets. 
Recently there have been some positive outcomes from the use of the CSC hypothesis, 
namely the development of Metformin (currently a treatment for diabetes) alongside 
traditional chemotherapeutics to selectively target cancer stem cells, so far with a great 
deal of success (Cufí et al. 2010; Hirsch et al. 2009).  It is now thought that Metformin 
functions by inhibiting Transforming Growth Factor-β (TGF-β) driven Epithelial-
Mesenchymal Transition (EMT). Metformin is beginning to show its worth as a breast 
cancer treatment in a variety of trials (Martin-Castillo et al. 2010) and as data 
accumulates it will be interesting to see whether drugs which target CSCs in this way 
will reduce the risk of relapse post-recovery. 
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Aims and Objectives 
 The importance of the relationship between ISCs and intestinal tumourigenesis is clear, 
not only due to the identification of ISCs as the “cell of origin” of intestinal adenomas 
(Barker et al. 2008), but because conditional homozygous loss of the tumour suppressor 
gene Apc results in an increase in undifferentiated cell types (Sansom et al. 2004b). This 
indicates that an early stage of tumourigenesis may involve an expansion of the 
intestinal stem cell compartment. 
Currently, assessment of the ISC compartment relies on the use of gene expression 
markers, either by in situ hybridisation or qRT-PCR. The specificity of these genes to 
mark the ISC population is continually debated (Barker et al. 2012), and they do not 
provide a readout of changes in the functional potency of the ISC compartment.  
The two main objectives of this thesis are therefore to develop a functional assay for the 
assessment of the ISC compartment and to apply this assay to a variety of mouse models 
of colorectal cancer in order to identify how changes in the ISC compartment contribute 
to tumourigenesis. 
To address the first objective I will be utilising the known functional properties of ISCs; 
the ability to produce daughter cells of all of the intestinal epithelial lineages, and as 
such, form intestinal organoids in culture (Sato et al. 2009). I will use this technique to 
investigate the potential of organoid formation efficiency as a readout of the functional 
stem cell compartment. 
In order to assess how changes in the ISC compartment contribute to tumourigenesis I 
will be using a number of novel models. The role of Wnt-signalling in the maintenance 
of the ISC compartment will be interrogated through loss of the Wnt-target gene Cited-1, 
individual and combined loss of Apc and its homologue Apc2, and cross talk with the 
PI3K pathway will be examined using loss of the negative regulators of PI3K, Pml and 
Pten on an Apc deficient background. The intestinal phenotype of these models will be 
described, not only by analysing the effect of gene deficiency on tumourigenesis and 
intestinal homeostasis but in relation to changes within the ISC compartment, as 
assessed by gene expression patterns and ISC functionality. 
33 
 
2 Materials and Methods 
 Experimental Animals 2.1
2.1.1 Animal Husbandry 
All animals were housed according to UK Home Office Regulations; mice were given 
access to the Harlan standard diet (Special Diets Service UK, expanded diet) and water 
ad libitum. 
2.1.2 Breeding 
All mice were maintained on an outbred background. Mice of 6 weeks and older of 
known genotype were bred in trios of one male and two females. Pups were weaned at 
approximately 4 weeks old when feeding independently. Pups were sexed and 
separated at weaning then ear clipped for identification purposes. 
 Genetic Mouse Models 2.2
A number of transgenic mouse models were utilised within this project, see Table 1. The 
transgenes used either resulted in a constitutive deletion of the gene of interest or 
contained exons of the gene of interest flanked with LoxP sites, to enable conditional 
deletion of the genes. The only Cre-recombinase transgene used in this thesis was 
VillinCreER which is expressed in the intestinal epithelium where it is inactive whilst 
fused to a mutated estrogen receptor. This Cre-recombinase becomes active in the 
presence of tamoxifen. 
 Experimental Procedures 2.3
All procedures were conducted according to appropriate UK Home Office Regulations, 
and fell within the remit of the project licence code 30/2737. 
2.3.1 Ear biopsy for genotyping 
As the tissue from the ear biopsy taken for identification purposes was also used for 
DNA extraction and genotyping, (see section 2.4.1) the ear biopsy is defined as an 
experimental procedure. As such it was performed by a licensed individual in a 
designated procedure room. Ear biopsies were taken using a 2 mm ear punch (Harvard 
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apparatus). When DNA from ear biopsy was not suitable for genotyping, tail biopsy was 
utilized to surgically remove 3-5 mm of the tail tip under local anaesthetic. 
 
Transgene Effect 
VillinCre ERT (El Marjou et al. 2004) Intestinal epithelial cells, tamoxifen 
inducible 
LoxP targeted Apc allele (Shibata et al. 
1997) 
Endogenous Apc allele bearing LoxP 
sites flanking exon 14 
LoxP targeted Pten allele (Suzuki et al. 
2001) 
Endogenous Pten allele bearing LoxP 
sites flanking exons 4 and 5 
Pml- allele (Wang et al. 1998) Constitutive Pml knockout. 
Cited1- allele (Rodriguez et al. 2004) Constitutive Cited1 knockout 
Apc2 - allele (Van der Meer et al. 2001) Constitutive Apc2 knockout 
Table 1 Outline of the transgenic mouse models used within this thesis 
 Genotyping of mice using Polymerase Chain Reaction (PCR) 2.4
PCR was performed to genotype weaned mice using genomic DNA (gDNA) extracted 
from ear biopsy. Confirmatory genotyping was also performed at time of death to 
ensure the mouse was assigned to the correct experimental cohort. PCR was kindly 
performed by Mark Bishop. 
2.4.1 DNA extraction 
Ear biopsies were placed in a labelled microtube and stored at -20°C until use. Cell Lysis 
Solution (Gentra, 250 µl) and Proteinase K (Roche, 5 µl of 20 mg/ml) were added and 
incubated in a shaking incubator at 40°C overnight (O/N). Protein Precipitation Solution 
(Puregene, 100 µl) was added and mixed by inversion. Following centrifugation for 10 
minutes at 13000 rpm, the supernatant was carefully removed and placed in a fresh 
microtube with 250 µl isopropanol. This was mixed by inversion and centrifuged at 
13000 rpm for a further 15 minutes then the supernatant removed and discarded. The 
pellet containing the precipitated gDNA was resuspended in 250 µl of Ultrapure H2O 
(Sigma). gDNA was stored short term at room temperature (RT) and at 4°C for long 
term storage.  
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2.4.2 PCR Protocol 
PCR was carried out in thin-wall 12-well strip tubes (Grenier, Bio-One). 2.5 µl of gDNA, 
extracted as described above, was added to each tube with 47.5 µl of PCR mix 
(described in Table 2) containing the DNA polymerase and buffer appropriate to the 
PCR (see Table 3), Ultrapure H2O (Sigma), Magnesium Chloride (Promega), dNTPs 
(Bioline) and gene specific primers. One control tube, made up as described above but 
with the DNA replaced with Ultrapure H2O (Sigma), was run with every PCR reaction. 
Primers were either designed using Primer3 software (http://primer3.ut.ee/) and 
specificity confirmed using BLAST engine against the Ensembl database 
(http://www.ensembl.org/Mus_musculus/Info/Index) or used as described from 
previous publications. Specific primer sequences used can be found in Table 3. 
The caps were then firmly placed on the tubes and the PCR reactions run on a 
thermocycler (G storm). Conditions are described in Table 3. 
 




Table 3 PCR conditions required for genotyping. 
 
2.4.3 Visualisation of PCR products 
PCR products were visualised using gel electrophoresis. Agarose gels were made by 
dissolving 10 g agarose in 400 ml 1 × Tris-Boreate-EDTA (TBE) buffer (Sigma) in a 
conical flask by heating in a microwave until boiling. The gel was then cooled by running 
cold water over the base of the conical flask while agitating to prevent uneven cooling. 
14 µl of Safe View fluorescent nucleic acid stain (NBS Biologicals) was added to the 
melted gel and agitated carefully to ensure even distribution of the Safe View without 
incorporating air bubbles into the gel. 200 ml of gel solution was then poured into each 
of two moulds (Bio-Rad) and combs inserted to create wells. Once the gels were set, the 
combs were removed and they were placed into gel electrophoresis tanks and covered 
with 1 × TBE with Safe View (10 μl Safe View/100 ml 1 × TBE).  
5 µl of loading dye (50% Glycerol [Sigma], 50% Ultrapure H2O, 0.1% bromophenol blue 
[Sigma]), was added to the PCR product and mixed by pipetting. 20 µl of the coloured 
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PCR product was added to each well of the agarose gel, and run alongside a molecular 
weight ladder (Promega) of appropriate size to the estimated PCR product. The gel was 
run at 120 V until the loading dye had run more than halfway across the gel 
(approximately 30 minutes) and the gel was visualised using a GelDoc UV trans 
illuminator (Bio-Rad). Depending on the size of the PCR products produced, the gel was 
frequently run for longer in order to clearly separate the bands.  
 Experimental Cohorts 2.5
After the genotype of mice had been ascertained by PCR, Cre-recombinase mediated 
recombination was induced in appropriate mice around 8-10 weeks of age using 
tamoxifen administration. Once induced, long term cohorts were monitored closely for 
signs of ill health, and were culled when they presented either an intestinal tumour 
phenotype (hunched appearance, piloerection, paling feet, large rectal prolapse which 
caused discomfort or was ulcerated) or any other signs of loss of condition.  
Short term cohorts were induced at 8-10 weeks of age and then sacrificed 3 days after 
the first induction day to study the short term effects of gene deletion. 
2.5.1 Tamoxifen administration 
Powdered Tamoxifen (Sigma) was dissolved in corn oil (Sigma) at a concentration of 10 
mg/ml in an 80°C water bath. An 80 mg/kg dose of tamoxifen was administered to each 
experimental mouse via intraperitoneal (I.P.) injection daily, for four consecutive days. 
For short term cohorts, 3 injections of 60 mg/kg were administered in a single day. I.P. 
injections were performed using a 1 ml syringe (BD Plastipak) and 25 G needle (BD 
Microlance3). 
2.5.2 5-Bromo-2-deoxyuridine administration 
Sort term experimental animals were injected with 250 µl of the thymidine analogue 5-
Bromo-2-deoxyuridine (BrDU, Amersham Biosciences) either 2 or 24 hours prior to 
sacrifice in order to label cells currently undergoing, or which have passed through, S-
phase within the 2 hours during which BrDU is bioavailable. 
38 
 
 Tissue Preparation 2.6
2.6.1 Tissue Dissection 
Mice were culled via cervical dislocation according to Home Office Licence procedures. 
The mouse was sprayed with 70% EtOH and the skin and muscle wall of the abdomen 
cut through to open the abdominal cavity. The genitourinary tract, kidneys, pancreas 
and spleen were fixed together, liver was dissected out and fixed alone, and the small 
and large intestine and stomach were flushed out using 1 × PBS and fixed as described 
below.  
For the short term cohorts, the small intestine was divided into small sections, with 
some being snap frozen for RNA extraction, some being opened longitudinally, rolled 
and placed in formalin and a third section being used for epithelial cell extract using 
Weiser preparation. All organs were collected into 10% formalin on ice.   
For long term cohorts, once sacrificed due to ill health, where possible the cause of 
death was established. All organs were collected and formalin fixed. The intestine was 
opened longitudinally and fixed in methacarn. 
2.6.2 Tissue Fixation using Formalin 
All organs were formalin fixed unless otherwise stated. Small and large intestine were 
flushed with cold 1 × PBS and opened longitudinally. The gut was then rolled using 
dissection tweezers and pinned in place using a syringe needle. The gut roll was placed 
in 10% formalin (Sigma) on ice. Organs were incubated in formalin for 24 hrs at 4°C 
then stored in 70% EtOH at 4°C until paraffin embedding. 
2.6.3 Fixation Using Methacarn 
For long term cohorts where an accurate tumour count was required, small and large 
intestines were flushed with cold 1 × PBS and opened longitudinally on 3MM paper 
(Whatman). This was then placed in a sealed container of Methacarn (4:2:1 Methanol: 
Chloroform: Glacial Acetic Acid (Fisher)) and stored overnight (O/N) at RT in a fume 
hood. Tumour counts and location were then performed and the gut was rolled using 
dissection tweezers and pinned in place using a syringe needle. This was placed in 70% 
EtOH at 4°C prior to paraffin embedding. 
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2.6.4 Paraffin Embedding Fixed Tissue 
Fixed tissues were removed from 70% EtOH and placed in a cassette (Fisher) and 
processed using an automatic processor (Leica TP1050). The tissues were incubated in 
an increasing gradient of EtOH for dehydration (70% EtOH for 1 hour, 95% EtOH for 1 
hour, 2 × 100% EtOH for 1 hour 30 minutes and 100% EtOH for 2 hours), then in 2 × 
xylene for 2 hours. The tissue samples were then placed in liquid paraffin for 1 hour, 
followed by 2 × 2 hours. The samples were removed from the cassette and embedded in 
paraffin wax by hand and left to solidify.  
2.6.5 Sectioning Fixed Tissue 
In order to enable microscopic analysis of the tissue, sections of tissue were fixed onto 
slides in preparation for H&Es, cell-specific staining or IHC. Paraffin embedded tissues 
were cut to 5 µm sections using a microtome (Leica RM2135) and placed on Poly-L-
Lysine coated slides (PLLs) and baked at 58°C for 24 hours.   
Paraffin embedding and sectioning was performed by Derek Scarborough and Mark 
Isaac. 
2.6.6 Snap freezing tissue 
Several sections of normal intestinal tissue and intestinal tumour tissue (approximately 
2 mm × 2 mm) were placed in lockable microtubes and placed in liquid nitrogen until 
frozen then stored at -80°C until required. 
2.6.7 Epithelial Cell Extraction using Weiser Preparation 
When RNA or protein analysis was required, Weiser preparation was performed in 
order to extract intestinal epithelium and therefore minimise interference from stromal 
and smooth muscle compartments. The 10 cm of the small intestinal proximal to the 
pyloric junction was dissected out, and flushed with ice cold PBS. The gut was opened 
longitudinally and cut in half longitudinally, and one half rolled and formalin fixed. This 
enabled direct comparison between gene expression levels and phenotype. The other 
half was washed 3 × in 15 ml ice cold Weiser solution (Table 4) by shaking in a 50 ml 
Falcon tube. The sample was then incubated on ice for a maximum of 20 minutes in 15 
ml Weiser solution then vortexed for 15 minutes. The solution was removed and 
retained on ice and a further 15 ml ice cooled Weiser solution added to the sample, this 
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was repeated twice. The removed fractions were combined and centrifuged at 1500 
rpm for 5 minutes at 4°C. The supernatant was discarded and the pellet washed 2 × with 
20 mls of ice cold PBS. The pellet was then resuspended in 3 ml PBS and aliquoted into 3 
× 1 ml samples in microtubes which were then centrifuged at 13000 rpm and the 
supernatant removed. Two of these pellets were resuspended in 500 µl Trizol before 
snap freezing in liquid nitrogen and stored at -80°C for future RNA extraction. The third 
pellet was snap frozen in liquid nitrogen then stored at -80°C for future protein 
extraction. 
 
Table 4 Constituents of Weiser Solution for epithelial extraction. * DTT should only be added on 





 Histological Analysis  2.7
2.7.1 De-waxing and Rehydrating PLLs 
Prior to IHC or cell staining, PLL sections were de-waxed by 2 × 10 minute submersion 
in Xylene and rehydrated through 5 minute incubations in each of the following 
gradients of EtOH; 2 × 100% EtOH, 1 × 95% EtOH and 1 × 70% EtOH. Slides were placed 
in dH2O in preparation for IHC or cell staining.  
2.7.2 Haematoxylin and Eosin (H&E) staining 
Staining with H&E enables the visualisation of tissue morphology. Haematoxylin stains 
the cell nuclei blue, whereas Eosin stains protein red. PLL sections were de-waxed and 
rehydrated, as described in section 2.7.1, and then immersed in a bath of Mayer’s 
Haemalum (R.A. Lamb) at RT for 45 seconds. The slides were removed and placed in a 
fresh bath with running water to remove any excess Haemalum and then placed in a 
bath of Eosin (R.A. Lamb). The slides were removed and placed in a fresh bath with 
running water to remove any excess Eosin. Slides were then dehydrated and mounted 
as described in section 2.8.2.8. 
 Cell Type Specific Stains 2.8
 Alcian Blue Staining for Goblet Cells 2.8.1.1
Alcian blue stain the mucins which are present in the secretory intestinal epithelial cell 
type, goblet cells. 
PLL slides were de-waxed and dehydrated as described in section 2.7.1 then immersed 
in a bath of alcian blue staining solution (1% Alcian blue (Sigma), 3% Acetic acid 
(Fisher) in distilled water (dH2O) at pH 2.5) for 2 minutes then placed in a bath with 
running water for 5 minutes. Tissue sections were then counter stained with Haemalum 
(R.A. Lamb) for 45 seconds then returned to a bath with running water for a further 5 
minutes. Slides were then dehydrated and mounted as described in section 2.8.2.8. 
 Grimelius Staining for Enteroendocrine Cells 2.8.1.2
The hormone-secreting enteroendocrine cells of the intestinal epithelium contain 
argyrophilic granules, which bind silver ions. These can be precipitated in the presence 
of a reducing solution which results in enteroendocrine cells appearing black. 
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All glassware was washed in double distilled H2O (ddH2O) prior to use to prevent 
contamination by any reducing agents. Slides were de-waxed and rehydrated as 
described in section 2.7.1 then incubated in silver staining solution (see Table 5) for 3 
hours at 65°C. The slides were then incubated in preheated reducing solution (see Table 
5) at 45°C for 1-10 minutes until the tissue sections had a visible yellow background 
stain, thereby eliminating the need for a counter stain. Slides were then dehydrated and 
mounted as described in Section 2.8.2.8. 
 
Table 5 Constituents of Solution required for a Grimelius stain for the presence of 
enteroendocrine cells. 
 
2.8.2 Immunohistochemistry (IHC) 
IHC was performed to enable the visualisation of the presence and location of specific 
proteins within the tissue sections. The specific conditions for each IHC performed are 
outlined in Table 6, and a generic protocol is described below.  
PLL slides were dewaxed and rehydrated as described in section 2.7.1 prior to antigen 
retrieval. 
 Antigen retrieval 2.8.2.1
In order to unmask the antigens, the cross-linking bonds formed between proteins 
during fixation were broken via antigen retrieval. Slides were boiled in pre-warmed 
citrate buffer (2.94 g Sodium citrate tribasic dehydrate (Sigma) in 1 L dH2O, pH 6) in a 
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pressurized cooker for 10 minutes then left to cool to room temperature and washed in 
dH2O. 
 Blocking of endogenous peroxidises 2.8.2.2
Antibody visualisation involves an enzymatic reaction catalysed by horse radish 
peroxidise (HRP), and so it was necessary to block the activity of endogenous 
peroxidises. This was achieved by the incubation of slides in hydrogen peroxide. The 
slides were either incubated in hydrogen peroxide (Sigma) diluted to the appropriate 
concentration in dH2O, or a commercial peroxidise blocking solution (Envision+Kit, 
DAKO). Hydrogen peroxide concentrations and blocking time can be found in Table 3. 
Slides were then washed 3 × 5 minutes in wash buffer (Table 6) at RT with agitation. 
 Blocking of non-specific antibody binding 2.8.2.3
Binding of non-specific antibodies was blocked by incubating the sections with serum 
derived from a species other than that in which the primary antibody was raised. A 
hydrophobic barrier pen (Immedge, VectorLabs) was used to draw around the sections 
and serum diluted in wash buffer to the correct concentration (Table 6) was added to 
the slides and incubated for 30 minutes at room temperature.  
 Primary Antibody Treatment 2.8.2.4
Primary antibodies were diluted to the working concentration (Table 6) using the 
working serum stock used in the previous step. The serum block was removed from the 
slides and the primary antibody applied and incubated in a moist chamber for the 
appropriate time. 
 Secondary Antibody Treatment 2.8.2.5
Slides were washed 3 × 5 minutes in wash buffer at room temperature with agitation 
then the secondary antibody, which was either a biotinylated antibody diluted to the 
correct concentration in the working stock of blocking serum, or a HRP-conjugated 
antibody from the EnVision plus kit (DAKO), was applied and incubated for the 
appropriate time (Table 6).  
 HRP Conjugation for Signal Amplification 2.8.2.6
When a biotinylated antibody had been used as a secondary (but not when the EnVision 
plus kit had been used), a signal amplification step which involves the binding of HRP to 
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the biotin of the secondary antibody was performed. This was achieved using the 
Avidin-Biotin Complex (ABC) kit (Vector Labs). The ABC reagent was prepared 
according to manufacturers’ instructions 30 minutes prior to use and stored at RT.  
Sections were washed 3 × 5 minutes in wash buffer at RT with agitation then the ABC 
reagent applied and incubated at RT for 30 minutes in a moist chamber.  
 Visualisation of Antibody Binding 2.8.2.7
Visualisation was achieved by the use of diaminobenzidine (DAB), which is a substrate 
for HRP, and when catalysed results in a brown coloured stain.  
 Sections were washed 3 × 5 minutes at RT with agitation and the DAB reagents (DAKO) 
prepared according to manufacturers’ instructions immediately prior to incubation. 
DAB was applied and incubated for 5-10 minutes until a brown stain could be seen. 
Tissue sections were then washed in dH2O, and counterstained in Mayer’s Haemulum 
(R.A. Lamb) for 45 seconds and washed in a bath of running water to remove excess 
Haemulum.  
 Dehydration and Mounting of slides 2.8.2.8
Slides were dehydrated by incubation in a series of EtOH baths at an increasing gradient 
of EtOH. (1× 5 minutes 70% EtOH, 1 × 5 minutes 95% EtOH, 2 × 5 minutes 100% EtOH) 
then cleared in 2 × 5 minute incubations in xylene. Slides were removed from the xylene 
and mounted in DPX mounting medium (R.A. Lamb) and coverslips applied and allowed 





Table 6 Optimised conditions for IHC for the range of antibodies used. 
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2.8.3 Cell Counting 
Unless otherwise stated, all cell counts were performed on 50 half crypt-villus axes per 
mouse for a minimum of 4 mice per cohort. Positively stained brown cells from IHC 
were counted in this way, as were black enteroendocrine cells from Grimelius staining 
and blue goblet cells from alcian blue staining. 
 Crypt/aberrant cell number counts 2.8.3.1
The number of cells from the base of the crypt were counted per half crypt up to the 
crypt “shoulder” at the crypt-villus junction using H&E sections. Mice with homozygous 
deletion of Apc did not have clear crypt compartments due to cell mis-regulation, and so 
the number of cells in the region of aberrant proliferation within the crypt-villus axis 
were counted in a single line. 
 Apoptosis and Mitosis Scoring 2.8.3.2
When counting the crypts and the aberrant regions of the intestine, the number of 
apoptotic bodies and mitotic bodies and their positions were recorded. 
2.8.4 Tumour Severity Grading 
Tumour grading was carried out on all sections from aged Apcflox/+ Ptenflox/flox Pml-/- mice 
and associated control cohorts. From H&E slides from methacarn fixed gut roll, the 
intestine was examined under the microscope and the number and severity of lesions 
was counted and graded. Each lesion was graded according to the grading system 









 In Situ Hybridisation 2.9
In situ hybridisation was performed on gut PLL slides from formalin fixed tissue in 
order to assess the location of Ascl2 and Olfm4 mRNA, two markers of the ISC 
compartment. Markers of the ISC compartment are generally expressed at such low 
levels, and there are few useful antibodies against the proteins, that it is impractical to 
visualise expression using IHC.  
In situ hybridisation uses digoxigenin (DIG) labelled RNA probes (riboprobes) which 
specifically bind target mRNA due to their complementary sequence. Successful probe 
binding can be detected using an anti-digoxigenin alkaline phosphatase-conjugated 
antibody. BM purple, a chromogenic substrate for alkaline phosphatase, is then used to 
visualise the location of antibody binding through the development of a purple stain. 
DIG labelled sense RNA probes (of the same, not complimentary sequence to the mRNA) 
were used as a control. 
Previously published probes for Ascl2 (Guillemot et al. 1994) and Olfm4 (van der Flier et 
al. 2009a) cloned into a pBluescript vector flanked by a promoter sequence for T3 or T7 
RNA polymerase, were used to transform competent Escherichia coli (E.coli) cells. These 
were then cultured and the plasmid DNA extracted and linearised and the probe 
transcribed using the appropriate RNA polymerase. 
2.9.1 Transformation of competent cells with cDNA vectors 
The probes were supplied integrated into plasmid vector DNA, and so had to be 
amplified for long term use via transfection into E.coli cells. 50 μl of chemically 
competent JM109 E.coli cells (Promega) were incubated on ice for 30 minutes with 1 μg 
plasmid DNA. The cells were then heat shocked at 42°C for 45 seconds before being 
returned to ice for 2 minutes. 1 ml SOC medium (Invitrogen) was added to the cells and 
incubated at 37°C in a shaking incubator for 2 hours. 750 μl of the culture was then 
plated onto one agar plate containing ampicillin and 250 μl plated onto another. The 
plates were then incubated O/N at 37°C. 
A single colony from this plate, selected using a sterile pipette tip, was streaked onto a 
separate agar plate containing ampicillin, and incubated O/N at 37°C. Four isolated 
colonies were selected from this plate using a sterile pipette tip and cultured O/N at 
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37°C in 10 ml of ampicillin containing LB medium in a 50 ml falcon tube in a shaking 
incubator. Plasmid DNA was extracted from 3.5 ml of this culture using a Qiagen Mini-
prep kit and subjected to an analytical digest to ensure transfection of the correct 
construct had occurred (see below). Another 100 μl of this culture was then used to 
inoculate 200 ml of ampicillin containing LB medium which was cultured O/N at 37°C in 
a shaking incubator to enable large scale plasmid DNA extraction through the use of a 
midi-prep kit (Qiagen). A glycerol stock of each culture was prepared by mixing 0.5 ml 
of this culture with 0.5 ml 50% glycerol and freezing at -80°C. Future probe generation 
was performed by culturing E.coli directly from this stock. 
2.9.2 Plasmid DNA extraction and probe linearization 
Plasmid DNA was extracted using Qiagen mini-prep kit (for the analytical digest) or 
Qiagen midi-prep kit (for the probe preparation) according to manufacturer’s 
instructions and resuspending extracted DNA in 200 μl 10 mM Tris (pH 8). A NanoDrop 
machine was used to quantify the DNA. 
 Analytical digests were performed by digesting the Ascl2 probe-containing plasmid 
with EcoR1 (New England Biolabs), which had been used to insert the probe into the 
plasmid, whilst the Olfm4 probe-containing plasmid was digested with NotI and SacI 
(New England Biolabs) (see Table 7 for restriction digest protocol). For both constructs 
the resultant digestion product was analysed on a 4% agarose gel to assess the 
fragment size. The Ascl2 digest was approximately 1,700 bps after analytical digest, and 
the Olfm4 digest was approximately 700 bps. 
200 μg plasmid DNA was linearised for probe preparation using the appropriate 
restriction enzyme (seen in Table 8) and the linearised plasmid DNA was 
phenol/chloroform extracted. This was performed by making the volume of plasmid 
DNA up to 500 μl with 10 mM Tris (pH 8) and adding an equal volume of phenol. This 
was then mixed by inversion for 5 minutes at room temperature and centrifuged at 
room temperature at 13000 rpm for 10 minutes.  The upper aqueous phase was 
carefully pipetted into a clean microtube and an equal volume of chloroform added. This 
was mixed by inversion for 10 minutes at room temperature then centrifuged again for 
10 minutes at 13000 rpm at room temperature. The aqueous phase was then carefully 
pipetted into a clean microtube and 0.1 volume of 3 M NaOAc (ph 5.2) was added with 
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2.5 volumes of 100% EtOH. This was incubated at -20°C O/N in order to precipitate the 
DNA. This was then centrifuged at 4°C for 20 minutes at 13000rpm and the supernatant 
discarded. The pellet was washed twice with 70% EtOH and allowed to air dry before 
being resuspended in 40 μl of 10 mM Tris (pH 8). The DNA was quantified using a 
NanoDrop machine and adjusted to a concentration of 1 μg/μl using 10 mM Tris (pH 8). 
 
 
Table 7 The constituents required to perform a restriction digest of the plasmid DNA. 
 
 
Table 8 Restriction enzymes required for linearisation of plasmid DNA. All restriction enzymes 
were purchased from NEB and were associated with a specific buffer. For the analytical digest of 
Olfm4, the combination of two restriction enzymes resulted in the need for an alternative buffer, 
and buffer 2 (NEB) was used. 
 
2.9.3 Probe Preparation 
The probes were prepared using the linearised plasmid DNA as a template for the 
transcription of DIG-labelled riboprobes using T3 or T7. 1 μg of 1 μg/μl linearised 
plasmid DNA was labelled using the appropriate RNA polymerase (see Table 9) and a 
DIG labelling mix (Roche). The transcription reactions were set as detailed in Table 10, 
and incubated for 2 hours at 37°C and 20 units of DNaseI (Ambion) added and then 
incubated for a further 15 minutes at 37°C to digest the DNA template.  
1/10th of the volume of NaOAc and 2.5 volumes of 100% EtOH were then added to the 
transcription reaction in order to precipitate out the DIG-labelled riboprobe. This was 
centrifuged at 13000 rpm for 20 minutes at 4°C and the pellet washed twice with 70% 
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EtOH and air dried. The pellet was resuspended in 100 μl Ultrapure H2O (Sigma) and 
stored at -80°C in 10 µl aliquots until use. 
 
Table 9 RNA polymerase enzymes for probe transcription. DIG-labelled riboprobes were 
transcribed from linearised plasmid DNA using the appropriate RNA polymerase enzyme. 
 
 
Table 10 DIG-labelling mix. Table shows the constituents and volumes for a single reaction to 
produce a DIG-labelled riboprobe. 
2.9.4 Probe hybridisation 
Sections were dewaxed, rehydrated, treated with 6% H2O2 for 30 minutes, washed 2× in 
PBS and fixed in 4% paraformaldehyde for 20 minutes on ice.  Sections were washed 2× 
in PBS and digested in Proteinase K solution for 5 minutes (200 µg/ml proteinase K in 
50 mM Tris, 5 mM EDTA), washed once in PBS, post-fixed in 4% paraformaldehyde for 5 
minutes, and washed in DEPC H20 for 2 minutes.  The slides were then treated in acetic 
anhydride solution (2 M Acetic anhydride in 0.1 M triethanolamine hydrochloride) for 
10 minutes whilst stirring, washed once in PBS and once in 1× saline then dehydrated 
and allowed to air-dry. The olfm4 probe was diluted 1 in 100 in hybridisation buffer (5× 
SSC, 50% formamide, 5% SDS, 1 mg/ml heparin, 1 mg/ml calf liver tRNA) which was 
heated to 80˚C for 3 minutes. 100 μl of this was applied to each slide which was then 
covered in parafilm to prevent dehydration of the slide, and incubated overnight in a 
dark, moist chamber at 65˚C.  
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2.9.5 Post-hybridisation treatment 
Post hybridisation washes were performed 1× in 5× SSC at 65˚C for 15 minutes then 2× 
in 50% formamide, 5× SSC 1% SDS for 30 minutes at 65˚C. Post hybridisation washes 
were continued by washing twice in 0.5 M NaCl, 10 mM TrisHCl pH 7.5, 0.1% Tween for 
10 minutes, the first at 65˚C and the second at room temperature. Sections were then 
incubated for 45 minutes in 0.5 M NaCl, 10 mM TrisHCl pH 7.5, 0.1% Tween with 25 µg 
RNAse A (Qiagen) at 37˚C then washed once in 0.5 M NaCl, 10 mM TrisHCl pH 7.5, 0.1% 
Tween for 5 minutes at room temperature. Sections were washed 2× in 50% 
formamide, 5× SSC for 30 minutes at 65˚C and preblocked in 10% sheep serum in PBT 
in a dark, moist chamber at room temperature for 2-3 hours. Antibody solution was 
created by pre-absorption of Anti-digoxigenin alkaline phosphatise conjugated antibody 
(Roche) for 3 hours at 4°C in 1% heat-inactivated sheep serum in PBT containing 5 
mg/ml mouse intestinal powder.  100 μl of this antibody solution was applied to each 
slide which was then covered in parafilm and incubated in a dark, moist chamber at 4°C 
O/N. 
2.9.6 Signal Detection 
Sections were washed 3× in PBT for 5 minutes then 3× in PBT for 30 minutes then 
preconditioned to inhibit endogenous alkaline phosphatase by washing 3× in NTMT 
buffer for 5 minutes (100 mM NaCl, 100 mM Tris HCl, 50 mM MgCl2, 0.1% Tween, 2 mM 
Levamisole). The substrate (BM purple, Roche) was added directly to the slides and 
incubated in the dark at 4˚C for 24-72hrs until a sufficiently strong colour developed. 
Sections were washed in PBT and counterstained with eosin. Excess eosin was removed 
by washing in running H2O and the slides were dipped in xylene prior to air-drying and 
mounting using DPX. 
2.9.7 Preparation of intestinal tissue powder 
The small intestines of 5 adult mice were combined and homogenised in the minimum 
volume of ice cold PBS. 4 volumes of ice cold acetone were added to the homogenised 
intestine, which was mixed thoroughly and incubated on ice for 30 minutes. This was 
centrifuged and the pellet was washed using ice cold acetone. This was further 
centrifuged and the resulting pellet spread onto filter paper and allowed to dry. Once 
thoroughly dry the material was ground to a fine powder using a pestle and mortar.  
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 Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) 2.10
qRT-PCR was used to assess the relative expression levels of genes within intestinal 
epithelial tissue. Intestinal epithelium was isolated using the Weiser preparation 
method (see section 2.6.7) and stored in Trizol at -80°C prior to RNA extraction. This 
RNA was used as a template for cDNA synthesis and then the levels of gene expression 
of a range of Wnt-target genes and ISC markers was compared between a minimum of 4 
mice of each genetic cohort.  
2.10.1 RNA extraction 
Epithelial cell extract was defrosted in 1ml Trizol (Invitrogen) in Precellys® beaded 
microtubes. Once defrosted, the samples were homogenized using a Precellys®24 
homogenizer for 45 seconds followed by 1 minute incubation and a further 45 seconds 
homogenisation. The samples were removed from the machine and allowed to settle on 
ice for 5 minutes to remove bubbles. The samples were pipetted into fresh microtubes 
with 200 μl pre-chilled chloroform. This was incubated on ice with frequent agitation 
for 10 minutes. 
The samples were then centrifuged for 15 minutes at 13000 rpm at 4°C, and the 
aqueous phase of the supernatant carefully pipetted into fresh microtubes and 700 μl 
isopropanol added. This was incubated at -20°C O/N for optimal RNA precipitation. 
The samples were then centrifuged for 15 minutes at 13000 rpm at RT and the 
supernatant discarded. The pellets were washed twice with 500 μl pre-chilled 70% 
EtOH and air dried for 5 minutes then resuspended in 10μl Ultrapure H2O (Sigma) and 
incubated for 10 minutes at 65°C. Extracted RNA was quantified using the NanoDrop 
machine. 
2.10.2 DNase Treatment 
10 μg extracted RNA was mixed with 5 μl RQ1 buffer (Promega), 10 μl RQ1 DNase 
enzyme (Promega) and made up to 50 μl with Ultrapure H2O. This was incubated at 
37°C for 30 minutes for optimum DNase activity. 5 μl STOP solution (Promega) was 
added and the solution heated to 65°C for 10 minutes to prevent further DNase activity. 
This resulted in DNA-free RNA at a concentration of 10 μg/ 55 μl. 
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2.10.3 cDNA synthesis 
The RNA was used as a template for cDNA synthesis using the reverse transcriptase 
SuperScript II (Invitrogen). The constituents of the cDNA synthesis mix are outlined in 
Table 11 and made up in thin-walled 12 well strip tubes (Grenier, Bio-One). This was 
heated to 65°C for 3 minutes then placed on ice and 1 μl Superscript II (Invitrogen) was 
added. This was incubated within a thermocycler at 25°C for 10 minutes, 42°C for 1 
hour and 65°C for 15 minutes. cDNA samples were stored at -20°C. 
 
Table 11 Constituents of cDNA synthesis mix. 
2.10.4 SYBR Green Gene Expression Analysis 
qRT-PCR was carried out in MicroAmp fast optical 96-well reaction plates (Applied 
Biosystems). All reactions were carried out in duplicate and each cDNA sample was run 
with primers for the house-keeping gene β-actin in order to normalise the expression 
levels of target genes. Each well was made up of 10 µl SYBR green fast mix (Invitrogen) 
2 µl of cDNA, 0.5 µl of each primer (10 mM) and 8 µl Ultrapure H2O (Sigma). See Table 12 
for primer sequences. The plate was sealed and centrifuged for 1 minute at 8000 rpm. 
qRT PCR reactions were carried out using a Step One Plus real-time PCR system 
(Applied Biosystems). The relative mRNA abundance was determined by incorporation 
of SYBR green into the PCR product. Thermocycler conditions were: 95°C for 20 seconds 
followed by 40 cycles of 95°C for 3 seconds (denaturation) and 60°C for 30 seconds. The 
data were collected automatically using StepOne Software. 
When the abundance of the mRNA transcript within the intestinal epithelial extract was 
particularly low, SYBR green was inefficient at detecting expression levels, and so the 
more specific, probe based TaqMan assay was used for these genes (see Table 12). 
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2.10.5 TaqMan Gene Expression Analysis 
Each well of the plate was made up of 10 µl TaqMan gene expression master mix 
(Invitrogen), 2 µl cDNA, 1 µl TaqMan probe (10 mM) and 8 µl Ultrapure H2O (Sigma). 
See Table 12 for TaqMan probe details. The plate was sealed and centrifuged for 1 
minute at 8000 rpm. 
The TaqMan probes are pre-designed and consist of a forward and reverse primer for 
the gene of interest and a probe complimentary to an internal region of the amplified 
PCR product with a fluorescent molecule and quencher attached to the 5’ end. During 
thermocycling, the fluorescent molecule is cleaved from any cDNA bound probe by Taq 
polymerase activity, releasing it from the quencher and enabling fluorescent signal 
detection. 
qRT-PCR reactions were carried out using a Step One Plus real-time PCR system 
(Applied Biosystems). Thermocycler conditions were: 50°C for 2 minutes, 95°C for 10 
minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. The data 
were collected automatically using StepOne Software. 
 





2.10.6 Analysis of qRT-PCR data 
SYBR green melt curves were examined to ensure the presence of a single peak, as 
double peaks indicate the presence of primers dimers or primer contamination. A 
fluorescence threshold was set and the number of thermocycles required by each well 
to reach the threshold in fluorescence was recorded as the cycle threshold (CT value). 
Samples were only analysed if they had a single peak in the melting curve and the 
duplicate repeats were within 1 CT value of each other.  
In each assay, the sample CT value was calculated as an average of the duplicates, and 
normalised by the subtraction of the CT value of β-actin for the same sample, thereby 
generating a ΔCT value. The ΔCT values were used to determine significance of change in 
gene expression at N=4. If the data was normally distributed (tested by the Shapiro-
Wilk test in SPSS) then a two-tailed T-test was performed, whereas if the data was not 
normally distributed a Mann-Whitney test was performed. 
In order to calculate the fold changes in expression levels, the average of the ΔCT values 
of the control cohort was subtracted from the average of the ΔCT values of the test 
cohort producing a ΔΔCT value. The equation fold change = 2−ΔΔCT was used to calculate 
fold change in gene expression levels. 
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 Western Blotting 2.11
2.11.1 Protein Extraction 
40-100 mg of frozen intestinal epithelial tissue (prepared by Weiser preparation, see 
section 2.6.7, and stored at -80°C until use) was resuspended at 100 μl / 10 μg tissue in 
pre-chilled modified RIPA buffer (see Table 13) with protease inhibitor (Complete 
protease cocktail mini tablets (Roche), 1 tablet per 5 ml RIPA buffer). This was 
transferred into Precellys® beaded microtubes and homogenized on the Precellys®24 
homogenizer for 2 x 45 seconds. The samples were then stored on ice until the bubbles 
had settled and then transferred to a fresh microtube and incubated on ice for 20 
minutes. Samples were then centrifuged at 13000 rpm for 10 minutes at 4°C and the 
supernatant containing the protein was aliquoted into 50μl aliquots, snap frozen in 
liquid nitrogen and stored at -80°C until use. 
 
Table 13 Constituents of modified RIPA buffer 
2.11.2 Protein Quantification 
Protein was quantified using the bicinchonic acid (BCA) method. This method is based 
on a biuret reaction whereby the presence of peptide bonds reduces Cu2+ ions to Cu1+ 
ions, producing a violet colour. The BCA reagent (Pierce) strongly absorbs light at 562 
nm and so the extent to which Cu is reduced (and the quantity of protein present) can 
be determined through a colourimetric assay.  
Protein samples were created by adding 8 µl sample to 192 µl PBS and 2 serial dilutions 
resulted in 3 protein concentrations (1:25, 1:50, 1:100) in a final volume of 100 µl PBS. 
Stock Bovine Serum Albumin (BSA) was diluted in RIPA buffer and then PBS to produce 
6 standards of known concentration ranging from 0 µg/ml to 25 µg/ml.  All samples 
58 
 
were loaded and standards were loaded into a colourless, flat bottom 96-well plate in 
duplicate. 
BCA reagents (Pierce) were made up according to manufacturer’s instructions and 100 
µl added to each sample. The plate was then sealed and incubated at 37°C for 2 hours. 
The absorbance of each sample was then read on an ELx800 spectrophotometer 
(BioTek) at 590 nm. A standard curve of absorbance to concentration was calculated 
using the absorbance of the BSA standards and the concentrations of the samples 
calculated. 
2.11.3 Sample Preparation 
Protein samples were defrosted on ice and 30 µg was resuspended in laemlli buffer (4% 
SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromphenol blue and 0.125 M Tris 
HCl in Ultrapure H2O, pH 6.8. All reagents were purchased from Sigma) to make up a 
volume of 25 µl. Samples were heated to 95°C for 5 minutes and quenched on ice before 
loading into gels. 
2.11.4 Gel Casting 
Mini-Protein III (Bio-Rad) gel casting apparatus was used to prepare polyacrylamide 
gels. Solutions for a 5% stacking gel and a 10% resolving gel were made up without the 
addition of the TEMED (see Table 14). The gel casting apparatus was assembled and 
TEMED was added to the 10% gel solution which was then mixed and poured between 
the two glass plates, to 2 cm below the top of the glass plates. 2 ml of H2O was poured 
over the top of the gel to prevent drying out and the formation of bubbles. Once the gel 
was set, (typically 45 minutes) the H2O was poured off the gel and the TEMED added to 
the 5% stacking gel solution. This was then mixed and poured on top of the 10% gel 
until it overflowed the top of the glass plates, and the well comb was inserted. 
Once the gel was set, the well comb was removed and the gel placed in sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) apparatus and 1× running 
buffer (see Table 15 Recipes for running buffer and transfer buffer. 500 ml of 1 × running 
buffer is required per tank, and 1 L of 1 ×transfer buffer required for each transfer tank.) 




Prepared protein samples were loaded into the wells of the gel in the SDS-PAGE 
apparatus with 1× running buffer. One well was loaded with 7 µl of pre-stained full-
range Rainbow molecular weight ladder (GE Healthcare). The gels were then run at 
120-200 V until the dye reached the end of the gel. 
2.11.6 Protein transfer 
The gel containing the separated proteins was removed from the glass plates, the 5% 
stacking gel removed, and placed in transfer buffer (see Table 15). Amersham Hybond-
ECL nitrocellulose filter (GE Healthcare) was then cut to size and dipped in transfer 
buffer (Table 15) before being placed on top of the 10% gel. This was then sandwiched 
between two sheets of 3MM blotting paper (Whatman) which had been dipped in 
transfer buffer, and transfer buffer soaked sponges. This was placed into the plastic 
transfer supports and placed into the transfer tank so that the filter was between the gel 
and the positive electrode. Transfer buffer was added to the tank and it was run at 100 
V for 1 hour. After transfer, the filter was carefully removed from the transfer supports 
and placed in Tris Buffered Saline with 0.1% Tween (TBS/T, Sigma) until probing. 
2.11.7 Antibody probing of nitrocellulose filter 
The nitrocellulose filter was blocked in 5% milk powder in TBS/T for 1 hour at RT with 
agitation. 3× 5 minute washes in TBS/T were then performed and the primary antibody 
(diluted in 5% milk powder in TBS/T) was added (see Table 16). This was incubated 
O/N at 4°C with agitation. The filter was then washed 3× 5 minutes in TBS/T and 
incubated with HRP-linked secondary antibody in TBS/T for 1 hour at RT with agitation 




Table 14 Recipe to make up 5% and 10% polyacrylamide gels for Western blotting. 
 
Table 15 Recipes for running buffer and transfer buffer. 500 ml of 1 × running buffer is required 
per tank, and 1 L of 1 ×transfer buffer required for each transfer tank. 
 
 
Table 16 Antibody incubation conditions for protein expression analysis using Western Blotting 
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2.11.8 Signal detection 
The standard electrochemiluminescence (ECL) detection reagents (GE Healthcare) were 
prepared according to manufacturers’ instructions. The filter was incubated with 2 ml 
of the reagents at RT for 1 minute then excess ECL reagent removed and the filter 
placed in an X-ray cassette. The X-ray film (Fujifilm Super RC, blue background) was 
exposed in a dark room under safe light conditions and the film processed using an 
automatic processor (Xograph Compact X4 automatic X-ray film processor). A number 
of exposure times were attempted to produce a clear image. The developed film was 
then overlaid onto the filter and the band size measured against the molecular weight 
ladder to ensure the correct protein had been detected. 
2.11.9 Stripping the filter 
The filter could be re-used for probing with other antibodies, but if the protein of 
interest was of a similar size to that previously detected (for example phospho-AKT and 
total-AKT were the same size) the filter was stripped between probing. 20 ml of 
stripping buffer (1.2 ml 1 M Tris pH 6.8, 400 mg SDS made up to 20 ml in dH2O) was 
added to the membrane with 70 µl β-mercaptoethanol. This was incubated at 55°C for 
30 minutes with agitation and then the filter removed and re-probed as described in 
section 2.11.7. 
2.11.10 Confirmation of equal loading 
The filter was re-probed with β-actin antibody to ensure any changes in phospho-AKT 










 Intestinal organoid culture 2.12
The method outlined below for intestinal organoid culture has been adapted from the 
method originally presented by Sato et al., in order to increase efficiency (Sato et al. 
2009). 
2.12.1  Isolation of intestinal crypts 
15 cm of small intestine was flushed through with HBSS containing 1× 
penicillin/streptomycin (Invitrogen). The intestine was then opened longitudinally and 
scraped firmly using a glass cover slip in order to remove the villi. Once scraped, the 
intestine was chopped into 0.5 mm pieces and placed in 25 ml HBSS containing 1× 
penicillin/streptomycin and incubated for 15 minutes at RT. This solution was gently 
shaken then transferred into a primary tissue culture hood. All of the remaining steps 
were carried out in sterile conditions. The media was removed from the pieces of 
intestine, which were then washed gently 5 times in HBSS. The intestine was 
resuspended in 10 ml 8 mM EDTA in HBSS and incubated at RT for 5 minutes. The 
solution was then shaken vigorously and the EDTA in HBSS removed. The intestine was 
again suspended in 10 ml 8 mM EDTA in HBSS and incubated on ice for up to 30 
minutes. This was shaken vigorously and the solution removed and retained as the first 
crypt-containing fraction. This fraction was immediately diluted 1:1 in DMEM/F12 
containing Glutamax. 15 ml HBSS was added to the intestine and again shaken 
vigorously, this fraction added to the first and repeated until four fractions had been 
collected. The collected crypts were then spun at 6000 rpm for 5 minutes to remove 
single cells and resuspended in 10 ml DMEM/F12 containing Glutamax. This was then 
spun at 7000 rpm for 3 minutes and the pellet resuspended in 10 ml DMEM containing 
Glutamax and passed through a 70 µm cell strainer to remove clumps.  
2.12.2  Counting and seeding crypts 
The number of crypts within three 10μl aliquots were counted and the appropriate 
volume of solution to seed 60 wells at 200 crypts per well was calculated. This volume 
was taken then spun at 7000 rpm for 3 minutes and first resuspended in 20 µl 
DMEM/F12 (Invitrogen) (due to difficulty of resuspending directly into Matrigel) 
followed by dilution into the appropriate volume of Matrigel (BD Biosciences). Plates 
were pre-warmed in the incubator prior to seeding. 96 well Nunclon U-bottom plates 
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were seeded with 10 μl Matrigel, and 24 well Nunc plates were seeded with 50 μl 
Matrigel. 
2.12.3  Organoid growth media 
100 µl organoid growth media (Table 17) was then added to each well of 96 well plates, 
and 500 μl to each well of 24 well plates and the plates returned to the incubator 
immediately. Media was changed every two days. 
 
Table 17 Recipe for 100 ml of complete organoid culture medium including all growth factors. 
2.12.4 Organoid formation efficiency assay 
30 wells of a 96 well plate were seeded at 200 crypts/well in 10 μl Matrigel per well in 
each of two plates (one for the organoid formation assay, another for the PrestoBlue 
viability assay). Three batches of media were made up, one with 665 ng/ml R-spondin 
(R&D Systems), another with 332 ng/ml and the third with 0 ng/ml. 10 of the seeded 
wells of the 96 well plate were given each of the three concentrations of media. Media 
was changed every two days. 
The plate was read at day 1, day 3, day 5, day 7, day 9 and day 11 using the Gelcount 
(Oxford Optronix) machine and software. Data of average size was used from all of the 
readings in order to produce the growth curves whilst only data from day 1 and day 11 
were counted and analysed to produce a readout for the proportion of seeded crypts 
which grew into organoids. The CHARM settings (which define the thresholds for 
automated organoid identification through a number of different parameters) for each 
day and genotype can be seen in Table 18. When high quality images were required, a 
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preheated 24 well plate was also seeded at a density of 200 crypts per well in 50 µl 
matrigel per well and images taken daily for 14 days.  
2.12.5 PrestoBlue viability assay 
10 μl of Prestoblue (Invitrogen) was added per 100 μl media to each of the 30 wells in 
one of the 96 well plates and 3 extra wells were filled with 100 μl media and 10 μl 
Prestoblue without any cells as a negative control. This was incubated at 37°C for 2 hrs 
and then 50 μl of the media removed and placed into a black 96well flat bottomed plate 
(ThermoScientific 11359163). This was then read in a fluorescence plate reader. 
Relative fluorescence was calculated by subtracting the average of the negative controls 
from each of the well readings, then comparing the average of 10 wells from each R-









Table 18 CHARM settings devised for the detection of dissociated crypts and grown organoids over an 11 day period. Different settings were used to 
detect wildtype-like organoids and cyst-like organoids. 
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2.12.6 Fixing Intestinal Organoids for Immunohistochemistry 
From a 24-well plate, matrigel was disrupted using a 1 ml pipette tip and the matrigel 
pipetted up and down to free the organoids from the matrigel. It was then pipetted into 
a microtube. In a 96-well plate the wells were scraped using a 200 μl tip and then 
pipetted straight into a microtube, disrupting the Matrigel by abrasing the microtube 
over a microtube rack. When few organoids were present, the pipette tips were soaked 
in 0.1% BSA in PBS prior to use, to prevent organoid loss to the pipette tip surface. 
The organoids were centrifuged at 7000 rpm for 5 minutes then the supernatant and 
the clear layer of matrigel were carefully removed and discarded. 800 μl of formalin was 
then added to the organoids and the pellet broken up into the formalin by running along 
a microtube rack. This avoided unnecessary pipetting, which could cause organoid loss, 
and sonication, which could disrupt the structure of the organoid. Following 1 hour 
incubation on ice, the organoids were centrifuged for a further 5 minutes at 7000 rpm 
and the supernatant and any remaining matrigel removed. The organoids were 
resuspended in 70% EtOH (avoiding pipetting) and incubated on ice for a further 1 
hour. 
The organoids were centrifuged for 3 minutes at 7000 rpm and the EtOH removed and 
the organoids resuspended in 70 μl of Histogel (ThermoScientific) (pre-heated to 70°C) 
and placed in a specially made mould on top of parafilm and allowed to set (typically 3-
5 minutes). The pellet was then removed from the mould and stored in 70% EtOH prior 










 Data Analysis 2.13
Raw data obtained from cell counts, tumour grading and qRT-PCR were input into Excel 
(Microsoft) for the calculations of means and standard deviations for graphical 
representation.  
Comparison of means was carried out in SPSS data analysis software. All analysed data 
was tested for normality using the Shapiro-Wilk test. Normally distributed data was 
tested for significance using a two-tailed T test, and data which was not normally 
distributed was analysed using Mann-Whitney U Test. 
Survival data was analysed using Kaplan-Meier plots to present the data and 




3 Development and Optimisation of a novel ISC function assay 
 Introduction 3.1
The importance of understanding the relationship between changes in the ISC 
compartment and tumourigenesis was highlighted by the observation by Baker et al., 
that the ISC is the cell of origin of intestinal cancer (Barker et al. 2008). This was found 
by comparing the effects of conditional deletion of the tumour suppressor Apc using two 
different Cre-recombinases. One of these specifically recombined within the ISC 
compartment (using an Lgr5-linked Cre recombinase). The other Cre drove 
recombination efficiently within the proliferative crypt compartment but only very 
inefficiently within ISCs (using AH-linked Cre recombinase and a specially designed 
induction method). These experiments showed that loss of Apc from the ISC 
compartment initiated the formation and growth of multiple adenomas, whereas loss of 
Apc from the other cell types within the crypt produced fewer, smaller lesions.  
In addition to these experiments, it has been observed that in a model of early 
tumourigenesis, Apcflox/flox mice, one of the earliest characteristics observed following 
deletion of Apc is an increase in undifferentiated cell types (Sansom et al. 2004). Taken 
together, these experiments suggest that perturbation of the ISC compartment could 
play an essential role in tumourigenesis.  
In order to increase our understanding of the relationship between changes in the ISC 
compartment and tumourigenesis it is necessary to be able to accurately assess the ISC 
compartment.  
As previously discussed in section 1.3.1 there are a range of ISC markers which can be 
used for the identification of the presumed stem cell population (Barker et al. 2007; 
Besson et al. 2011; Potten et al. 1974; Sangiorgi and Capecchi 2008; van der Flier et al. 
2009a; van der Flier et al. 2009b). These markers have proven extremely useful when 
studying the mis-localisation of expression or expansion of the ISC compartment but are 
informative simply of gene expression patterns, rather than ISC functionality. In order 
to truly assess any changes occurring in the ISC population it is necessary to combine 
expression levels and localisation information of published stem cell markers with a 
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functional assay which can be used to determine whether these cells are capable of 
functioning as ISCs.  
Lineage tracing experiments have been previously very successful in determining 
whether or not a cell which expresses a particular gene is in fact an ISC due to its ability 
to produce daughter cells which can form any of the intestinal epithelial lineages. These 
methods, however, are not capable of comparing the number, location and potency of 
the ISC populations between individual mice of different genotypes. Furthermore, the 
necessity of a stem cell specific Cre to drive LacZ expression in order to perform these 
experiments presents numerous logistical problems, not only with the breeding of many 
mice, but the interference it may have with the required experimental phenotype. In 
order to study changes in ISC functionality between specific genotypes it has been 
necessary to expand our current toolkit for assessing this intestinal compartment. An 
ideal method would assess the functional capacity of ISCs, while being easily 
incorporated into traditional tissue harvesting techniques enabling it to be used in 
conjunction with other mechanisms for assessing the ISC compartment, such as gene 
expression analysis. 
The technique which appeared to hold the most potential as a method for assessing 
changes in the stem cell compartment was that of intestinal organoid culture. The 
method of culturing intestinal organoid structures in vitro, devised by Sato et al., is now 
well established as a useful tool to study crypt homeostasis (Sato et al. 2009). This 
method simply isolates intestinal crypts, and using knowledge of intestinal growth in 
vivo, simulates the conditions required for growth with the addition of the growth 
factors EGF and Noggin. Crypts are cultured in laminin-rich Matrigel in the presence of 
Rspo1. Epidermal Growth Factor (EGF) is associated in vivo with intestinal proliferation, 
and inhibition of BMP signalling via transgenic expression of Noggin is sufficient to 
induce a significant expansion in crypt numbers (Haramis et al. 2004). Sato et al. noted 
that intestinal cells undergo programmed cell death when isolated from normal 
intestine, an effect which can be overcome by the addition of laminin, which is present 
in vivo at high levels at the base of the intestinal crypt. Culturing the intestinal organoids 
in laminin-rich Matrigel not only prevents anoikis by providing the required laminin, 
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but also supports the 3-dimensional structures of the organoids thereby enabling 
epithelial cell growth. 
R-spondin1 (Rspo1) is a Wnt activator found endogenously at the base of the intestinal 
crypt. It has been shown that R-spondins interact with Lgr5 (de Lau et al. 2011), and it 
has recently been shown that, in vivo, Rspo1 is a ligand of the widely accepted ISC 
marker Lgr5 and its homologue Lgr4 (Schuijers and Clevers 2012). In organoid culture, 
the addition of Rspo1 enhances activation of the Wnt-signalling pathway specifically 
within Lgr5+ cells (Sato et al. 2010). Apc mutants have been shown to be capable of 
organoid formation in the absence of Rspo1, indicating that reliance on Rspo1 could be 
used as a measure of Wnt-signalling activation within the intestinal crypt. 
Once isolated, the crypts capable of regenerating and producing organoids in culture are 
able to do so as a consequence of containing functional ISCs. There remains a degree of 
inefficiency within this system, and consequently not all crypts are capable of producing 
organoids. However, increases in efficiency of organoid formation are likely to be 
concomitant with an increase in the number of ISCs per crypt and/or with augmented 
Wnt-activated stem cells per crypt. This can be extrapolated so that the number of 
organoids which grow from a known number of crypts seeded may be used to readout a 
level of “stemness” within each crypt. 
Not only is organoid culture a technically challenging method to initially establish 
within the laboratory, but the use of it in this manner poses more obstacles. The main 
difficulties that we aim to overcome are;  
1. Accurately calculating the number of seeded crypts. This is essential for the 
calculation of the percentage of seeded crypts which form organoids and subsequent 
determination of the level of “stemness” 
2. Accurately and efficiently counting the number of organoids grown in order to 
minimise the time outside of the specific culture conditions of the incubator, as 
organoids are extremely sensitive to changes in culture conditions 
3. Accurately quantifying the differences between the types of organoids which can 
grow.  Organoids grown from Apcflox/flox mice are reported to be of a different 
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morphology to those grown from wildtype, indicating that Wnt-activation alters the 
way in which organoids grow. Quantifying these differences is required to assess the 
level of Wnt activation in the ISCs in the crypts 
 Results 3.2
 Identifying and counting crypts 3.3
As previously mentioned, in order to calculate an accurate organoid formation 
efficiency, it is essential to have reliable data on the number of crypts seeded. In order 
to do this a counting method was optimised. Once the crypts were isolated and 
resuspended in 10 ml media, 3 x 10 µl samples were taken and counted. Only parallel 
rows of epithelial cells with a defined edge were counted (Figure 3.1). Variation in the 
quality of crypt preparations between mice was large, and the number of non-crypt 
epithelial cells (such as villus cells) is variable. Hence, by specifically counting crypts, 
rather than single cells, any other epithelial cells present do not skew the data. A further 
advantage of seeding crypts rather than single cells is that the efficiency of organoid 
formation from unsorted single cells is low (efficiency <0.003%, data not shown) such 
that very small variation can have a huge impact on the data, whereas organoid 
formation efficiency from crypts is much higher. 
Initially 100 crypts were seeded per 50 µl Matrigel in each well of a 24 well plate. The 
number of crypts per well were counted 3 times manually. Due to the 3-dimensional 
nature of the Matrigel crypts were present in various planes of vision and this was a 
source of variation between counts. Furthermore, this method of counting is a slow 
process, and results in the removal of the plates from the incubator for extended 





Figure 3.1 A typical crypt faction at counting. Red circles indicate crypts that would be counted. 
Although there is other cell debris and potentially fractions of intestinal crypts, crypts are only 
counted when there are clearly two parallel rows of epithelial cells which have a clear and 
distinct edge. Black bar represents 50 µm. 
 
Figure 3.2 The number of crypts counted in 6 wells when seeded at 100 crypts per well. Each 






The solution to this problem was to use an automated colony counter to count the 
organoids with greater speed and accuracy. In order to do this, the organoids have to be 
grown in a single plane of vision. This was achieved by using 96-well U-bottom plates 
and seeding 10 µl Matrigel per well. Using such a small volume in a U-bottom well 
prevented the Matrigel from setting in a dome shape. The newly designed plate reader 
and software used (Gelcount, Oxford Optronix) captured images of each well of the plate 
and automatically processed these to flatten the images from the U-bottom plate. 
Transferring the organoid culture from 24-well to 96-well plates, facilitated the 
production of a high throughput system in which accurate automated counting could be 
performed, removing much of the propensity for error in the system. 
 High variation between seeding densities in wells of 96-well plate 3.4
The conversion to growing the organoids in 96 well plates and reducing the seeding 
volume from 50 µl to 10 µl, resulted in a higher variation in seeding density between 
wells (Figure 3.3). In order to minimise the variation in organoid formation efficiency 
between wells, the problem of variations of seeding density between wells had to be 
addressed. This problem was overcome by using the automated plate reader to count 
wells individually and provide an accurate day 1 count. The number of organoids grown 
can thus be expressed, with confidence, as a percentage of the actual (rather than 
assumed) number of crypts present at day 1 for reach well. In order to assess the utility 
of this method it was necessary to ascertain whether seeding density, which clearly 
varied between each well, had an impact on this readout, see section 3.6. 
 Establishing CHARM settings for counting initially seeded crypts and number 3.5
of organoids at day 11 
In order to enable the Gelcount machine to perform automated organoid counts on 
images taken from 96 well plates, a script, entitled CHARM settings, had to be 
established. In order to establish these CHARM settings, threshold values for specific 
parameters such as optical density, size, circularity and quality of edge of objects 
detected within the well were set to enable the Gelcount programme to determine what 
type of object to count as a live organoid. The number of organoids within a well were 
manually counted and identified by the presence of an organised structure, and it was 
decided if they were alive or dead based on the quality of the “edge” of the organoid. 
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Dead organoids appear to lose the organisation of their outer edge and are less optically 
dense because of this. The parameters of the CHARM settings were adjusted until the 
Gelcount programme consistently counted organoids within 10% accuracy of the 
manual counts (see Figure 3.4). As both the manual counts and the Gelcount generated 
organoid counts are based on morphological criteria alone, there remains a propensity 
for error within the system, for example, an organoid may appear alive but actually be 
dead. In order to overcome this problem, the CHARM settings were adjusted for each 
day post seeding, and the size threshold altered, so that the only organoids within the 
well which were counted were those which had actively grown. This gives a level of 
accuracy and reproducibility which cannot be achieved through the use of manual 
counts alone, without measuring the size individual organoids. Final CHARM settings 
can be seen in section 2.12.4. 
 Seeding density does not affect the percentage of organoids which grow 3.6
The rate of organoid growth is greatly dependent on the presence or absence of the 
Wnt-activator Rspo1. Furthermore, Paneth cells are known to secrete other Wnt-
activators which can impact on ISC function and number and thereby influence 
organoid growth. It therefore follows that the initiation and subsequent growth rate of 
organoids could be influenced by the density of the seeded crypts. If the proportion of 
organoids formed per well is dependent on the initial seeding density, then the seeding 
density will need to be the same between wells and between mice, which as previously 
mentioned is difficult to achieve using 96-well plates. Initial counts of actual crypt 
number seeded into each well of a 96-well plate showed a wide variation in seeding 
density per well (Figure 3.3). In order to assess any alterations in growth rate due to 
initial seeding density within this range, 20 wells were seeded with either 100 crypts, or 
400 crypts. The number of crypts seeded was counted on the Gelcount machine at day 1 
to establish the exact number per well, and the number of organoids over 150μm per 
well were counted at day 11 using the Gelcount machine. There was no significant 
difference in the percentage of crypts seeded which grew into organoids by day 11 
when wells with an initial seeding density of less than 200 crypts per well (range 27-
200) were compared to those with an initial seeding density of 300-500 crypts per well 
(Figure 3.5). Thus differences in the seeding density within this range do not affect the 
percentage of organoids which grow. 
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 Number of wells of each genotype required to produce an accurate readout of 3.7
stemness 
In order to assess the number of wells of organoids required to give an accurate reading 
of organoid forming efficiency, 20 wells of a 96-well plate were seeded with 200 crypts 
per well and the percentage of crypts which formed organoids by day 11 was calculated 
per well. Using the running mean enabled the calculation of the number of wells 
required for an accurate reading of organoid forming efficiency. As organoid culture is 
both expensive and labour intensive, it is necessary to seed the least number of wells 
possible while still seeding enough to get an accurate result. It was found that the 
running mean had stabilised at around 6-7 wells (Figure 3.6) and so it was decided that 
10 wells would be seeded to ensure accuracy. 
 
 
Figure 3.3 GelCount counts of 10 wells of a 96 wells plate were seeded at a predicted 100 crypts 
per 10 µl in each well. Machine counts showed that the number of crypts actually present within 





Figure 3.4 Screenshot of GelCount programme when counting organoids using specially selected 
CHARM settings. The red triangles indicate organoids which have been counted based on their 
size, density and complete edge. A quantity of cell debris and dead organoids can also be seen 
within this well. 
 
Figure 3.5 Seeding density within a two-fold range does not affect the percentage of crypts 
which form organoids. 20 wells were seeded with an estimated 100 crypts per well (actual 
values ranged from 27-200) and 20 wells were seeded with 400 crypts (actual range 300-500). 
There was no significant difference in the organoid formation efficiency between crypts seeded 
at 0-200 crypts per well, and those seeded at 300-500 crypts per well, 2-tailed T-test p= 0.086. 





Figure 3.6 Running mean of the percent of crypts which form organoids in 20 wells. The average 





 Crypts from induced Apcflox/flox mice form cyst-like organoids  3.8
To date, Apc deficient organoids have only been studied following the conditional loss of 
Apc within the organoids (Onuma et al. 2013).  Our aim was to develop a system which 
permits the measurement of intestinal crypt “stemness” from the quantification of the 
percentage of seeded crypts which are capable of forming organoids. Therefore, we 
induced Apc loss within the mice using established tamoxifen induction of Cre-
combinase under control of a Villin promoter in order to induce loss of Apc specifically 
within the intestinal epithelium, 3 days prior to initiating the crypt culture. This method 
of forming Apcflox/flox organoids resulted in the development of cyst-like organoids 
forming at day 1-2 (Figure 3.7). The differences between organoid structure and growth 
rate can be visually ascertained, but difficult to quantify, due to the requirement for 
multiple photographs thereby requiring removal of the organoids from the incubator 
for long periods of time. As the Apcflox/flox organoids are different in structure from 
wildtype organoids (Figure 3.8), specific CHARM settings were devised for cyst-like 
organoids, as they are less optically dense, and are more circular than wildtype. The 
CHARM settings were developed by altering the detection parameters until the 
automated counts were consistently within 10% of manual counts. All CHARM setting 
can be found in section 2.12.4. 
3.8.1 Apcflox/flox form two distinct types of organoids 
Organoids grown from Apcflox/flox crypts 3 days post induction form two distinct types of 
organoids. As can be seen from Figure 3.7, all Apcflox/flox organoids are cyst-like in 
structure; however they can be subcategorized into those which have a single layer of 
undifferentiated cells in a regular structure and those which have thick outer layers of 
multiple undifferentiated cells in an irregular and disordered structure (Figure 3.9). 
Both subtypes of Apcflox/flox organoids grew in the absence and presence of Rspo1 and 
occured independently of whether recombination was induced in vivo or in vitro so the 
differences are not due to differential dependency on Rspo1, or incomplete 
recombination of Apc within the intestinal epithelium.  Regions of cells with polarised 
nuclei were observed in both subtypes of Apcflox/flox organoids, which contradicts what is 
observed in vivo whereby Apc deficiency results in loss of cell polarity within the 




Figure 3.7 Images of organoids grown from the crypts of wild type (top row) and induced Apcflox/flox mice taken daily for 14 days. Differences between 




3.8 Wildtype organoids form a regular structure with visible Paneth cells (indicated by the black 
triangle). The crypt structures protruding clearly display polarised cells with clear organisation 
enabling mitotic cells to move away from the basement membrane towards the interior of the 




3.9 Organoids derived from Apcflox/flox mice form cyst-like structures of two types. This H&E slide 
shows that many organoids (indicated with a black triangle) display edges which are many cells 
thick with large patches of unpolarized cells (insert A), whereas others have a single cell 










3.8.2 Apcflox/flox organoids contain fewer differentiated cell types than wildtype 
organoids 
Wildtype organoids present all the differentiated cell lineages found in vivo within the 
intestinal epithelium. However, organoids derived from Apcflox/flox mice 3 days post 
induction, only rarely stain positive for Alcian Blue, a marker of the mucins produced by 
goblet cells. It must be noted that goblet cells were only observed in Apcflox/flox organoids 
which had been cultured in the presence of Rspo1, and may represent organoids 
derived from intestinal crypts in which there had been incomplete recombination of Apc 
(Figure 3.10). Positive staining for alcian blue was not observed in Apcflox/flox organoids 
which had been grown in the absence of Rspo1, thereby selecting for organoids derived 
from crypts in which recombination of Apc was complete.  
Enteroendocrine cells were detected in wildtype organoids using Grimelius staining, 
although they were rare, however they were not observed in Apcflox/flox organoids under 
any growth conditions (Figure 3.11). 
Interestingly, Paneth cells were observed in Apcflox/flox organoids, although less 
frequently than were observed in wildtype organoids (Figure 3.12). Due to the lack of 
other differentiated cell types in Apcflox/flox organoids it is likely that rather than these 
Paneth cells being the result of differentiation in culture, they represent surviving 
Paneth cells which were present in the crypts when the organoid culture was 
established. Data courtesy of Nadia Panitz indicates that Paneth cells were not observed 
in Apcflox/flox cultures which had been cultured long term and had undergone multiple 
passages. 
These data show that intestinal Apcflox/flox cells with a stem-like phenotype, i.e. able to 
form organoids in culture and a high expression of ISC markers, cannot be described as 





3.10 Alcian Blue stain of wildtype and Apcflox/flox organoids. Multiple goblet cells can be seen in wildtype organoids throughout the structures, 




3.11 Grimelius stain of wildtype and Apcflox/flox organoids. Black arrows indicate enteroendocrine 
cells. Black bars represent 100 μm. 
 
Figure 3.12 Lysozyme IHC of wildtype and Apcflox/flox organoids. Paneth cells are stained brown 





3.8.3 Ki67 is expressed from a higher number of cells from wildtype organoids 
than from Apcflox/flox organoids 
It has been shown that conditional homozygous loss of Apc from the intestinal 
epithelium in vivo results in an increase in levels of cell proliferation (Sansom et al. 
2004). However, counts from IHC staining for the proliferative marker Ki67 in the 
organoids (Figure 3.13) show that a significantly higher percentage of cells are 
proliferating in cultured wildtype organoids than in Apcflox/flox organoids (Figure 3.13) 
(Wildtype 98±2, Apcflox/flox 49±29). This was measured by counting the total number of 
cells per sectioned organoid and representing Ki67 positive cells as a percentage of the 
total number of cells. Individual organoids were classed as a separate “n” value, 
although organoids derived from a minimum of 3 mice were counted for each genotype. 
BrDU stains, (courtesy of Nydia Panitz) show that exposing the organoids to BrDU for 1 
hour prior to fixing, results in a similar proliferative readout (Figure 3.15). 
3.8.4 Apcflox/flox and wildtype organoid cells undergo similar levels of apoptosis 
Levels of apoptosis within the organoids were assessed by expression of the apoptotic 
marker Caspase 3 (Figure 3.16). The percentage of organoid cells which were Caspase 3 
positive showed no significant difference between Apcflox/flox organoids and wildtype 
organoids (Figure 3.17) (Wildtype 0.6±0.6, Apcflox/flox 0.9±0.8). This is in direct contrast 
to the observation made in vivo, namely that loss of Apc results in an increase in 





3.13 A Ki67 IHC on wildtype and Apcflox/flox organoids. Brown cells represent Ki67 positive cells, c 
the vast majority of cells from wildtype organoids were Ki67 positive, and non-proliferating 
cells were extremely rare. In Apcflox/flox organoids both Ki67 positive and negative cells were seen 
frequently. Bars represent 100 μm. 
 
3.14 Percentage of wildtype and Apcflox/flox organoid cells which stain positive for Ki67. Error 
bars represent standard deviation. Wildtype organoids contained significantly more Ki67 cells 





3.15 BrDU IHC of uninduced Apcflox/flox organoids (equivalent to wildtype) and induced Apcflox/flox 
organoids after 1 hour of BrDU exposure. Slides courtesy of Nydia Panitz. There is an observable 
reduction in BrDU uptake from induced Apcflox/flox organoids compared to uninduced. Bars 






3.16 A Caspase3 IHC on wildtype and Apcflox/flox organoids. Caspase 3 positive cells (stained 
brown) are rare in both genotypes. Bars represent 100 μm.  
 
3.17 Percentage of Wildtype and Apcflox/flox organoid cells which are Caspase 3 positive. There 
was no significant difference in the percentage of organoid cells which were caspase positive 






 Apcflox/flox organoids grow faster than wildtype 3.9
Measuring the average diameter of the organoids on alternate days using the GelCount 
programme enabled assessment of the growth rate of the intestinal organoids. 
Organoids derived from Apcflox/flox crypts grew faster than those derived from wildtype 
crypts (Figure 3.18), however, by day 11 the sizes were not significantly different and 
there was no difference between the numbers of cells per organoid (as counted on H&E 
sections) at day 11 (Figure 3.19) (Wildtype 172±141, Apcflox/flox 159±91). It should be 
noted that sectioning of paraffin embedded organoids results in a high variation of 
visible cells per organoid due to differences in the plane of the section. 
3.9.1 Apcflox/flox organoids have higher levels of nuclear β-catenin than wildtype 
In vivo, loss of Apc is associated with a dramatic increase in Wnt-signalling, which is 
highlighted by an increase in nuclear β-catenin. This situation is mimicked in vitro, 
where intestinal organoids derived from Apc deficient crypts are high in nuclear β-









3.18 Apcflox/flox organoids grew faster than wildtype, but were not significantly larger at day 11. 
Average organoid diameter was measured using Gelcount machine. Ten wells of each genotype 
were measured. Error bars represent standard deviation. * represents p<0.05 at that time point 
using 2-tailed T-test. 
 
3.19 Wildtype and Apcflox/flox organoids have the same number of cells at day 11. Cell counts were 
performed using H&E sections of paraffin embedded fixed organoids. There was no significant 
difference in the total cell counts between the two genotypes, 2-tailed T-test p=0.651. Error bars 





3.20 β-catenin immunohistochemistry on wildtype and Apcflox/flox organoids, brown nuclei 
represent nuclear β-catenin. Nearly 100% of Apcflox/flox organoid cells are positive for nuclear β-
catenin, whereas the levels of nuclear β-catenin in wildtype organoids are variable. Nuclear β-












 Assessing changes in the ISC compartment as a result of Apc loss using 3.10
traditional gene expression methods 
Using qRT PCR to determine the relative expression levels of a range of intestinal stem 
cell markers shows an increased expression of these markers in Apcflox/flox intestinal 
tissue when compared to wildtype intestinal epithelium (Figure 3.21). The most 
commonly used markers of the intestinal stem cell compartment, Lgr5, Ascl2, Olfm4, 
Msi1 and Bmi1 (Barker et al. 2007; Kayahara et al. 2003; Sangiorgi and Capecchi 2008; 
van der Flier et al. 2009a; van der Flier et al. 2009b) were all significantly upregulated 
following loss of Apc from the intestinal epithelium. Intestinal epithelium was extracted 
using Weiser preparation to minimise interference from the stromal and muscle 
compartments of the intestine. 
In situ hybridisation is a commonly used method for identifying the location of the ISC 
compartment (Ziskin et al. 2012). In situ hybridisation for the ISC markers Ascl2 and 
Olfm4 shows an expansion of the ISC compartment following Apc loss. These in situ 
hybridisations support the qRT-PCR data and indicate that loss of Apc does not simply 
lead to an increase of expression of these markers, but also a mis-localisation. These 
data taken together indicate an expansion of intestinal stem-like cells as a result of loss 






3.21 qRT-PCR results of relative expression levels of a range of proposed intestinal stem cell 
markers from wildtype versus Apcflox/flox intestinal epithelial cell preparation. * indicates p<0.05, 
** indicates p<0.01 using 2-tailed T-test. 
 
3.22 In situ hybridisation for stem cell markers Olfm4 and Ascl2 in wildtype and day 4 Apcflox/flox 
murine intestine. Mis-localisation and increase of expression was observed following Apc loss. 




 A higher percentage of Apcflox/flox crypts are capable of forming organoids than 3.11
wild type crypts and grow in the absence of Rspo1 
Using the specially adapted CHARM settings it was possible to directly compare 
efficiency of organoid formation between wildtype and Apcflox/flox crypts. It was found 
that the percentage of Apcflox/flox crypts which had formed organoids by day 11 was more 
than 2 fold greater than that seen in wildtype crypts (Figure 3.23) (Wildtype 16±8, 
Apcflox/flox 38±11). These data support the qRT-PCR and in situ hybridisation results 
which suggest an increase in number of functional ISCs. 
The number of Apcflox/flox crypts which form organoids was found to be independent of 
the presence of Rspo1 in the media, whereas wildtype organoids did not form without 
Rspo1 (Figure 3.24), demonstrating that not only are there more ISCs in Apc deficient 











3.23 Organoid forming efficiency of wildtype and Apcflox/flox crypts. Crypts deficient for Apc are 
significantly more efficient at forming organoids, 2-tailed T-test p=0.004. N>6. 
 
3.24 Organoid forming efficiency of wildtype and Apcflox/flox crypts in the absence of Rspo1. 
Crypts deficient for Apc are capable of forming organoids in the absence of Rspo1, whereas 






 Using the organoid culture method as a readout of Wnt-activation in the 3.12
Intestinal Stem cell compartment 
As the ability to grow in vitro independently of Rspo1 concentration could represent a 
readout of the level of Wnt-activation of the ISCs, the ability to quantify the level of 
Rspo1 dependency of the crypts of various genotypes became essential. As previously 
discussed the addition of the growth factor Rspo1 results in the activation of the Wnt-
signalling pathway specifically within the Lgr5+ ISC population. It can therefore be 
inferred that genotypes of organoids which are more capable of growing in the absence 
of Rspo1 contain more highly Wnt-activated ISCs.  
Using the plate reader to count the number of organoids each day post seeding when 
cultured in the absence of Rspo1 is not currently possible, as the CHARM settings cannot 
differentiate between organoids which are alive or recently dead (as the size and 
density of organoids does not alter for a few days after death). Therefore in order to 
quantify the ability of intestinal organoids to grow in the absence of Rspo1 it was 
necessary to explore the use of cell viability assays. 
The PrestoBlue cell viability reagent uses the reducing ability of the cytosol in living 
cells to reduce a blue, non-fluorescent, cell-permeant compound into a red, highly 
fluorescent compound, enabling the detection of changes in levels of absorbance 
without affecting cell viability. This enables the measurement of cell viability in the 
presence or absence of Rspo1 without damaging the organoids. 
Previous culturing of organoids has shown that wildtype crypts can survive for 2 days in 
the absence of Rspo1, so the PrestoBlue assay was used on day 3 for 2 hours at 3 
different Rspo1 concentrations. The normal culture conditions include Rspo1 at 6.5 
μg/ml, and the fluorescence produced by PrestoBlue exposure to 10 wells of these 
organoids was used as a baseline for mitochondrial activity. The fluorescence measured 
as a result of PrestoBlue exposure to wells containing organoids grown with the other 
Rspo1 concentrations (3.25 μg/ml and 0 μg/ml) was normalised as relative to those 




 Mitochondrial activity within Apcflox/flox organoids is not affected by Rspo1 3.13
concentration whereas wild type organoids respond in a dose dependant 
manner 
Calculating relative mitochondrial activity using the PrestoBlue assay for wildtype vs 
Apcflox/flox organoids shows that loss of Apc renders organoids independent of Rspo1 for 
their survival and growth. As an Lgr4/5 ligand (Wang et al. 2013a), Rspo1 activates the 
Wnt-signalling pathway specifically within Lgr4/5 expressing cells, identified as the 
ISCs. Ability to grow in the absence of Rspo1 must therefore reflect the presence of ISCs 
with already highly activated Wnt-signalling, as would be expected from ISCs derived 




3.25 Relative mitochondrial activity of wildtype and Apcflox/flox organoids in different Rspo1 
concentrations using the PrestoBlue assay. ** indicates p<0.001 using 2-tailed T-test. 
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 Assessing the utility of the organoid formation assay using a Cited-1 deficient 3.14
mouse model  
In order to assess whether the stem cell functionality assay could provide useful 
insights into the early stages of tumourigenesis, we must be able to demonstrate that it 
can detect more subtle changes in the ISC compartment than those caused by 
homozygous deletion of Apc. Also, as loss of Apc results in large, cyst-like structures as 
opposed to differentiated organoids, the method must also be able to distinguish 
between genotypes which have a similar phenotype in vitro. 
3.14.1 Cited-1 
It was shown in a mouse melanoma cell line that the bi-functional transcriptional 
cofactor encoded by Cited-1 plays a role in activation and repression of expression of a 
wide range of target genes (Shioda et al. 1996; Yahata et al. 2001). The complex role 
that Cited-1 could play in tumourigenesis was hinted at by its ability to inhibit Wnt 
signaling but activate Smad-4 dependent transcription resulting in enhanced 
TGFβ/BMP signaling (Plisov et al. 2005).  A role for CITED-1 in tumourigenesis has also 
been implicated in several human cancers such as nephroblastoma, melanoma and 
Wilm’s tumours where disregulation of CITED-1 expression is observed (Lovvorn Iii et 
al. 2007; Nair et al. 2001). In a mouse model of mammary cancer (MMTV-
Cre/FloxNeoNeuNT), it was shown that Cited-1 expression is elevated within the 
tumours  where it functions alongside Egr2 to drive expression of the oncogene ErbB2 
(Dillon et al. 2007). 
Microarray data from this laboratory has shown that loss of Apc immediately results in 
an increase in expression of the gene Cited-1, an upregulation that is dependent on the 
presence of functional C-myc. Loss of the Wnt target C-myc in an Apcflox/flox mouse not 
only rescues the phenotype of Apc loss (Sansom et al. 2007), but also returns Cited-1 
expression levels to those found in wildtype. Our laboratory has recently shown that an 
upregulation of CITED-1 is observed in human colorectal cancers, and that loss of Cited-
1 expression in the Apc heterozgygous mouse model of colorectal tumourigenesis, 
Apcmin/+, increases survival via a reduced intestinal tumour burden (Méniel et al. 2013).  
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Loss of Cited-1 alone does not result in intestinal tumourigenesis, but does markedly 
increase levels of dephosphorylated β-catenin within the intestinal epithelium. 
Interestingly, loss of Cited-1 in the context of homozygous Apc loss using AhCre Apcflox/flox 
mice results in a further increase in both dephosphorylated β-catenin and associated 
Wnt-target genes (Méniel et al. 2013).  
The subtle deregulation of Wnt signaling observed in Cited-1 null intestinal epithelia 
without grossly affecting the intestinal phenotype, provides a perfect model for testing 
the ability of the organoid formation assay to analyze small changes in the ISC 
compartment that may arise as a result of Wnt-deregulation. 
 Cited-1 loss and the ISC compartment 3.15
qRT-PCR was used to show that expression of the ISC markers Lgr5, Msi1 and Ascl2 were 
significantly higher in the intestinal epithelia of Cited-1 null mice than wildtype 
(p<0.05). There was a trend for increased expression of the markers Bmi-1 and Olfm4 
but it was not significant at n=6 (p>0.05). 
In situ hybridisation revealed that expression of the intestinal stem cell marker Olfm4 
was still limited to the crypt base in Cited-1 null mice, and the probe signal appears no 
different to that observed in wildtype. This indicates that there is no mislocalisation of 
the ISC compartment, however, there could be an increase in ISC number around the 
base of the crypts, which would not be visible from the cross-sections of the crypt 
structure shown in Figure 3.27. Also, it should be noted that Olfm4 is one of the ISC 
markers whose expression is not significantly upregulated as a result of Cited-1 loss. 
Olfm4 was chosen for in situ hybridisation as in situ hybridisation for this marker results 
in a tighter staining pattern than that observed with Ascl2. In addition to this, Olfm4, 
unlike Ascl2, is not a direct Wnt target gene, and so changes in expression pattern are 
less likely to be due to an increase in Wnt-signalling as opposed to an increase in ISC 







3.26 qRT-PCR results of relative expression levels of a range of proposed intestinal stem cell 
markers from wildtype versus Cited-1-/- intestinal epithelial cell preparation. * indicates p<0.05, 
** indicates p<0.01. N=6 
 
 
3.27 In situ hybridisation for the intestinal stem cell marker Olfm4 in wildtype and Cited-1-/- 







3.15.1 Cited-1-/- organoids 
Cited-1-/- organoids are phenotypically identical to wildtype (Figure 3.28), displaying 
multiple crypt-protrusions containing goblet cells, enteroendocrine cells and Paneth 
cells (images not shown). As there were no gross differences between Cited-1-/- 
organoids and wildtype organoids, the same CHARM setting for organoid counting and 
measurement of growth rates were used. 
3.15.2 Cited-1-/- crypts form organoids more efficiently than wildtype 
The organoid formation assay revealed that a significantly higher percentage of Cited-1-
/- crypts were capable of forming organoids than wildtype (Figure 3.29) (Wildtype 14±5, 
Cited-/- 21±3). This supports the expression marker data which indicates that loss of 
Cited-1 results in an expansion of the ISC compartment. The organoid formation 
efficiency of Cited-1-/- crypts was still significantly lower than that seen in Apcflox/flox 
crypts. 
3.15.3 Cited-1-/- organoids are Rspo1 dependent 
The PrestoBlue mitochondrial activity assay shows that Cited-1-/- organoids are 
dependent on the presence of Rspo1 in the culture medium for their growth and 
development in a dose dependent manner equivalent to that of wildtype. This indicates 





3.28 H&E of a Cited-1-/- organoid. Cited-1-/- organoids are phenotypically identical to wildtype 
organoids displaying multiple crypt-like protrusion containing differentiated cell types. Bars 









3.29 Organoid formation efficiency of Cited-1-/- compared to wildtype crypts. Loss of Cited-1 
resulted in a significant increased organoid formation efficiency, 2-tailed T-test p=0.026. N>4. 
 
3.30 Relative mitochondrial activity of wildtype and Cited-1-/- organoids in differenct Rspo1 




 Discussion  3.16
The final protocol for the ISC functionality assay with the CHARM settings used can be 
found in section 2.12.4 of Materials and Methods.   
3.16.1 Apcflox/flox crypts form two distinct types of organoids 
The difference between the two types of organoids formed from Apc deficient crypts 
indicates that potentially there are two types of cells in these crypts capable of forming 
organoids. This could represent the two different ISC populations which, once Wnt-
activated as a result of Apc loss, can both grow in culture (Yan et al. 2012). Alternatively 
it could represent the difference between organoids grown from Wnt-activated ISCs and 
those grown from highly Wnt-activated cells of the proliferative compartment of the 
crypt which are not “true” ISC.  
As both types of organoids are observed when Apc was recombined in vitro as well as in 
vivo, it is difficult to assess why they are different. One potential method would be to 
sort Apc deficient intestinal cells based on expression of Lgr5hi Ckitlo and Lgr5lo Ckithi 
using Lgr5 expression as a marker of the ISC population and Ckit expression as a 
marker of the proliferative zone. This would enable assessment of both the efficiency of 
organoid formation and the different types of organoid which each cell type can 
produce. The difficulty of this method is the likelihood of plasticity within the system, 
especially within Apc deficient tissue, whereby stem cells are defined by their 
microenvironment, and all cells are capable of becoming “stem-like” given exposure to 
specific conditions. This plasticity means that some cells can be more “stem-like” than 
others, and measures of “stemness” are difficult to quantify. 
It was also noted that Apcflox/flox organoids often contain polarized cells, whereas 
Apcflox/flox intestinal tissue in vivo does not. This is most likely due to the environment in 
vitro whereby sealed cyst-like organoids have a clearly defined “inside” and “outside” 
with the outside being rich in growth factors and the inside being the area of cell death 
and so high in apoptotic signals. This clear gradient of signals may give the cells 
stronger positional cues than occur in vivo when a high level of proliferation occurs. 
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3.16.2 Apcflox/flox organoids contain fewer differentiated cells than wildtype 
The observation that Apcflox/flox organoids contain fewer differentiated cells than 
wildtype matches the in vivo data whereby loss of Apc results in an increase in 
undifferentiated cell types. No enteroendocrine cells were observed in Apcflox/flox 
organoids and goblet cells were only observed in Apcflox/flox organoids which had been 
cultured in the presence of Rspo1. The organoids containing goblet cells most likely 
represent organoids derived from crypts in which incomplete recombination of Apc had 
occurred, as these organoids would not survive in the absence of Rspo1.  
By contrast, Paneth cells were occasionally observed in Apcflox/flox organoids which had 
been cultured in the absence of Rspo1. As these organoids were only cultured for 11 
days it is likely that the observed Paneth cells are those from the original crypts which 
were seeded that survived rather than ones which had differentiated in culture. Paneth 
cells are long-lived and can survive for up to 20 days (Ayabe et al. 2004). This 
hypothesis is supported by microscopic analysis of fixed Apcflox/flox organoids which have 
undergone long-term culture and passage (courtesy of Nydia Panitz) and did not 
revealed the presence of any Paneth cells. 
As previously discussed, the inability of Apcflox/flox organoids to differentiate indicates 
that they are not derived from true ISCs, as the definition of an ISC is its ability to 
produce all the differentiated cell types found within the epithelium. For this reason, 
despite the utility of comparing wildtype and Apcflox/flox organoid formation in order to 
calibrate this assay, the stem cell function assay should only be used to compare 
formation efficiency of organoids which display a wildtype phenotype with all the 
differentiated cells present or the formation efficiency of cyst-like structure producing 
genotypes with that seen in Apcflox/flox crypts. 
3.16.3 Wildtype organoids are more highly proliferative than Apcflox/flox organoids 
The interesting and unexpected observation that wildtype organoids express higher 
levels of the proliferation marker Ki67 and contain more cells in “S”-phase of mitosis (as 
measured by number of cells which uptake BrDU in a one hour period) indicates that 
wildtype organoids are proliferating at a greater rate than Apcflox/flox organoids. This is in 
direct contrast with in vivo data where loss of Apc and subsequent Wnt-signalling 
activation results in a great increase in proliferation (Sansom et al. 2004). This 
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observation does not fit with the data showing that Apcflox/flox organoids grow faster 
than wildtype. However, as the growth rate data shows, by day 11 (which is when the 
organoids were fixed) Apcflox/flox growth has reached a plateau, whereas wildtype 
organoids are still growing. This could be due to the lack of organized structure of 
Apcflox/flox organoids, which just form cyst-like sacks of dead matter and toxins. 
Potentially there is a maximum size the organoids can reach before proliferation is 
reduced to maintain this size. This is supported by the observation that larger organoids 
appear to collapse in on themselves by day 12-13 (see Figure 3.7). 
The organized structure of wildtype organoids enables them to continue growing 
despite the large quantity of dead material inside, as a “crypt” can bud further away 
from the necrotic matter, and often a “leak” of dead matter will form within wildtype 
organoids with the crypts budding on the opposite side of this “leak”. This could explain 
why proliferation rate of wildtype organoids are so much higher than those seen in 
Apcflox/flox organoids, and could be easily tested by fixing organoids at day 5 when growth 
rates between genotypes are very different, and assessing proliferation using Ki67 and 
BrDU. Nearly 100% of wildtype organoid cells are proliferating which indicates that 
they only represent the proliferative compartment of the intestinal epithelium with the 
crypt protrusion and there is no compartment of the organoid which represents the 
non-proliferating villus region. 
The observation that loss of Apc does not appear to result in an increase in apoptosis (as 
measured by Caspase 3 expression) in vitro, but does in vivo (Sansom et al. 2004), could 
be explained by the presence of laminin within the cultures, which prevents cell anoikis 
(Sato et al. 2009). The loss of cellular organisation seen in vivo as a result of Apc loss, 
may interfere with cell-cell contact and positional cues, thereby resulting in cellular 
anoikis. An alternative hypothesis is that in vivo, mice do not survive loss of Apc using 
Villin-Cre for more than 5-6 days and so the increase in apoptosis may be an earlier 
phenotype. This could again be assessed by fixing organoids at earlier time-points and 
assessing Caspase 3 expression. 
 These data not only show the differences between wildtype and Apcflox/flox organoids 
but also highlight that despite the utility of this in vitro system to recapitulate aspects of 
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in vivo work, there are still many areas in which it does not truly represent the situation 
seen in the mouse intestine. 
3.16.4 Development of a functional stem cell assay 
By testing this method using Apcflox/flox mice as an example of a Wnt activated mutant, 
we have developed a sound methodology to examine ISC functionality which is capable 
of determining changes in the ISC population due to aberrations in Wnt signalling. The 
changes in ISC compartment can be supported by in situ hybridisation to determine 
whether the number of stem cells, or simply their potency, has changed. 
There is one major drawback to this technique which is currently being addressed, 
namely that in order for it to be a true representation of “stemness”, the ability of the 
organoids to self-renew would need to be assessed. At present, this has not been 
possible due to the inefficiencies of passage. The major difficulty of gaining a readout of 
the number of organoids which grow after passage is the variability in the passage 
preparation. In order to passage intestinal organoids, it is necessary to manually disrupt 
their structures until they are once more single crypts. In published data this is often 
taken down to single cells using trypsin or similar in order to disassociate the cells, then 
passed through a 40μm filter to ensure that only single cells are seeded. However, due 
to the nature of this assay, it is necessary to seed crypts as opposed to single cells. This 
is due to the inefficiency of organoid growth from unsorted single epithelial cells, as 
sorting for a specific marker, such as Lgr5, would impose pre-selection for defined 
parameters of “stemness”, and what is required from this assay is a global analysis of 
ISC functionality within the whole intestinal crypt. Passage involving the breakdown of 
organoids and re-seeding of crypts as opposed to single cells is routinely done for the 
long term maintenance of intestinal organoid cultures, but not in a manner whereby the 
quality of crypt preparation is essential, or the number of single crypts seeded needs to 
be quantified. When this was attempted, it was found that the quality of the crypt 
preparation was variable, with many individual crypts, or partial organoids, and other 
complete organoids which were undisrupted by the passage process. 
The problem lies in both the difficulty of extracting a large quantity of organoids from 
cultures grown in a 96 well plate, and the inability to consistently break these organoids 
down to a single crypt level. In order to confirm that only single crypts (and not large 
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chunks of organoids, or whole organoids) have been seeded it is necessary to pass the 
sample through a 70 μm filter (pre-soaked in PBS + 0.1%BSA), which results in a great 
reduction in crypt numbers. At present the maximum number of crypts successfully 
passaged from a culture which was originally seeded with approximately 75,000 crypts, 
is 400 crypts. This has meant that incorporating a self-renewal assay into this method 
has as yet been unfeasible. 
It must also be taken into consideration that intestinal organoid function and phenotype 
is not always a direct representation of that seen in vivo. For example, Farin et al., 
recently showed that despite the dispensable nature of Wnt3 in the intestinal 
epithelium in vivo, the loss of Wnt3 cannot be supported in intestinal organoids (Farin 
et al. 2012).  
Other methods for using the intestinal organoid method to assess the ISC compartment 
in vivo have previously been suggested, and other laboratories are using the number of 
crypt-like protrusions as a readout of “stemness”, due to the clear difference between 
wildtype and Apcflox/flox organoids in this characteristic (Ernlund 2011). However, these 
protrusions arise via crypt fission (Sato et al. 2009), and there is no evidence that crypt 
fission occurs as a result of an expansion of the ISC compartment. Furthermore, 
measuring organoid formation efficiency more accurately recapitulates the “gold 
standard” of stem cell assays used in other tissues, such as the neurosphere or cleared 
fat pad transplant assay (Deome et al. 1959; Reynolds and Weiss 1992), whereby cells 
capable of forming a differentiated tissue structure in vitro are measured as stem cells. 
3.16.5 The effect of Cited-1 loss on the ISC compartment 
The data presented here showing that loss of Cited-1 results in an increased organoid 
forming efficiency indicates the potential utility of this method for gaining an 
understanding of the effect of subtle deregulations of Wnt on the intestinal stem cell 
compartment. Although loss of Cited-1 is not alone sufficient to cause intestinal 
tumourigenesis, the subtly increased Wnt-signalling levels, as observed by increased 
nuclear β-catenin, are resulting in an increase in ISCs. Despite this increase in the pool 
of potential “cells of origin” of colorectal cancer, there is not an increase in 
tumourigenesis as these cells are not highly Wnt-activated, as determined by their 
dependency on Rspo1.  
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These data show that a small expansion of the ISC compartment is not alone sufficient to 
drive tumourigenesis, as transforming mutations must still occur within these ISCs 
which result in high levels of nuclear β-catenin.  
The increased number of ISCs should theoretically increase the likelihood of 
tumourigenesis as the number of potential “cells of origin” has increased, however, as 
spontaneous colorectal tumourigenesis in mice is very rare, the number of mice 
required in order to see such an effect would be large. Recently, it has been shown that 
Cited-1 loss is not sufficient for the initiation of intestinal tumourigenesis (Méniel et al. 
2013). Interestingly, despite loss of Cited-1 resulting in an apparent expansion in the ISC 
compartment, Cited-1 loss in a model of Wnt-driven intestinal tumourigenesis, Apcmin/+ 
mice, results in a decrease in tumour burden and a significant increase in survival. This 
is thought to be due to Cited-1 loss resulting in an increase in Wnt signalling, which 
when coupled with Wnt-activation due to Apc deficiency results in an over activation of 
this pathway and an associated increase in apoptosis. This is thought to cause Wnt 
signalling to elevate above tumour-permissive levels, and therefore actually decrease 
tumourigenesis (Méniel et al. 2013). This indicates the complexity of intestinal 
tumourigenesis, and shows that if changes within the ISC compartment are playing a 
role in potential for tumour initiation, then that role may be overridden by alterations in 
Wnt signalling levels. 
 Summary 3.17
This is the first time that an assay to determine the functionality of ISCs has been 
developed and, despite some drawbacks, could prove itself to be an exceptionally useful 
technique. In order to overcome these drawbacks, the assay should always be used in a 
combined approach to assess changes to the ISC compartment, in conjunction with qRT-
PCR data of ISC marker expression levels and in situ hybridisation techniques. 
Apc loss results in such a gross alteration in organoid phenotype that comparisons of 
organoid formation efficiency between organoids of a wildtype phenotype and those of 
an Apc deficient phenotype may be irrelevant. However, it is possible to draw 
comparisons between genotypes which present a similar organoid phenotype. 
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 Future Work 3.18
Growing organoids from single cells would be arguably led to more accurate 
quantification of organoids grown. Single cell organoid culture was attempted (with the 
addition of Wnt3a and the Rho kinase inhibitor Y-27632 to the growth media) however, 
the organoid formation efficiency was so low (<0.03%) that very few total organoids 
grew (typically about 1 per animal) leading to very high variability as well as preventing 
the use of the Rspo1 dependency test. Sato et al., were able to grow organoids at a 
higher efficiency by sorting for the expression of Lgr5 using an Lgr5-GFP transgene 
(Sato et al. 2010).  However, efficiency was still low unless co-cultured with Paneth cells 
and for the purposes of a stem cell function assay this method would not be viable, as it 
would involve artificial selection of proposed ISCs prior to seeding. Ideally, sorting cells 
on the basis of expression of Lgr5 would also enable a cell count of total number of 
epithelial cells compared to Lgr5hi expressing cells, however, as currently no reliable 
antibodies exist for Lgr5, this method would rely on the use of the Lgr5-GFP linked 
transgene (which is also linked to a Cre-recombinase for lineage tracing experiments). 
One of the main technical issues experienced in using the Lgr5-GFP transgene is that it 
is expressed in a mosaic manner, meaning that counts between mice cannot be 
compared. 
However Wang et al. recently published a method of sorting out single intestinal cells 
based on a combination of stem cell associated cell surface markers. When single 
intestinal epithelial CD44+ CD24lo CD166+ GRP78lo/- ckit+ cells are FACs sorted they are 
reported to grow into organoids in culture at an efficiency of more 20% (Wang et al. 
2013b). This is a vast improvement on what was published from Lgr5hi sorted cells and 
could represent a much purer population of ISCs. If this is shown to be correct, and that 
CD44+ CD24lo CD166+ GRP78lo/- ckit+ cells are in fact representative of the ISC 
population, then using FAC sorting to count the percentage of epithelial cells which 
meet these expression requirements could also prove useful as a readout of changes in 
the ISC compartment due to genetic mutations.  This method would be cheaper than 
assessing organoid formation efficiency but would miss out on the functional aspect of 
assessing the ISC compartment as it is a method based purely on expression of ISC 
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markers, as opposed to interrogation capacity of intestinal epithelium cells to function 
as ISCs. 
In order to develop the organoid formation efficiency assay into a more accurate 
readout of ISC capability, self-renewal must be assessed. One of the attributes of a stem 
cell is its ability to self-renew, and so assessing organoid formation efficiency over a 
series of passage events would provide a more comprehensive ISC function assay. 
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4 The roles of Pml in the context of Apc and Pten dependent 
colorectal tumourigenesis 
 Introduction 4.1
APC is an important negative regulator of the Wnt-signalling pathway, and mutations of 
this gene are known to  initiate colorectal tumourigenesis (Lamlum et al. 2000). 
However, tumourigenesis is a multistep process in which many other gene mutations 
and mis-regulations play significant roles. One pathway which is known to be important 
in the progression of tumour development is the PI3K pathway. Activation of the PI3K 
pathway results in activation of mTOR as well as inhibition of the pro-apoptotic factor 
BAD (She et al. 2005) and the Wnt regulator GSK3, all of which cause increased cell 
growth and survival (see Section 1.4.1.1). Understandably, tumour cells containing 
mutations which result in constitutive activation of PI3K have a selective advantage 
within a tumour and so may drive clonality within that tumour. More than 40% of 
human colorectal cancers contain mutations which in constitutive activation of this 
pathway. 
The inhibition of GSK3 via activation of the PI3K pathway highlights the potential of 
crosstalk between the Wnt and the PI3K signalling pathways, as GSK3 forms part of the 
β-catenin destruction complex which is an integral regulator of Wnt-signalling (Voskas 
et al. 2010). 
4.1.1 PTEN in tumourigenesis 
The important role of PTEN as a tumour suppressor is well known through its function 
as a negative regulator of the PI3K pathway. PTEN converts PIP3 into PIP2, thereby 
preventing the recruitment of AKT to the membrane where it is activated by 
phosphorylation. In this way PTEN negatively regulates the amount of the oncogenic 
factor phosphorylated AKT (pAKT) available within the cell, see Section 1.1.1.1, (Cully et 
al. 2006). 
Germ line PTEN mutations are known to play a role in a number of autosomal dominant 
syndromes such as Cowden’s syndrome, which predisposes patients to the development 
of multiple hamartoma growths (Liaw et al. 1997). PTEN mutations have also been 
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identified in many sporadic tumour types such as glioblastoma (Wang et al. 1997) and 
prostate cancer (Cairns et al. 1997). Interestingly, loss of an allelic region close to that of 
PTEN has been associated with up to 30% of human colorectal cancers (Frayling et al. 
1997), although the frequency of PTEN mutations observed in sporadic colorectal 
cancers has been controversial. It has previously been shown that PTEN mutations are 
relatively common, with 19.5% of microsatellite stable human sporadic colorectal 
cancers displaying a PTEN mutation,  (Nassif et al. 2004) whilst hypermethylation and 
subsequent inactivation of PTEN is associated with 19.1% of microsatellite instability-
high sporadic colorectal tumours (Goel et al. 2004). However, there is contradictory 
evidence which shows that this hypermethylation may not be associated with a 
decrease in expression, as it refers to the methylation status of a PTEN pseudo gene, and 
not PTEN itself (Zysman et al. 2002).  
Nassif et al. showed that reduced PTEN expression was associated with a later clinical 
stage in human colorectal tumours, indicating that PTEN loss may not be an initiating 
mutation in sporadic colorectal tumourigenesis, but a driver of clonality within the 
tumour (Nassif et al. 2004).  This theory was supported through the use of Cre-Lox 
technology to cause homozygous disruption of Pten alleles in a specific tissue, as 
homozygous knockout of the gene is embryonic lethal (Cristofano et al. 1998). 
Homozygous loss of Pten within mouse intestinal epithelium had no effect on the 
homeostasis of normal mouse intestine, but did cause accelerated tumourigenesis when 
coupled with deficiency of Apc, showing the importance of the PI3K pathway as a driver 
of tumour progression (Marsh et al. 2008). Interestingly, He et al. found that Pten 
deletion from the ISC compartment of the intestinal epithelium was sufficient to initiate 
tumourigenesis (He et al. 2007).  
4.1.2 PML in tumourigenesis 
The oncogenic effect of Pten loss is reportedly exacerbated by the loss of another 
tumour suppressor gene; Pml (promyelocytic leukaemia protein) (Trotman et al. 2006). 
In this study Trotman et al. demonstrated that in a mouse model with heterozygous 
deletion of Pten, Pml deficiency resulted in a higher tumour burden, earlier onset and 
notably reduced survival due to the formation of colorectal and prostate tumours 
(Trotman et al. 2006).  
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PML was originally identified as a potential gene of interest in tumourigenesis due to its 
association with acute promyelocytic leukaemia (APL) where it is disrupted in 99% of 
all cases (Goddard et al. 1991). For many years the treatment of this disease was 
retinoic acid (RA), arsenic trioxide or a combination of the two, which seemed to cure 
most APL patients. It is now known that the mechanism of this cure is through targeting 
of the PML/RARα (retinoic acid receptor alpha) fusion protein (Chen 2010).  
The protein encoded by PML localizes to the subnuclear structure of the PML-nuclear 
body (PML-NB), which interacts with a vast number of proteins ex vivo but only a small 
number of these interactions are fully understood. Using microarray techniques, 
Gurrieri et al. showed that levels of PML protein were reduced or lost in 31% of colon 
adenocarcinomas, and this was associated with reduced number of PML-NBs (Gurrieri 
et al. 2004).  
The function of these PML-NBs is largely unknown although it has been shown to be 
required for the nuclear localization of PTEN (Song et al. 2008), as well as being 
involved in the inhibition of nuclear function of pAKT by actively recruiting pAKT and 
the AKT phosphatise, PP2a (Trotman et al. 2006). It is important to note that PML also 
plays a crucial role within apoptosis, modulating calcium release at the endoplasmic 
reticulum (Giorgi et al. 2010) and that lack of Pml can protect cell lines and mice from 
apoptosis resulting from a range of apoptotic stimuli (Bernardi et al. 2008). The link 
between PML and apoptosis may be an important factor in its role as a tumour 
suppressor. 
PML has also been linked to a role in cellular senescence, and overexpression of PML 
increases levels of cellular senescence through a p53 dependent pathway (Pearson et al. 
2000). As cell senescence is an important mechanism for minimising the effects of DNA 
damage, it could therefore contribute to the role of PML as a tumour suppressor 
(Collado et al. 2007). 
4.1.3 PTEN, PML and stem cells 
PTEN and PML have been described as playing some role in the maintenance of adult 
stem cell compartments, and as such their role within intestinal tumourigenesis could 
be of great importance. The role of PTEN within the maintenance of the ISC 
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compartment has been explored by He et al. who found that knocking out Pten in the ISC 
compartment initiated intestinal polyposis and also resulted in reduced levels of 
nuclear ß-catenin, an important regulator in ISC self-renewal, within the stem cells (He 
et al. 2007). Pml on the other hand has been shown to inhibit mTOR, which is an 
important driver of the ISC regulator STAT3 (Bernardi et al. 2006; Matthews et al. 
2011). Bernardi et al. showed that inhibition of mTOR by Pml occurred under hypoxic 
conditions, and not only could this affect the ISC compartment, but could also play a role 
by inhibiting angiogenesis, a process which is essential for the growth of solid tumours.  
Interestingly, PML has more recently been shown to play a role in the maintenance of 
“stemness” of hematopoietic stem cells (HSCs) and leukaemia-initiating cells (Ito et al. 
2008; Ito and Ito 2013; Zhou and Bao 2013). In this case, PML deletion results in 
inhibition of the PPAR-δ and  fatty acid oxidation (FAO) pathways which cause an 
increase in symmetric division of HSCs (Ito et al. 2012). The role of PML in the 
regulation of the PPAR-δ-FAO pathway has also been shown to play an important part in 
supporting cell survival in breast cancer cells, so also has a relevance to solid tumours 
(Carracedo et al. 2012).   
Pml and Pten have previously been shown to interact in their suppression of the PI3K 
pathway (Trotman et al. 2006). Here the role of Pml and its synergy with Pten in Wnt-
dependent tumourigenesis has been investigated, with a view to establishing the nature 
of the relationship between these two genes. As these genes have both been implicated 
as regulators of stem cell compartments, their role in maintenance of the ISC 







4.2.1 Pml deficiency does not affect survival, tumour burden or tumour grade, but 
results in increased intussusception in  Apcflox/+ mice 
Villin CreERT positive mice carrying one floxed allele of Apc (Shibata et al. 1997) with or 
without an additional homozygous constitutive knockout of Pml (created and kindly 
gifted to us by Pier Pandolfi) were induced with tamoxifen I.P. injection at 8-10 weeks of 
age and aged for survival analysis. At signs of loss of condition, mice were culled and the 
size, location and number of intestinal and colon tumours were recorded.  
Loss of Pml resulted in no change in either survival (Apcflox/+=345±123, Apcflox/+Pml-/-
=295±21) or tumour burden (Figure 4.1). Interestingly, 3/7 of the Apcflox/flox Pml-/- mice 
displayed gross intussusception upon dissection, whereas none of the 9 Apcflox/flox mice 
displayed this phenotype. This change in frequency of intussusceptions was found to be 
significant when tested using Chi-squared1 (Chi-squared value=6.7, the 0.05 significance 
chi value for n=1 being 3.8). Intussusception has previously been associated with Pten 
deficiency in Apcmin mice and was reported to be coupled with the presence of 
particularly large tumours (Shao et al. 2007). Although all 3 cases of intussusception 
were associated with the presence of a large tumour at the start point of the intestinal 
involution, the tumours were not the largest found in the small intestine (maximum size 
7 mm x 6 mm). 
As Pml deficiency has no effect on overall tumour burden, the level of progression was 
assessed using a tumour grading system. Tumours were divided into 5 categories; grade 
1: single crypt lesions, grade 2: microadenomas, grade 3: adenomas, grade 4: 
adenocarcinoma with submucosal invasion and grade 5: adenocarcinomas with smooth 
muscle invasion (see Section 2.8.4). Loss of Pml had no significant effect on the level of 
tumour progression (Figure 4.2). 
                                                        
1 The significance of this change was assessed using Chi-squared, however, Chi-squared cannot be 
performed if any of the categories (i.e. intussusceptions or no intussusception) of the expected cohort 
(which in this case was the Apcflox/+ mice) were equal to 0. As no cases of intussusception were observed 
in this cohort, the Apcflox/+ Pml-/- cohort had to be used as the basis for the expected results. So in effect, 
the frequency of cases of intussusception in Apcflox/+ mice was compared to that seen in Apcflox/+ Pml-/- 
mice. A more accurate readout of significance could be obtained with a higher N-number, which would 





4.1 A Survival Plot of Apcflox/+ mice with or without Pml deletion, cross represents mouse still 
living. No significant difference in survival between the two cohorts was observed (Wilcoxon 
p=0.748); B Comparison of tumour number in Apcflox/+ mice with Apcflox/+ Pml-/- mice, there was 
no significant difference in tumour number between the two cohorts (2-tailed T-Test p=0.273); 
C Comparison of average tumour size in Apcflox/+ mice with Apcflox/+ Pml-/- mice, there was no 




4.2 Graphical representation of the proportion of each lesion type found per genetic cohort. 
N>5. Chi-squared test showed no significant difference in proportion of tumour grade between 












 Pml loss has no effect on the survival of Apcflox/flox mice  4.2.1.1
As no role was found for Pml as a tumour suppressor in a long term model of Wnt-
dependent tumourigenesis, the potential role of Pml as a regulator of PI3K was 
interrogated using a short term model of early tumourigenesis, the Apcflox/flox mouse. 
After induction of Apc loss from the intestinal epithelium using tamoxifen injection, the 
mice were monitored closely (twice daily) for signs of loss of condition. At signs of ill 
health the animals were culled and the survival time recorded. Additional deficiency of 
Pml resulted in no change in mean survival time of Apcflox/flox mice (Apcflox/flox=4.6±0.7, 
Apcflox/flox Pml-/-=4.6±0.4) (Figure 4.3).   
 
4.3 Cumulative survivals of Apcflox/flox and Apcflox/flox Pml-/- mice after administration of tamoxifen. 





4.2.2 Pml deficiency does not alter the phenotype of Apcflox/flox mice 
Mice were induced with tamoxifen on day 0 and injected with BrdU on day3, they were 
then culled 2 hours later to analyse the short term effect of Pml deletion on the Apcflox/flox 
phenotype. There was no obvious phenotypic difference between the intestinal 
compartments of Apcflox/flox and Apcflox/flox Pml-/-mice (Figure 4.4). 
The number of cells within the zone of aberrant intestinal epithelial cells was 
determined by counting cells in a single line from the base of the crypt to the top of the 
zone of aberrant cells (as defined by larger, darker, unpolarized and disordered cells). 
There was no difference in the number of aberrant cells due to additional loss of Pml 
(Apcflox/flox= 45.8±5.3, Apcflox/floxPml-/-= 49±3.4) (Figure 4.5). 
Because subtle changes in intestinal homeostasis can be identified by alterations in the 
numbers and distributions of differentiated cell types, paraffin sections of intestine 
taken from Apcflox/flox and Apcflox/flox Pml-/-mice were stained for markers of differentiated 
cells, and the numbers of these cell types counted. No difference in the number of goblet 
cells as marked by staining of mucins by alcian blue was observed (Apcflox/flox= 7.2±1.1, 
Apcflox/floxPml-/-= 8.1±3.1) (Figure 4.6), nor the number of Paneth cells as detected by 
lysozyme IHC (Apcflox/flox= 1.4±0.3, Apcflox/floxPml-/-= 1.4±0.1). Loss of Pml did result in a 
trend for an increased number of enteroendocrine cells as detected by Grimelius 
staining (Apcflox/flox= 0.13±0.05, Apcflox/floxPml-/-= 0.18±0.03), however, this was not 









4.4 H&E Stain of Apcflox/flox and Apcflox/flox Pml-/- mouse intestine day 3 post induction with 
tamoxifen. The region of aberrant proliferation is indicated by the black brackets. There was no 
gross morphological difference between the two genotypes. Black bars represent 100 μm. 
 
4.5 Counts of the number of cells in the region of aberrant proliferation per crypt-villus axis in 
Apcflox/flox and Apcflox/flox Pml-/- mice. There was no significant difference in number of aberrant 






4.6 A Alcian Blue IHC of Apcflox/flox and Apcflox/flox Pml-/- intestine. Black bars represent 100 μm; B 
Counts of the number of alcian blue positive cells per crypt-villus axis in Apcflox/flox and Apcflox/flox 
Pml-/- mice. There was no significant difference in number of goblet cells between the two 








4.7 A Paneth cell IHC of Apcflox/flox and Apcflox/flox Pml-/- intestine, brown stained cells represent 
Paneth cells. Black bars represent 100 μm; B Counts of the number of brown cells per crypt-
villus axis in Apcflox/flox and Apcflox/flox Pml-/- mice. There was no significant difference in number of 
Paneth cells between the two genotypes, 2-Tailed T-test p=0.28, N=4. Error bars represent 





4.8 A Grimelius stain of Apcflox/flox and Apcflox/flox Pml-/- intestine, black stained cells represent 
enteroendocrine cells. Black bars represent 100 μm; B Counts of the number of enteroendocrine 
cells per crypt-villus axis in Apcflox/flox and Apcflox/flox Pml-/- mice. There was no significant 
difference in number of enteroendocrine cells between the two genotypes, 2-Tailed T-test 






4.1.1.1 Pml loss results in no effect on apoptosis in Apcflox/flox intestinal epithelium 
Despite the reported role of Pml in protecting cells from apoptosis (Bernardi et al. 2008; 
Giorgi et al. 2010), Pml loss did not result in an increase in number or location of 
apoptotic bodies in Apcflox/flox mice (Apcflox/flox 0.03±0.01, Apcflox/flox Pml-/- 0.03±0.002), 
results were normalised for the number of cells within the aberrant region. This was 
confirmed using a Caspase 3 IHC and counting positively stained cells (Apcflox/flox 
0.61±0.1, Apcflox/flox Pml-/- 0.67±0.03) (Figure 4.9). 
4.1.1.2 Pml loss results in increased mitosis in Apcflox/flox intestinal epithelium 
Counting the number and location of mitotic bodies revealed no significant change in 
number of mitotic bodies as a result of Pml loss in Apcflox/flox intestine (Apcflox/flox 
2.4±0.01, Apcflox/flox Pml-/-2.5±0.8) (Figure 4.10). However, IHC for the presence of 
incorporated BrDU after a 2 hour exposure to BrDU prior to mouse sacrifice revealed a 
significant increase in BrDU uptake due to additional Pml loss (Apcflox/flox 11.6±1.6, 
Apcflox/flox Pml-/- 20.7±2.8) (Figure 4.10). This indicates a higher number of cells at “S” 
phase of mitosis due to Pml loss. IHC for the more generic marker of proliferation, Ki67, 
was conducted in order to confirm this finding. The Ki67 IHC corroborated the 
observation that loss of Pml resulted in an increased level of proliferation (Apcflox/flox 
22.8±3.1, Apcflox/flox Pml-/- 28.8±1.5. 2-tailed T-test p= 0.029), data not shown.  
4.2.3 Pml loss does not activate the PI3K pathway in Apcflox/flox intestinal 
epithelium 
As Pml has been reported to play a role as a negative regulator of the PI3K pathway, 
protein was extracted from the intestinal epithelium of mice from the two genotypes, 
and analysed for changes in levels of phosphorylated-AKT (pAKT) compared to total- 
AKT (tAKT) using western blotting analysis. As pAKT is the downstream effector of the 
PI3K pathway, levels can be used as a direct readout of PI3K activity. Western blotting 
revealed no evidence of pAKT in either Apcflox/flox or Apcflox/flox Pml-/- mice, and no change 
in the levels of tAKT. This indicates that in the context of Apc deletion, Pml does not play 
a role in the regulation of this pathway (Figure 4.11). IHC for pAKT was performed and 
supported the evidence from western blotting that loss of Pml does not result in an 




4.9 Comparison of levels of apoptosis in Apcflox/flox and Apcflox/flox Pml-/- mice. A Apoptotic Index as 
measured by number of apoptotic bodies per crypt-villus axis and normalised for the number of 
cells in the region aberrant proliferation. There was no significant difference between the two 
genotypes, 2-tailed T test p=0.842, N=4; B Number of Caspase positive cells as counted from 
Caspase IHC. There was no significant difference between the two genotypes, 2-tailed T test 
p=0.411, N=4; C Caspase 3 IHC on Apcflox/flox and Apcflox/flox Pml-/- intestine. Brown cells represent 








4.10 Comparison of levels of mitosis in Apcflox/flox and Apcflox/flox Pml-/- mice. A Mitotic Index, as 
measured by number of mitotic bodies per crypt-villus axis and normalised for the number of 
cells in the region aberrant proliferation. There was no significant difference between the two 
genotypes, 2-tailed T test p=0.789, N=4; B Number of BrDU positive cells as counted from BrDU 
IHC after a 2 hour BrDU exposure. Pml loss led to a significant increase in BrDU uptake 2-tailed 
T test p=0.001, N=4; C BrDU IHC on Apcflox/flox and Apcflox/flox Pml-/- intestine. Brown cells 








4.11 Phospho-AKT levels as a measure of activation of the PI3K pathway due to additional 
deletion of Pml form Apcflox/flox mice. A Western blot analysis shows that total levels of Akt 
protein within the protein extracted from intestinal epithelium of the two genotypes was high, 
but no phospho-Akt was detected; B IHC for phospho-Akt confirmed that the PI3K pathway was 








4.2.4 Pml loss results in a significant increase in expression of ISC markers in 
Apcflox/flox mice 
Given that Pml is cited as a tumour suppressor, and that mis-regulation of the ISC 
compartment may play an important role in tumourigenesis, the ISC compartments of 
Apcflox/flox and Apcflox/flox Pml-/- mice were analysed.  
qRT-PCR for a number of published ISC markers was performed and revealed a 
significant increase in expression of Lgr5 due to Pml loss (Figure 4.12). Trends for 
increased expression of the ISC markers Ascl2, Olfm4, Msi1 and Bmi1 were found not to 
be significant at N=6.  
As changes in the expression levels could indicate either an increase in expression by 
the same number of ISCs or a loss of localisation of expression, in situ hybridisation was 
performed using an anti-Olfm4 riboprobe on paraffin embedded intestinal tissue of 
Apcflox/flox and Apcflox/flox Pml-/-mice. In situ hybridisation revealed an apparent increase in 
the zone of Olfm4 expression due to additional Pml loss (Figure 4.13). However, due to 
the tissue disruption caused by the proteinase K step of in situ hybridisation, this 






4.12 qRT-PCR analysis of selected ISC markers showed a trend for increased expression due to 
Pml loss in Apcflox/flox mice. * Indicates significance at p<0.05 using a 2-tailed T-test. N=6. 
 
 
4.13 In situ hybridisation to visualise Olfm4 mRNA expression location. Loss of Pml results in an 





4.2.5 Pml deficiency does not affect the survival or tumour burden in Apcflox/+ 
Ptenflox/flox mice 
Mice were induced at 8-10 weeks old (+/- 10 days) and aged until displaying loss of 
condition, when they were culled. Using Wilcoxon survival analysis it was demonstrated 
that the survival of Apcflox/+ Ptenflox/flox Pml-/- mice is not significantly different from 
Apcflox/+ Ptenflox/flox mice (Apcflox/+ Ptenflox/flox 136 days ± 97, Apcflox/+ Ptenflox/flox Pml-/- 97 
days ± 42 days) (Figure 4.14). Intussusception was only observed in 1/12 of the 
Apcflox/+Ptenflox/flox mice (where it was associated with a large tumour, 9mm x 9mm in 
size), and 0/16 of the Apcflox/+Pten+/+ Pml-/- mice. 
Tumour counts in both the small and large intestine were performed, and the tumour 
size recorded. It was found that loss of Pml resulted in no change in the numbers of 
tumours found in the small and large intestine or the size of tumours in Apcflox/+ 
Ptenflox/flox mice. 
4.2.6 Pml deficiency increases tumour progression Apcflox/+ Ptenflox/flox mice 
The tumours seen on one section of H&E per mouse were graded using the tumour 
grading system explained in Section 3.8.2. Using Chi-squared it was possible to 
determine that there was a significant difference in the ratios of tumour grades 
observed, with loss of Pml resulting in a higher proportion of tumours displaying 
submucosal and smooth muscle invasion, and therefore fewer lower grade lesions 











4.14 A Survival Plot of Apcflox/+ Ptenflox/flox mice with or without Pml deletion, there was no 
difference in survival times between the two cohorts (Wilcoxon p=0.478); B Comparison of 
tumour number in Apcflox/+ Ptenflox/flox  mice with Apcflox/+ Ptenflox/flox Pml-/- mice, no significant 
difference was seen between the two cohorts (2-tailed T-test p=0.495) ; C Comparison of 
average tumour size in Apcflox/+ Ptenflox/flox mice with Apcflox/+ Ptenflox/flox Pml-/- mice, no significant 




4.15 Graphical representation of the numbers of each lesion type found per genetic cohort. 
N>10. Chi-squared test showed a significant difference in proportion of tumour grade between 












4.2.7  Pml deficiency significantly reduces survival of Apcflox/flox Ptenflox/flox mice 
Following induction of Villin-CreER via injection of tamoxifen, Apcflox/flox Ptenflox/flox mice 
have a median survival time of 4.5 days. In mice carrying the additional Pml mutation, 
median survival following tamoxifen injection was reduced to 3 days (mean values 
Apcflox/flox Ptenflox/flox 4.5±0.4, Apcflox/flox Ptenflox/flox 3.2±0.4). Upon dissection there was no 
discernible difference in phenotype between the two cohorts, except that the gut of 
Apcflox/flox Ptenflox/floxPml-/- mice was noticeably more vascularised. However, this was not 
quantified. 
 
4.16  Cumulative survival of Apcflox/flox Ptenflox/flox and Apcflox/flox Ptenflox/flox Pml-/- mice after 
administration of tamoxifen. Loss of Pml significantly reduced the survival time of Apcflox/flox 





4.2.8 Pml deficiency does not alter the histological phenotype of Apcflox/flox 
Ptenflox/flox mice 
Despite the decrease in survival of Apc Pten-deficient mice due to loss of Pml, there was 
no gross difference in intestinal phenotype (Figure 4.17). Counting the number of 
aberrant intestinal epithelial cells per crypt-villus axis showed that Pml deficiency does 
not affect the number of cells in this region in Apcflox/flox Ptenflox/flox mice (Apcflox/flox 
Ptenflox/flox 65±4.5, Apcflox/flox Ptenflox/flox 62±10.7) (Figure 4.18).  
Pml deficiency resulted in no significant alteration in the differentiated cell composition 
of the intestinal epithelium when associated with additional Pten loss. In Apcflox/flox 
Ptenflox/flox mice, Pml deficiency had no effect on the number of alcian blue positive 
goblet cells (Apcflox/flox Ptenflox/flox 8.2±0.7, Apcflox/flox Ptenflox/flox 8.7±2.1) (Figure 4.19), but 
did result in a trend for decreased numbers of Paneth cells (Apcflox/flox Ptenflox/flox 
1.5±0.25, Apcflox/flox Ptenflox/flox 1.3±0.04) (Figure 4.20), and enteroendocrine cells 
(Apcflox/flox Ptenflox/flox 0.32±0.001, Apcflox/flox Ptenflox/flox 0.21±0.0001) (Figure 4.21). 
Similarly, Pml loss had no effect on levels of apoptosis in Apc and Pten deficient mice, as 
determined by counting the number of apoptotic bodies per half-crypt (Apcflox/flox 
Ptenflox/flox 0.024±0.006, Apcflox/flox Ptenflox/flox 0.038±0.009), and confirmed by Caspase 3 
IHC (Apcflox/flox Ptenflox/flox 0.69±0.09, Apcflox/flox Ptenflox/flox 0.68±0.05)( Figure 4.22). Levels 
of mitosis were also unaffected, as determined by counting mitotic bodies (Apcflox/flox 
Ptenflox/flox 2.8±1.2, Apcflox/flox Ptenflox/flox 2.5±0.9), and confirmed by BrDU IHC following a 
2hour BrDU exposure prior to animal sacrifice (Apcflox/flox Ptenflox/flox 19.9±4.3, Apcflox/flox 










4.17 H&E Stain of Apcflox/flox Ptenflox/flox and Apcflox/flox Ptenflox/flox Pml-/- mouse intestine day 3 post 
induction with tamoxifen. The region of aberrant proliferation is indicated by the black 
brackets. There was no obvious morphological difference between the two genotypes. Black 
bars represent 100 μm. 
 
4.18 Counts of the number of cells in the region aberrant proliferation per crypt-villus axis in 
Apcflox/flox Ptenflox/flox and Apcflox/flox Ptenflox/flox Pml-/- mice. There was no significant difference in 
number of aberrant cells between the two genotypes, 2-Tailed T-test p=0.634, N=4. Error bars 




4.19 A Alcian Blue IHC of Apcflox/flox Ptenflox/flox and Apcflox/flox Ptenflox/flox Pml-/- intestine. Black bars 
represent 100 μm; B Counts of the number of alcian blue positive cells per crypt-villus axis in 
Apcflox/flox Ptenflox/flox and Apcflox/flox Ptenflox/flox Pml-/- mice. There was no significant difference 








4.20 A Lysozyme cell IHC of Apcflox/flox Ptenflox/flox and Apcflox/flox Ptenflox/flox Pml-/-, brown stained 
cells represent Paneth cells. Black bars represent 100 μm; B Counts of the number of brown 
cells per crypt-villus axis in Apcflox/flox Ptenflox/flox and Apcflox/flox Ptenflox/flox Pml-/- mice. Despite a 








4.21 A Grimelius stain of Apcflox/flox Ptenflox/flox and Apcflox/flox Ptenflox/flox Pml-/-, black stained cells 
represent Grimelius containing enteroendocrine cells. Black bars represent 100 μm; B Counts of 
the number of black cells per crypt-villus axis in Apcflox/flox Ptenflox/flox and Apcflox/flox Ptenflox/flox Pml-







4.22 Comparison of levels of apoptosis in Apcflox/flox Ptenflox/flox and Apcflox/flox Ptenflox/flox Pml-/- mice. 
A Apoptotic Index, as measured by number of apoptotic bodies per crypt-villus access and 
normalised for the number of cells in the region aberrant proliferation. There was no significant 
difference between the two genotypes, 2-tailed T test p=0.059, N=4; B Number of Caspase 
positive cells as counted from Caspase IHC There was no significant difference between the two 
genotypes, 2-tailed T test p=0.411, N=4; C Caspase 3 IHC on Apcflox/flox Ptenflox/flox and Apcflox/flox 










4.23 Comparison of levels of mitosis in Apcflox/flox Ptenflox/flox and Apcflox/flox Ptenflox/flox Pml-/- mice. A 
Mitotic Index, as measured by number of mitotic bodies per crypt-villus access and normalised 
for the number of cells in the region aberrant proliferation. There was no significant difference 
between the two genotypes, 2-tailed T test p=0.672, N=4; B Number of BrDU positive cells as 
counted from BrDU IHC after a 2 hour BrDU exposure. There was no significant difference in 
BrDU uptake between the two genotypes, 2-tailed T test p=0.895, N=4; C BrDU IHC on Apcflox/flox 
Ptenflox/flox and Apcflox/flox Ptenflox/flox Pml-/- intestine. Brown cells represent BrDU positive cells. 





4.2.9 Pml loss does not activate the PI3K pathway in Apcflox/flox Ptenflox/flox intestinal 
epithelium 
Western-blot analysis of protein extracted from intestinal epithelial cells of Apcflox/flox 
Ptenflox/flox and Apcflox/flox Ptenflox/flox Pml-/- mice showed that additional Pml deficiency had 
no effect on the levels of pAKT. This result was confirmed by IHC, which showed no 
visible change in levels of pAKT between the two genotypes (Figure 4.24).  
4.2.10 Pml loss results in a significant increase in expression of ISC markers in 
Apcflox/flox Ptenflox/flox mice 
Due to loss of Pml resulting in an increased tumour grade in Apc and Pten deficient mice, 
the ISC compartment was analysed. ISCs have been shown to be the cell of origin of 
intestinal tumourigenesis, and loss of Apc specifically within ISCs results in more 
aggressive adenomas than when Apc is lost from other intestinal epithelial cell types 
(Barker et al. 2008), hence once possible reason for the observed increase in the grade 
of adenomas may be a change in the ISC compartment.   
Loss of Pml in the context of combined Apc and Pten deficiency had a clear effect on the 
ISC compartment, with a trend for increased expression of the ISC markers Ascl2, Msi1 
and Bmi1, and a significant increase in the expression of the markers Lgr5 (t-test 
p=0.03) and Olfm4 (t-test p=0.03) at N=6 (Figure 4.25). 
Interestingly, in situ hybridisations for the ISC marker Olfm4 did not display any change 






4.24 Phospho-AKT levels as a measure of activation of the PI3K pathway due to additional 
deletion of Pml from Apcflox/flox Ptenflox/flox mice. A Western blot analysis shows that total levels of 
both total- Akt protein and phospho-Akt were high in both cohorts with no difference between 
the two cohorts; B IHC for phospho-Akt confirmed that the PI3K pathway was activated equally 










4.25 qRT-PCR analysis of selected ISC markers showed a trend for increased expression due to 
Pml loss in Apcflox/flox mice. * Indicates significance at p<0.05 using a 2-tailed T-test. N=6. 
 
 
4.26 In situ hybridisation to visualise Olfm4 mRNA expression location. Loss of Pml results in no 
gross change in the zone of expression. Black bars indicate 100 μm. 
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4.2.11 Organoids from all cohorts are cyst-like, with few differentiated cell types 
The ability of Pml loss to seemingly expand the ISC compartment, and therefore the 
potential number of “cells of origin” of intestinal tumourigenesis, without having an 
impact on the number of tumour initiation “events” is contradictory and so it is 
necessary to assess the effect of Pml loss on the functional ISC compartment separately 
from its effect on the expression of ISC markers. 
Apcflox/flox Pml-/-, Apcflox/flox Ptenflox/flox and Apcflox/flox Ptenflox/flox Pml-/- intestinal crypts all 
produced organoids which were cyst-like with few differentiated cells, which were 
indistinguishable from Apcflox/flox organoids (Figure 4.27). Due to the similarities with 
Apcflox/flox organoids, the Apcflox/flox Pml-/-, Apcflox/flox Ptenflox/flox and Apcflox/flox Ptenflox/flox 
Pml-/- organoids were analysed using the Apcflox/flox CHARM programme. See section 
2.12.4. 
4.2.12 Pml loss does not affect organoid formation efficiency in Apcflox/flox or 
Apcflox/flox Ptenflox/flox mice 
In contradiction to the in vivo results which showed that Pml loss resulted in an 
increased expression of Lgr5, loss of Pml had no effect on the organoid forming 
efficiency of intestinal crypts from any of these cohorts (Figure 4.28). All organoid 








4.27 H&E displaying organoids representative of Apcflox/flox Pml-/-, Apcflox/flox Ptenflox/flox and 
Apcflox/flox Ptenflox/flox Pml-/- organoids. Image actually taken of fixed Apcflox/flox Ptenflox/flox Pml-/- 
organoids. Black bars represent 100 μm. 
 
 
4.28 Intestinal organoid formation efficiency of Apcflox/flox, Apcflox/flox Pml-/-, Apcflox/flox Ptenflox/flox 
and Apcflox/flox Ptenflox/flox Pml-/- intestinal crypts. No significant difference was observed between 






4.3.1 Pml deficiency results in subtle phenotypic changes in Apcflox/+ and Apcflox/flox 
mice, but no change in survival or tumour burden 
Despite Pml loss resulting in no change in survival or tumour burden of Apcflox/+ mice, 
there was an increase in the levels of intussusception observed upon dissection. 
Heterozygous loss of Pten has been previously shown to increase levels of 
intussusceptions in an Apcmin model of colorectal tumourigenesis (Shao et al. 2007). 
Although intussusception is normally viewed as a result of the presence of large 
tumours, rather than a tumour independent phenotype, this was not the case in the 
Apcflox/+ Pml-/- mice, which did not have significantly larger tumours than were seen in 
Apcflox/+ mice alone. In order to assess whether the observed intussusception is due to a 
mechanism which is independent of tumour size, it would be necessary to generate a 
much higher N-number and record the size and location of the tumour associated with 
it.  
Shao et al. noted that in Apcmin Pten+/- mice where intussusception was observed, 
expression of the gene Osteopontin (Opn) was significantly upregulated (Shao et al. 
2007). Opn is a secreted phosphoglycoprotein which plays important roles in cell 
adhesion, motility, apoptosis and inflammation. Furthermore, high levels of OPN are 
associated with tumour progression in colorectal and breast cancers (Yeatman and 
Chambers 2003). Interestingly, Opn is an important driver of Interleukin17 (Il17) 
expression, which in turn regulates inflammation and immune response. It is currently 
believed that intussusception which is not tumour associated is likely to be induced by 
infection and inflammation (Nissan et al. 1997).  Pml-NBs have been implicated in the 
inflammatory process through their association with inflammatory tissue, and have 
been observed at high levels in macrophages (Terris et al. 1995). In order to assess the 
role inflammation is playing in intussusception caused by Pml deletion in Apcflox/+ mice, 
expression levels of Opn, Il17 and Tumour Necrosis Factor-α (TNFα) could be assessed. 
There is evidence that one of the ways in which PML regulates the PI3K pathway is 
through its role in regulating the localisation of PTEN. Specifically, this occurs within the 
nucleus where loss of Pml is associated with mis-localization of Pten (Song et al. 2008; 
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Trotman et al. 2006), and mis-localization of PTEN is associated with disease 
progression in CRC (Zhou et al. 2000). Despite the role of Pten within the PI3K pathway 
taking place at the cell membrane, mis-localisation of Pten may explain the proposed 
role of Pml in intestinal tumourigenesis. However, the work presented here shows that 
loss of Pml alone had no effect on the survival of either Apcflox/+ or Apcflox/flox mice, 
indicating that any mis-localisation of Pten is not comparable to loss of Pten function, 
which decreased survival time of these mice (Marsh et al. 2008).  
In our Apcflox/flox model it is clear that Pml is not playing a significant role in the 
regulation of the PI3K pathway, as loss of Pml does not result in any increase in levels of 
pAKT. It is therefore unsurprising that loss of Pml does not result in a change in survival 
or tumour burden of these mice, as in this context it is not regulating PI3K upstream of 
pAKT (Trotman et al. 2006). However, Pml may be playing a role downstream of pAKT, 
due to the ability of Pml-NBs to sequester mTOR (Bernardi et al. ; Carracedo and 
Pandolfi 2008). In order to test this in our model, levels of mTOR could be assessed 
using Western blotting, however, any significant increase in mTOR due to loss of Pml 
would presumably result in increased tumourigenesis and decreased survival of Apcflox/+ 
mice, which we did not observe.  
As PML-NBs are known to play a role in apoptosis, and loss of PML from cell lines 
resulted in decreased apoptosis (Bernardi et al. 2008; Gao YM et al. 2013), it was 
expected that loss of Pml from an Apcflox/flox model of acute Wnt activation would protect 
cells from apoptosis. However, this was not the case, and potentially the mechanism 
which drives apoptosis in Apcflox/flox mice, which is likely the result of highly activated 
Wnt-signalling increasing genetic damage, may be Pml-NB independent. 
In Apcflox/flox mice, we showed that loss of Pml results in increased mitosis, which 
supports the previously described role of Pml as a promoter of cell senescence, with loss 
of Pml resulting in increased proliferation (Ferbeyre et al. 2000; Melnick and Licht 
1999), although we have no evidence for senescence occurring in the intestinal 
epithelium of Apcflox/flox mice. 
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4.3.2 Pml deficiency does not affect the survival or tumour burden in Apcflox/+ 
Ptenflox/flox but results in increased tumour progression 
As it had previously been published that Pml deficiency increased tumour initiation, 
burden and progression in Pten+/- mice (Trotman et al. 2006), it was thought that a 
similar effect would be observed in a Wnt-driven model of intestinal tumourigenesis 
with homozygous Pten loss. Surprisingly, neither survival or tumour burden were 
affected by additional Pml loss, however, there are a number of potential mechanisms 
which would cause this effect. 
In the work presented by Trotman et al. a heterozygous model of Pten deletion is used, 
resulting in Pten deficiency in all tissues (Trotman et al. 2006). Heterozygosity for this 
allele of Pten alone, has already been shown to be adequate to drive the development of 
microscopic benign colonic polyps (Suzuki et al. 1998), whereas the conditional 
homozygous deletion of Ptenflox/flox using Villin-CreER does not result in any immediate 
change in intestinal or colonic homeostasis (Langlois et al. 2009; Marsh et al. 2008). 
These bodies of work suggest that any role played by Pten in initiating intestinal 
tumourigenesis in these models may occur outside of the intestinal epithelium, and may 
be due to changes in gene expression within the stromal compartment of the intestine. 
Consistent with this, conditional homozygous deletion of Pten using a fibroblast specific 
Cre-recombinase (Col1A2CreER (Zheng et al. 2002)), which specifically recombined in 
the intestinal stroma and smooth muscle compartments, resulted in tumourigenesis 
throughout the small intestine and colon (Davies 2011). However, He et al. found that 
Pten deletion from the ISC compartment was sufficient to induce intestinal 
tumourigenesis (He et al. 2007). The mechanism for Pten deletion in this instance was 
through the use of a Cre-recombinase linked to expression of Mxi1, which is upregulated 
due to interferon expression (Kühn et al. 1995). The use of this Cre means that not only 
is there a lack of specificity (with Pten recombination appearing to occur within the 
stromal compartment as well as the ISC compartment) but that the Cre is induced by the 
injection of polyinosinic-polycytidylic acid (pipC), which stimulates inflammation and 
immunity in order to upregulate interferon levels. This means that Pten loss within the 
intestinal epithelium may not be responsible for tumour initiation in this model as it 
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could either be due to Pten deletion within the stroma, or due to the stimulation of 
inflammation and the immune response. 
Potentially, the network through which Pten and Pml interact to suppress intestinal 
tumourigenesis is a stromal specific one, and as Villin-CreER recombines between LoxP 
sites of Pten specifically within the intestinal epithelium, the model used here is not an 
accurate representation of the interactions between Pten and Pml within the intestinal 
stroma. Alongside the cohorts shown here, Ptenflox/flox Pml-/- mice were also generated 
and aged (in the absence of Apc mutations), and they showed no decrease in survival 
compared to wildtype mice or any instances of intestinal tumourigenesis at death (data 
not shown).  
In our model, tumourigenesis is initiated by loss of Apc, but progression is driven by 
loss of Pten from the intestinal epithelium. In this context, constitutive loss of Pml does 
not play a role in tumourigenesis, and therefore does not increase tumour number.  
However, loss of Pml results in increased tumour progression. This supports the finding 
of Bernardi et al. that Pml acts to repress tumour progression in a mouse model of 
kidney cancer (Bernardi et al.). In this study it was shown that this repression of tumour 
progression was due to the role of Pml as an inhibitor of mTOR. Increased tumour 
progression in our Apcflox/+ Ptenflox/flox due to Pml loss could be a result of 
hyperactivation of the PI3K pathway specifically within the tumours.  
4.3.3 Pml deficiency significantly reduces survival of Apcflox/flox Ptenflox/flox mice but 
does not grossly alter intestinal phenotype 
Despite Pml deficiency resulting in no change in survival in an Apcflox/+ Ptenflox/flox model 
of long term tumourigenesis, the effect on survival of the short term model of early 
tumourigenesis, Apcflox/flox Ptenflox/flox mice, was dramatic. Pml deficiency resulted in a 
more than 25% decrease in survival, despite no gross microscopic gut phenotype when 
assessed at day 3 post induction. There was also no change in the number of cells in the 
region aberrant proliferation, apoptosis, mitosis or differentiated cell types. The health 
status of mice following combined loss of Apc and Pten is severely compromised, the 
supposed cause of death in Apcflox/flox mice is dehydration caused by complete intestinal 
failure. Furthermore, the intestine undergoes a gross immune response following loss of 
Apc, with visible gut inflammation. Pml has been shown to play an important role in 
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innate immunity, and Pml-/- mice have previously been found to develop lethal 
botryomycosis (BTM), which are granulomatous lesions caused by an inability to clear 
pathogenic microorganisms (Lunardi et al. 2011). Potentially, the decrease in survival 
time due to Pml loss in these models is due to an abnormal immune response. 
Despite the proposed role of Pml as a negative regulator of phosphorylation of AKT, loss 
of Pml did not result in any increase in pAKT in Apcflox/flox Ptenflox/flox mice, as confirmed 
by Western blots and IHC. Trotman et al. showed that Pml-NBs specifically recruit both 
PP2a (an Akt phosphatase) and pAKT, and that loss of Pml results in an increase in 
nuclear pAKT. This is directly contradictory to our observations. However, it should be 
noted that nuclear pAKT levels have not been analysed directly, rather pAKT levels 
were from complete intestinal epithelial extract. As the proposed roles of Pml in 
regulating the PI3K pathway are diverse, it is possible that loss of Pml in the epithelium 
is not increasing pAKT levels, but may be increasing mTOR activity (Bernardi et al. 
2011; Carracedo and Pandolfi 2008; Ito et al. 2009). IHC for phosphorylated mTOR 
could help elucidate this function.  
4.3.4 Pml loss results in a significant increase in expression of ISC markers in both 
Apcflox/flox and Apcflox/flox Ptenflox/flox mice 
The role of Pml as a promoter of quiescence (Ito et al. 2008), is particularly relevant 
when considering its role in maintaining the ISC compartment. Cell quiescence is 
commonly associated with stem cells, as adult stem cells generally rarely divide as a 
protective mechanism against genetic damage. However, Lgr5+ ISCs have been shown to  
proliferate rapidly and so cannot be said to be quiescent (Lopez-Garcia et al. 2010; 
Schepers et al. 2011). This is clear since loss of Pml, in the context of both conditional 
homozygous deletion of Apc alone and Apc and Pten loss, results in an increase in 
expression of the ISC marker Lgr5, and a trend for increased expression of the other 
ISCs examined.  
The increased expression of ISC markers observed due to loss of Pml supports its role as 
an inhibitor of mTOR, which has a reported role in the maintenance of breast cancer 
stem-like cells through its interactions with Stat3 signalling (Zhou et al. 2007). The 
increase in ISC marker expression due to Pml loss could provide a mechanism for how 
Pml loss results in an increased level of tumour progression in Apcflox/flox Ptenflox/flox mice. 
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In another mouse model of intestinal tumourigenesis, the Apcmin mouse, it has been 
shown that Stat3 regulates tumour progression (Musteanu et al. 2010). Stat3 is also an 
important regulator of the ISC compartment, and may provide a link between changes 
in tumour grade and expansion of the ISC compartment (Matthews et al. 2011). 
ISCs, specifically the Lgr5+ population, are known to be the cell of origin of intestinal 
tumourigenesis (Barker et al. 2008). As such, it would be expected that an expansion of 
the ISC population (as evidenced by an increase in expression of ISC markers) would 
result in an increased level of “cells of origin” and therefore an increased level of 
tumourigenesis. However, there is a great deal of controversy surrounding the 
relevancy of many of the ISC markers previously published (Barker et al. 2012; Muñoz 
et al. 2012). One of the main concerns with the use of many of these ISC markers is that 
they do not play a functional role in the maintenance of the ISC population. For example, 
the most commonly used marker of the ISC population is Lgr5, yet Lgr5 expression is 
dispensable for the maintenance of intestinal homeostasis (Tian et al. 2011). This 
highlights the fact that the ISC markers used here are not an adequate readout of 
changes in the ISC compartment. 
Despite the increased expression of ISC markers as a result of Pml loss in both Apcflox/flox 
and Apcflox/flox Ptenflox/flox mice, this did not translate into an increase in organoid 
formation efficiency. This paradox highlights one of the pitfalls of assessing the ISC 
compartment using gene expression markers alone, as they do not relate to a function 
capacity of ISCs. Loss of Pml in these contexts increased expression of ISC markers, but 
had no quantifiable effect on the functional ISC compartment (as assessed by organoid 
formation efficiency). This may explain why an increase in ISC marker expression did 
not correspond with an increase in tumourigenesis in these models. 
Equally, the result could indicate that organoid formation efficiency is not a relevant 
readout of changes in the ISC compartment within Apcflox/flox mice, as potentially, over-
activation of the Wnt-signalling pathway enables non-ISCs to form organoids in culture. 
As previously discussed, organoids derived from Apcflox/flox mice do not differentiate and 
therefore may not be derived from a population of true ISCs, and so potential changes in 
the ISC compartment due to Pten and Pml loss, may be being masked in this assay by the 




Much of the research regarding Pml has struggled to produce confident mechanisms for 
its role as a tumour suppressor due to its diverse interactions and seemingly tumour-
specific functions. The primary role of Pml as a tumour suppressor within the intestine 
was thought to be due to its role in interacting with Pten to regulate the PI3K pathway 
(Trotman et al. 2006). However, in the context of Wnt-driven tumourigenesis, Pml has 
not been shown to play a role in either survival or tumour burden. It is possible that the 
interaction between Pml and Pten, which drives tumourigenesis, occurs in the stroma, 
as epithelial Pten loss is not tumour initiating, whereas stromal Pten does result in 
tumourigenesis. Any interaction between Pten and Pml in the model presented here 
(where Pten is lost specifically within the intestinal epithelium and tumourigenesis is 
initiated by Apc loss) results in an increase in tumour progression, but not tumour 
formation. 
Interestingly, constitutive loss of Pml did result in an increased tumour grade in a model 
of Apc heterozygous and Pten homozygous deletion from the intestinal epithelium. This 
increase in tumour grade due to Pml loss correlated with an increase in expression of 
ISC markers, both of which may be being controlled by changes in Stat3 levels, but not 
an increase in ISC functionality as assessed by the organoid formation efficiency assay. 
Pml loss, in the context of Apc and Pten homozygous deletion, resulted in a significantly 
decreased survival time, without altering the gross intestinal phenotype. It is thought 
that in this context, immune-deficiency brought about by Pml loss maybe causing 
decreased survival by increasing the susceptibility to and the severity of innate 
infectious reagents. However, there is no evidence for this as cause of ill health of these 
animals remains unclear. 
 Future Work 4.5
In order to ascertain the mechanism by which loss of Pml is resulting in an increase in 
both expression of ISC markers and invasion, levels of both phospho-mTOR and Stat3 




In order to understand the mechanism by which Pml loss resulted in a decreased 
survival of Apcflox/flox Ptenflox/flox mice, the immune response of these mice could be 
analysed, by looking at levels of gut inflammation and plasma macrophage levels. The 
effect any changes in immune response may be having on survival could be tested by 
challenging the immune system of Apcflox/+ Ptenflox/flox mice with a known pathogen, and 
assessing the response with or without additional Pml loss. 
It is thought that one reason why our model did not recapitulate the results observed by 
Trotman et al., may be due to the importance of the relationship between Pten and Pml 
in tumour initiation within the stromal rather than the intestinal epithelium. Therefore 
it would be interesting to study the effect of Pml deletion when recombination of 




5 Investigating the effects of loss of Apc2 on the ISC compartment 
 Introduction 5.1
The identification of the APC homologue APC2, which shares many structural 
similarities with APC, led to the hypothesis that these two genes may share certain 
functions (Nakagawa et al. 1998; Van Es et al. 1999). One of these structural similarities, 
the presence of a 20-amino acid repeat motif, was shown to be capable of binding β-
catenin, and as a result APC2 is capable of depleting the levels of intracellular β-catenin, 
albeit less efficiently than APC (Nakagawa et al. 1998).  The drosophila homologue of 
Apc2 has also been shown to rescue mis-expression of Wnt-target genes due to loss of 
Apc (Kunttas-Tatli et al. 2012), and in APC deficient colorectal cancer cell lines, transient 
expression of APC2 was shown to result in a reduced TCF-Topflash readout equivalent 
to that seen as a result of transient expression of APC (Van Es et al. 1999). 
As well as a potential role as a negative regulator of Wnt-signalling, either in co-
operation with or independently from APC, it has emerged that APC2 may play a role as 
a tumour suppressor independently from APC. 
 APC2 has been fine mapped to a region of chromosome 19p13.3, which contains the 
markers D19S883 and WI-19632, which are frequently lost in a range of different cancer 
types, most markedly in ovarian cancer (Jarrett et al. 2001; Sobottka et al. 2000). 
Patients with Peutz-Jeghers syndrome (PJS), a heritable condition causing multiple 
intestinal polyps and increasing susceptibility to colon cancer, are missing this 
chromosome region. PJS patients also show an increased susceptibility to a range of 
other cancer types including breast, ovarian and testis. Loss of heterozygosity (LOH) of 
this region of chromosome 19p13.3 is also observed in certain sporadic cancers 
(Sobottka et al. 2000). 
Despite the rarity of known APC2 mutations, loss of gene function can occur through 
other mechanisms. Epigenetic regulation of gene expression by methylation is an 
extremely important means of controlling gene expression. Methylation is a process by 
which a methyl group is attached to a CpG sequence in the gene’s promoter region, 
thereby preventing transcription of the gene, and is an essential process during 
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development. Hypermethylation of tumour suppressor gene promoters is commonly 
seen in a variety of cancers and is how many of these genes are down regulated without 
having been identified as commonly mutated (Baylin 2005; Das and Singal 2004; 
Ehrlich 2002). 
Hypermethylation of APC2 has been recorded in a number of different cancer types 
including neurological, breast and colorectal cancer (Nakagawa et al. 1998; Schuebel et 
al. 2007). Interestingly, hypermethylation of APC2 is also associated with the 
progression from inflammatory bowel disease (IBD) to IBD associated neoplasia (Dhir 
et al. 2008). Chan et al. demonstrated that hypermethylation of APC2 was seen in 100% 
of primary colon tumours and that increased methylation directly correlated with a 
decrease in levels of APC2 protein (Chan et al. 2008). Studies by (Mokarram et al. 2009) 
confirmed that hypermethylation of APC2 occurs in 90-98% of colorectal tumour 
samples. Hypermethylation is associated with decreased gene expression, and previous 
work within our laboratory has shown that APC2 expression is indeed significantly 




5.1 Expression of Apc2 is downregulated in the majority of human colorectal cancers. Median 
fold change -2.754, p<0.01. Tumour samples and qRT-PCR analysis courtesy of Fei Song. 
 
Despite the embryonic lethality of a constitutive knockout of Apc in mice (Moser et al. 
1995), a constitutive Apc2 mutant is viable, and such a mouse was produced by 
Professor Hans Clevers’ laboratory and gifted to us for analysis of the intestinal 
phenotype. The Apc2-/- mouse was produced by the insertion of a stop codon into the 
open reading frame of the gene, resulting in a shortened protein which is lacking the β-
catenin and axin binding sites (Van der Meer et al. 2001). 
Previous work conducted by Carl Daly within this laboratory has shown that loss of 
Apc2 in the mouse results in no obvious phenotype and no change in the numbers of 
differentiated cell types, but does result in an increase in expression of Wnt target 
genes, and an increase in nuclear β-catenin (Daly 2013). However, despite this increase 
in Wnt-signalling levels, it was shown that in Apcfl/+ mice, additional loss of Apc2 had no 
effect on survival or tumour burden. This unexpected result highlights the need for a 
thorough examination of the Apc2-/- phenotype, alone and in the context of homozygous 




 Analysis of Apc2-/-intestinal phenotype in vivo and in vitro 5.3
5.3.1 Apc2 loss results in significantly shorter crypt lengths 
Despite no obvious difference in structure of the intestinal crypts between wildtype and 
Apc2-/- crypts (Figure 5.2), cell counts revealed that loss of Apc2 results in significantly 
shorter crypt lengths  (24.9±1.97 for Apc2-/- compared to 28.1±1.25 for wildtype, 
p<0.05) (Figure 5.3). There was no significant difference observed in the length of villi 
between the two genotypes. 
5.3.2 Apc2 loss does not affect levels of apoptosis or mitosis but does alter the 
location of apoptotic bodies 
As levels of apoptosis and mitosis are reportedly increased due to loss of Apc in vivo, 
increases in the levels of cell death and proliferation are seen as early markers of Wnt-
activation (Sansom et al. 2004b). Using H&E slides the apoptotic and mitotic indices 
were calculated by counting the number of apoptotic and mitotic bodies per 50 half 
crypts and then calculating the percentage of these cells based on average crypt length. 
It was found that Apc2 loss has no effect on levels of mitotic cells (Figure 5.4), or their 
position (Figure 5.5). Interestingly, previous work performed by Carl Daly showed that 
uptake of BrDU in a two hour period was increased by loss of Apc2 (data not shown), 
indicating an increase in cells at “S” phase of mitosis. 
There was a trend for increased apoptosis in the Apc2-/- mice (wildtype 0.55±0.37, Apc2-
/- 0.93±0.4) (Figure 5.6), however this was not significant (Independent sample T-test 
p=0.166). Positional information on the location of the apoptotic bodies showed that 
loss of Apc2 resulted in apoptosis occurring further down the crypt towards the stem 
cell compartment than seen in wildtype (Figure 5.7). This change in location was found 






5.2 H&E of crypt villus structure of wildtype and Apc2-/- intestine. There is no gross intestinal 
phenotype observed due to loss of Apc2. Black bars indicate 100μm. 
 
 
5.3 Cell counts for wildtype and Apc2-/- intestinal crypts. There was a significant decrease in 






5.4 Mitotic Index of wildtype versus Apc2-/- crypts. This was calculated by counting the number 
of mitotic bodies per crypt and normalising it to the number of cells per crypt. No significant 
difference was seen in the mitotic index between the two genotypes, two tailed T-test p=0.782. 
N>5. 
 
5.5 Cumulative distribution of mitotic cells within the intestinal crypt of wildtype and Apc2-/- 




5.6 Apoptotic Index of wildtype versus Apc2-/- crypts. This was calculated by counting the 
number of apoptotic bodies per crypt and normalising it to the number of cells per crypt. No 
significant difference was seen in the mitotic index between the two genotypes, two tailed T-test 
p=0.166. N>5. 
 
5.7 Cumulative distribution of apoptotic cells within the intestinal crypt of wildtype and Apc2-/- 






5.3.3 Loss of Apc2 results in an increased level of Wnt-signalling within the 
intestinal epithelium 
Loss of Apc from the intestinal epithelium results in a failure to form the β-catenin 
destruction complex, leading to a build-up of nuclear β-catenin and increased Wnt-
signalling. This increase in Wnt-signalling is thought to be responsible for the severity of 
the Apcflox/flox phenotype, as additional loss of the Wnt-target C-myc attenuates the 
phenotype (Sansom et al. 2007; Wilkins and Sansom 2008). It was predicted that loss of 
Apc2, which can also bind β-catenin, would also result in increased expression of a 
range of Wnt-target genes.  
 Intestinal epithelium was extracted using the Weiser preparation method (see section 
2.6.7) and RNA extracted for qRT-PCR analysis. This enabled the investigation of the 
effect of loss of Apc2 on Wnt-signalling levels specifically within the intestinal epithelia 
without interference from the stromal or muscle compartments of the intestine. 
However, it should be noted that as Apc2-/- is a constitutive knockout, it is also lost from 
these extra-epithelia compartments as well as the intestinal epithelium.  
As predicted, the loss of Apc2 results in an increased level of Wnt-signalling within the 
intestinal epithelium as measured by expression levels of a number of Wnt-target genes. 
Loss of Apc2 resulted in a significant upregulation of Axin2, Ephb3 and C-myc (p<0.05), a 
trend for increased expression of CyclinD1 and Ephb2 (p>0.05) and no change in 
expression levels of Cd44 (Figure 5.8). These results support the observation made by 
Carl Daly that loss of Apc2 results in an increased level of nuclear β-catenin (Figure 5.9). 
Due to the increase in Wnt-signalling levels as a result of Apc2 loss, the expression levels 
of the Wnt-inhibitors Groucho and Dikkopf were investigated. Expression of Groucho 
was found to be more than 4fold upregulated whereas there was no significant change 





5.8 qRT-PCR results showing the relative expression levels of Wnt-target genes in wildtype and 
Apc2-/- intestinal epithelium. Loss of Apc2 resulted in significant upregulation of Axin2, Ephb3 
and Cmyc (Two sample independent T-test p=0.0401, 0.0472 an d0.0439 respectively). N<4 
 
5.9 A Immunohistochemistry for β-catenin showing increased nuclear localisation in wildtype 
and Apc2-/- intestinal crypts. Black arrows indicate nuclear β-catenin, black bars represent 
50μm; B Counts of cells with nuclear β-catenin show significantly increased levels as a result of 





5.10 qRT-PCR results showing the relative expression levels of Wnt-inhibitor genes in wildtype 
and Apc2-/- intestinal epithelium. Expression of Groucho was found to be significantly 
upregulated due to Apc2 loss (Mann-Whitney U-test p=0.27) whereas there was no significant 














5.3.4 Loss of Apc2 results in an increased level of expression of intestinal stem cell 
markers, but no mis-localisation of expression 
The importance of Wnt-signalling in the maintenance of the ISC compartment (Reya and 
Clevers 2005) and the observation that loss of Apc2 results in increased nuclear β-
catenin and expression of Wnt-target genes indicates that loss of Apc2 may result in 
expansion of the ISC compartment.  
qRT-PCR analysis examining a range of published ISC markers within the intestinal 
epithelium demonstrated that expression of the ISC markers Lgr5 and Ascl2 was 
significantly upregulated (independent sample T-test p<0.01). Furthermore, there was a 
trend for increased expression of the markers Olfm4 and Bmi1, although this was not 
significant at n=5 (independent sample T-test p>0.05). Interestingly, expression of Msi1 
was found to be more than 5 fold down regulated (independent sample T-test p<0.05) 
(Figure 5.11). 
In situ hybridisation was used to assess the location of expression of the ISC markers. An 
anti-Olfm4 riboprobe on paraffin embedded sections of fixed wildtype and Apc2-/- 
intestine, showed that expression of this representative ISC marker was still limited to 
the base of the intestinal crypt (Figure 5.12). It should be noted that as the in situ 
hybridisations were performed on cross-sections of the crypt-villus axis, it cannot be 
determined from these images whether the qRT-PCR results indicate an increased 
expression of stem cell markers from the same number or fewer cells, or an increase in 
the number of cells expressing these markers as a result of increase ISCs around the 









5.11 qRT-PCR results showing the relative expression levels of intestinal stem cell marker genes 
in wildtype and Apc2-/- intestinal epithelium. Lgr5 and Ascl2 were significantly upregulated due 
to Apc2 loss (Independent samples T-test p=0.0089 and 0.0077 respectively) whereas Msi1 was 
significantly downregulated (Independent samples T-test p=0.038). N>4 
 
 
5.12 In situ hybridisation for Olfm4 expression in Wildtype and Apc2-/- intestine. Expression 





5.3.5 Apc2-/- organoids are phenotypically identical to wildtype 
Increased expression of ISC markers and Wnt-signalling targets within the crypt due to 
Apc-loss is associated with a cyst-like phenotype when cultured in vitro. In order to test 
the level of Wnt-activation of Apc2-/- crypts by assessing their phenotype in orgnoid 
culture, Apc2-/- crypts were disassociated and cultured and found to form organoids 
with crypt like protrusions and all of the differentiated cell types in a manner 
phenotypically identical to wildtype (Figure 5.13). These organoids grow at the same 
rate as wildtype and to the same size by day 11 (Figure 5.14). 
5.3.6 Apc2-/- crypts form organoids at a lower efficiency than wildtype 
Due to increased expression of ISC markers it was predicted that Apc2-/- crypts would 
form organoids at a higher efficiency than wildtype. This, however, did not occur. Apc2-/- 
crypts form organoids only rarely with just 5.2% of crypts (±2.51) capable of forming 
organoids compared to 15.59% (±7.46) of wildtype (Figure 5.15). This difference was 
found to be significant using independent sample T-test (p=0.014). This indicates that 
loss of Apc2 results in a reduction in functional ISCs.  
5.3.7 Apc2-/- organoids are less dependent on R-spondin than wildtype 
Both wildtype and Apc2-/- organoids were cultured in 6.5μg/ml, 3.25μg and 0μg/ml R-
spondin, and it was observed that although wildtype crypts die in culture in the absence 
of R-spondin by day 2-3, many Apc2-/- organoids survived until day 3 and only began to 
die by day 4 (Figure 5.16). The Prestoblue assay, a mitochondrial activity assay used in 
order to test the survival of organoids at different R-spondin concentrations (see 
section 2.12.5), was therefore performed on both day 3 and day 4 and showed that 
mitochondrial activity of Apc2-/- organoids is still high in the absence of R-spondin at 
day 3, but has dropped to wildtype levels by day 4 (Figure 5.17). This indicates that 
despite an apparent decrease in the number of functional stem cells, the ISCs which 






5.13 Phenotype of Apc2-/- intestinal organoids. A, H&E slide displaying mutliple crypt 
protrusions. B, Alcian blue stain showing presence of blue goblet cells. C, Lysozyme immuno of 
Apc2-/- organoids showing the presence of brown Paneth cells. D, Grimelius stain of Apc2-/- 






5.14 Growth rates of wildtype and Apc2-/- organoids. There was no difference between the 
average diameters of the organoids at any of the timepoints measured. N<20 (10 wells of 
organoids were measured for a minimum of 2 mice). 
 
5.15 Organoid formation efficiency of wildtype and Apc2-/- crypts. Apc2-/- crypts formed 




5.16 Wildtype crypts die by day 3 post seeding in the absence of R-spondin, whereas Apc2-/- 
crypts survive until day 4. Black bars represent 50μm. 
 
5.17 Prestoblue assay showing the mitochondrial activity of wildtype and Apc2-/- organoids day 
3 post seeding as well as Apc2-/- organoids at day 4 in various R-spondin concentrations. The 
relative mitochondrial activity of wildtype organoids at day 3 responded to R-spondin 
concentration in a dose dependent manner, whereas Apc2-/- organoids do not show a response 
to R-spondin concentration via a change in mitochondrial activity at day 3, but did show a dose 




 Analysis of Apc2-/- intestinal phenotype in the context of Apc homozygous 5.4
deletion, in vivo and in vitro 
As the loss of Apc2 appears to result in a reduced yet more highly activated ISC 
compartment, it could be assumed that there would be some effect on Wnt-dependent 
tumourigenesis. As was observed previously in the lab, loss of Apc2 does not affect 
tumour burden or survival of Apcfl/+ mice (Daly 2013). In order to further elucidate the 
role of Apc2 in intestinal tumourigenesis, it was necessary to investigate the effect of 
Apc2 loss on the early phenotype of intestinal tumourigenesis. The model used to 
recapitulate the early phenotype of intestinal tumourigenesis is the Villin-CreER+ 
Apcflox/flox mouse, whereby Apc is homozygously deleted from the intestinal epithelium 
upon injection with tamoxifen. It has been previously published that loss of Apc from 
the intestine results in an increase in Wnt-signalling, an increase in apoptosis and 
mitosis and an increase of undifferentiated cell types (Sansom et al. 2004b). As 
previously shown in section 3.11, this expansion of undifferentiated cell types and 
increase in expression of ISC markers is associated with an increased efficiency of 
organoid formation.  
Here we used two cohorts of mice, Villin-CreER+ Apcflox/flox Apc2wt/wt (referred to as 
Apcflox/flox) and Villin-CreER+ Apcflox/flox Apc2-/- (referred to as Apcflox/flox Apc2-/- or double 
mutants). Mice were induced using tamoxifen and sacrificed at day 4. For the purposes 
of the organoid experiments they were sacrificed on day 3.  
Previous work within the laboratory has shown that additional loss of Apc2 resulted in 
an increased survival of Apcflox/flox mice post induction. Conditional homozygous loss of 
Apc alone using Villin-CreER resulted in a median survival of 4.5 days (n=8), whereas 
additional loss of Apc2 extended the median survival to 6 days (n=5) (Figure5.18).  In 
order to understand the mechanism by which Apc2 loss increases survival in Apcflox/flox 
mice, the intestinal phenotype of both cohorts were closely analysed. 
5.4.1 Additional loss of Apc2 does not alter the intestinal morphology resulting 
from Apc deletion 
The increased survival observed in double mutants indicates that disregulation of the 
intestinal tissue may not be as severe as that seen due to Apc loss alone. As loss of Apc 
results in loss of distinct crypt structures the crypt length cannot be measured (Sansom 
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et al. 2004b). In order to overcome this problem, the severity of tissue disregulation was 
assessed by counting the number of cells in the aberrant region of the intestinal tissue 
in a straight line from bottom to top (Figure 5.19). 50 half “crypts” were counted per 
mouse and a minimum of 5 mice were counted. The aberrant region can be identified by 
the disordered, larger cells which stain slightly darker using H&E (as indicated in Figure 
5.19). There was no significant difference in number of cells in the region of aberrant 
proliferation between genotype on day 4 post induction (Figure 5.20). However, further 
counts of the number of cells in the zones of abberant proliferation within the crypt 
show that by day5 post induction, the region of aberrant proliferation is significantly 












5.18 Cumulative survival plot of Apcflox/flox and Apcflox/flox Apc2-/- mice post tamoxifen induction. 




5.19 H&Es of Apcflox/flox and Apcflox/flox Apc2-/- intestine at day 4 post induction. The vertical black 
bars indicate the region of aberrant proliferation, with darker, disordered and undifferentiated 





5.20 Number of cells in the region of aberrant proliferation per crypt-villus region of Apcflox/flox 
(Apc) and Apcflox/flox Apc2-/- (ApcApc2) intestine at day 4 post induction. The number of cells in a 
direct line from the crypt base to the top of the visible region of aberrant proliferation were 
counted. There was no significant difference between the two genotypes. N=4 
 
5.21 Number of cells in the region of aberrant proliferation per crypt-villus region of Apcflox/flox 
(Apc) and Apcflox/flox Apc-/- (ApcApc2) intestine at day 5 post induction. Additional deletion of 
Apc2 resulted in a significant decrease in the number of cells within the region of aberrant 




5.4.2 Additional loss of Apc2 results in increased apoptosis 
There was no change in levels of mitosis (Figure 5.22) or location of mitotic bodies 
(Figure 5.23) as a result of the additional loss of Apc2. 
The increase in apoptosis which is observed after the Apc loss in vivo is a result of 
increased proliferation and genetic damage, resulting in more cell death, and appears to 
be a natural defence mechanism against increased Wnt-signalling which is not potent 
enough to override the phenotype. This effect is augmented in the double mutants 
resulting in even higher levels of apoptosis as measured by the number of apoptotic 
bodies counted in the region of aberrant proliferation in 50 crypts/villus structures 
(Figure 5.24). The number of apoptotic bodies was normalised to account for the 
average number of cells within this region to produce an apoptotic index. Interestingly, 










5.22 Mitotic Index of Apcflox/flox versus Apcflox/flox Apc2-/-. Counts were normalised using the 
average number of cells per region of aberrant proliferation. There was no significant difference 
between the two genotypes (Independent sample T-test p=0.402). N=4.  
 
 
5.23 Cumulative frequency graph showing the location of mitotic bodies within the region of 
aberrant proliferation of Apcflox/flox (Apc) and Apcflox/flox Apc2-/- (ApcApc2) intestines. There was 
no significant difference in the location of mitotic bodies between the two genotypes using 





5.24 Apoptotic Index of Apcflox/flox versus Apcflox/flox Apc2-/- at day 4 post induction. Counts were 
normalised using the average number of cells within the region of aberrant proliferation. 
Additional loss of Apc2 resulted in a significant increase in apoptosis (independent sample T-
test, p=0.034). N=4. 
 
 
5.25 Cumulative frequency graph showing the location of apoptotic bodies within the region of 
aberrant proliferation of Apcflox/flox (Apc) and Apcflox/flox Apc2-/- (ApcApc2) intestines. The 
Kolmogorov-Smirnov Z-test showed that additional loss of Apc2 resulted in apoptosis occurring 





5.4.3 Additional loss of Apc2 attenuates the increased Wnt-signalling phenotype of 
Apcflox/flox mutants 
As loss of Apc2 alone results in a small increase in Wnt signalling, and Apc loss results in 
a large increase in Wnt-signalling, it was predicted that combined loss of Apc2 and Apc 
would result in augmented expression of Wnt-target genes. Interestingly, combined loss 
of Apc and Apc2 resulted in an attenuated Wnt-signalling phenotype compared to that of 
Apc alone (Figure 5.26). The Wnt-target genes Axin2, EphB2, Cmyc and Cd44 were all 
expressed at a significantly lower level in double mutants than in Apcflox/flox intestinal 
epithelia (Independent sample T-test p<0.05), whereas there was no significant 
difference in expression levels of EphB3 and CyclinD1. 
5.4.4 Additional loss of Apc2 attenuates expansion of the ISC compartment 
associated with Apc loss 
As previously discussed, loss of Apc results in an expansion of the ISC compartment, 
with an increase in undifferentiated cell types, an increase in expression of ISC markers 
and a mis-localisation of expression of the stem cell markers Ascl2 and Olfm4. qRT-PCR 
analysis of cDNA synthesised from RNA extracted from epithelial cell extracts from 
Apcflox/flox mutants and double mutants reveals that additional loss of Apc2 results in 
reduced expression of the ISC markers Ascl2, Olfm4 and Msi-1 (p<0.05) with no change 
in expression of Lgr5 or Bmi-1 at n=5 (Figure 5.27). 
In situ hybridisations for Olfm4 revealed that the expression of Olfm4 in double mutants 
is still mislocalised, but both the mislocalisation of expression and the intensity of the 
staining do not appear as severe as seen in the Apcflox/flox gut alone (Figure 5.28). The 
images shown are representative of the genotypes (n=3), however, as in situ 






5.26 qRT-PCR results showing the relative expression levels of Wnt-target genes in Apcflox/flox 
(Apc) and Apcflox/flox Apc2-/- (Apc Apc2) intestinal epithelium. Additional loss of Apc2 resulted in 
significant down-regulation of the Wnt-targets Axin2, EphB2, Cmyc and Cd44, independent 








5.27 qRT-PCR results showing the relative expression levels of ISC marker genes in Apcflox/flox 
(Apc) and Apcflox/flox Apc2-/- (Apc Apc2) intestinal epithelium. Ascl2, Olfm4 and Msi1 expression 
are all significantly lower due to additional loss of Apc2 independent sample T-test 
p=0.047,0.029 and 0.04 respectively. N=5. 
 
 
5.28 In situ hybridisation for Olfm4 expression in Apcflox/flox and Apcflox/floxApc2-/- intestine. 
Expression is still mis-localised due to Apc loss, but intensity of staining is dramatically reduced 





5.4.5 Organoids derived from Apcflox/flox Apc2-/- crypts are phenotypically identical 
to Apcflox/flox organoids 
In order to assess any changes in the number functional stem cells using the organoid 
formation assay, it was necessary to determine which of the CHARM settings (the 
parameters used to define an organoid on the GelCount machine which vary between 
wildtype and Apcflox/flox –like organoids, see section 2.12.4) to use in order to analyse the 
organoids. This required establishing whether the organoids formed from 
Apcflox/floxApc2-/- crypts were more like Apcflox/flox organoids (large, cyst-like with few 
differentiated cell types) or more like wildtype organoids with discrete crypt 
protrusions containing all of the differentiated cell types. 
Organoids derived from double mutant mice, were instantly recognisable as similar to 
Apcflox/flox organoids in structure and organisation (Figure 5.29) and so the Apcflox/flox 
CHARM settings were used for their analysis. The organoids grew at the same rate as 
Apcflox/flox and showed the same undifferentiated cell types with patches of polarised and 
unpolarised nuclei. 
5.4.6 Apcflox/floxApc2-/- crypts form organoids less efficiently than Apcflox/flox crypts  
Using the organoid formation assay as a readout of functional stem cell activity within 
the intestinal crypts showed that additional loss of Apc2 attenuates the Apcflox/flox 
phenotype of increased organoid formation efficiency (Figure 5.30). Interestingly, the 
organoid formation efficiency was not significantly higher than that of wildtype. 
This indicates that the number of functional stem cells in Apcflox/flox intestine is reduced 
by the additional loss of Apc2. However, as previously discussed, since the organoids 
formed do not present differentiated cells types it is not possible to describe them as 
“true” stem cells in this instance. 
5.4.7 Apcflox/floxApc2-/- organoids are R-spondin independent 
Using the PrestoBlue assay of relative mitochondrial activity, it was possible to 
demonstrate that despite double mutants having lowered Wnt-signalling levels in the 
intestinal epithelium, the organoids they form still retain high enough levels of Wnt-
signalling to enable their survival and growth in the absence of R-spondin, and are as 





5.29 Phenotype of Apcflox/flox Apc2-/- intestinal organoids. A, H&E slide displaying large cyst-like 
organoids. B, Alcian blue stain showing no visible blue goblet cells. C, Lysozyme IHC of Apc2-/- 
organoids showing the absence of brown Paneth cells. D, Grimelius stain showing no intensely 





5.30 Organoid formation efficiency of Apcflox/flox (Apc) and Apcflox/flox Apc2-/- (Apc Apc2) crypts. 
Apc2-/- crypts formed organoids significantly less efficiently than wildtype. Independent sample 
T-test p=0.047. N>4. 
 
 
5.31 Prestoblue assay displaying mitochondrial activity of Apcflox/flox versus Apcflox/flox Apc2-/- 
organoids at a range of R-spondin concentrations. Organoids of both genotypes can grow 






5.5.1 Loss of Apc2 alone subtly alters intestinal homeostasis 
An interesting phenotype of Apc2 loss alone was the increased levels of apoptosis at the 
base of the crypt. This indicates that apoptosis is occurring at a higher level in either the 
ISC compartment or the ISC niche. While homozygous loss of Apc from the intestinal 
epithelium results in increased apoptosis, there is no evidence that location of apoptotic 
bodies is altered. However, loss of Apc2 in this model is constitutive and universal 
throughout the mouse, and so it is possible that the subtly increased levels of Wnt-
signalling as a result of Apc2 deletion within the stromal compartment as well as the 
intestinal epithelium can disrupt the regulation of the ISC niche. The ISC niche plays an 
important role in intestinal homeostasis by regulating the number of daughter cells 
which retain stem cell identity thereby blocking the expansion of the stem cell 
compartment. There is already known to be a gradient of Wnt-signalling from the base 
of the crypt to the villus and it is easy to suppose that an increase in Wnt-signalling 
within the stromal compartment could affect the ISC niche.  
5.5.2 Loss of Apc2 results in increased Wnt-signalling 
As Apc2 is capable of forming a β-catenin destruction complex independent from that 
formed by Apc, it was assumed that loss of Apc2 would result in increased Wnt-
signalling levels. As shown here, this is indeed the case and indicates that in normal 
intestinal homeostasis Apc2 plays a role in regulating levels of nuclear β-catenin. 
5.5.3 Loss of Apc2 results in increased expression of intestinal stem cell markers 
but less efficient organoid formation 
As Wnt-signalling plays such an integral role in maintaining the ISC compartment, it is 
not surprising that a subtle increase in Wnt-signalling results in an increased expression 
of some ISC markers. However, this did not translate to an increased organoid 
formation efficiency, and Apc2-/- crypts were less efficient than wildtype at growing into 
organoids in culture. In order to explain this observation, it is necessary to develop our 
understanding of the ISC markers and their physiological function with regards to the 
maintenance of the ISC population. 
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 Lgr5, which is significantly upregulated as a result of loss of Apc2, is widely regarded as 
the most accurate marker of the crypt-base columnar stem cell. It was recently 
identified that Lgr5 interacts with R-spondins in order to increase Wnt-signalling within 
Lgr5 expressing cells. However, it has also been shown that despite marking the ISC, it 
has no essential functional role in the maintenance of the ISC. Using a diphtheria toxin 
receptor knocked into the Lgr5 locus, it was found that Lgr5 is dispensable for intestinal 
homeostasis (Tian et al. 2011). This was used as evidence of the ability of second ISC 
population, the +4 stem cells, to compensate for the loss of CBC SCs. However, it should 
be noted that use of diphtheria toxin would not have resulted in 100% Lgr5+ cell death 
and that single ISCs are capable of repopulating a great deal of damaged intestinal 
epithelium.  
It could be argued that increased expression for Lgr5 is the result of increased Wnt-
signalling and confers no added ISC functionality benefit as it is a marker of the ISC 
population and not a definer of “stemness”. Indeed, conditional homozygous deletion of 
Lgr5 alone does not result in a loss of intestinal homeostasis, and it is loss of its 
homologue Lgr4 that results in an intestinal phenotype of loss of crypts, although this 
effect is accentuated by additional loss of Lgr5 (de Lau et al. 2011). This indicates that 
redundancy in the system may cause expression levels of Lgr5 to be uninformative 
about ISC functional status when not combined with Lgr4 expression levels. 
Ascl2 expression levels were also significantly increased due to loss of Apc2. Ascl2 is also 
a Wnt-target gene, however, it appears that Ascl2 plays an important functional   role in 
maintaining the ISC compartment. Ascl2 is a basic helix-loop-helix transcription factor 
with a tightly restricted expression pattern which is controlled by imprinting during 
embryonic development (Miyamoto et al. 2002).  Despite the lack of knowledge 
concerning the interactions of Ascl2, the importance of this gene in regulating the ISC 
compartment has been convincingly demonstrated. Transgenic over expression of Ascl2 
within the intestinal epithelium resulted in crypt expansion and hyperplasia, as well as 
mislocalisation of crypts, whereas loss of Ascl2 within the intestinal epithelium resulted 
in crypt ablation (van der Flier et al. 2009b). 
However, despite this evidence of Ascl2’s role in maintaining the ISC compartment, mis-
expression of Ascl2 in these experiments was induced throughout the entire intestinal 
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epithelium and so does not represent what is observed in the Apc2 model. In the Apc2 
model we observe elevated expression, but the in situ hybridisation indicates that 
expression is still limited to the crypt base. This is more accurately represented by our 
2012 paper in which Ascl2 was entopically overexpressed at physiologically relevant 
levels and showed no significant intestinal phenotype (Reed et al. 2012). This 
demonstrates that despite the importance of Ascl2 in maintaining the ISC population, it 
is a question of localisation of expression, and despite loss of Apc2 causing an increase 
in levels of expression of Ascl2, there is no mislocalisation, and so could represent the 
same number of or even fewer ISCs than wildtype expressing higher levels of markers. 
Olfm4 encodes an anti-apoptotic factor that has been shown to promote tumour growth 
and facilitate cell adhesion and is associated with the Lgr5+ intestinal epithelium cells 
(van der Flier et al. 2009a). There was no significant increase for expression of Olfm4 
due to loss of Apc2, although there was a trend for increased expression at n=5. In situ 
hybridisations also showed that the expression pattern was unaltered. This is 
interesting as Olfm4 is the only ISC marker used here which is not a direct target of Wnt-
signalling (van der Flier et al. 2009a). The in situ hybridisations indicate that there is no 
significant expansion of the ISC compartment, but as in situ hybridisation is not a 
quantifiable technique, it is impossible to tell whether there is in fact an increased 
expression of Olfm4 in fewer cells. This is made more difficult by the crypt-villus cross 
sections taken on the slides, as it is possible that there are in fact fewer ISCs around the 
base of the crypt. Despite the trend for increased expression of Olfm4 as detected by 
mRNA levels, levels of the protein were not examined, and the increased levels of 
apoptosis seen at the base of the crypt are not indicative of an increased level of an anti-
apoptotic factor such as Olfm4. 
Bmi1 is also a Wnt-target gene, however, its role as a marker of ISCs is controversial. 
The gene encodes a Polycomb Repressing Complex 1, which is essential in maintaining 
chromatin silencing. Bmi1 was initially examined as a potential marker of the ISC 
population as it has been shown to play a role in self renewal in a variety of different 
cell types (Lessard and Sauvageau 2003; Molofsky et al. 2003). It has more recently 
been cited as a definitive marker of the +4 population of ISCs (Sangiorgi and Capecchi 
2008; Yan et al. 2012),however, it has been shown many times that Bmi1 is expressed 
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throughout the crypt and although it is more frequently located at the +4 
position(Sangiorgi and Capecchi 2008; Yan et al. 2012). Bmi1+ cells are capable of 
forming organoids in culture. However, from the literature it is not known whether or 
not Bmi1+ Lgr5- epithelial cells are capable of forming organoids, and Bmi1 and Lgr5 
expression overlaps within the intestinal crypt (Barker et al. 2012). In Apc2 null mice, 
there was no significant change in expression of Bmi1, however, as Bmi1 is such a broad 
marker of the intestinal crypt, this alone cannot be used as evidence that there has been 
no change to the ISC compartment. 
Msi1 encodes an RNA binding protein which plays an important role in the asymmetric 
division in neural progenitor cells (Okano et al. 2002). The role of Msi1 as a marker of 
the ISC population is interesting for two reasons, one being that its role as a marker has 
only ever been shown by localisation of expression using in situ hybridisation which 
revealed expression to be localised to the crypt base and upregulated in tumours. The 
second reason is that as well as being a Wnt-signalling target gene, Msi1 is involved in a 
double-negative feedback loop which results in increased Wnt-signalling (Spears and 
Neufeld 2011). This double-negative feedback loop was discovered by the observation 
that Msi1 binds to Apc mRNA and so negatively regulates Apc translation. This results in 
reduced Apc protein available for formation of the β-catenin destruction complex and so 
an increase in nuclear β-catenin and an increased level of expression of Wnt-target 
genes such as Msi1. Interestingly, Msi1 was the only ISC marker examined which was 
significantly down regulated. This means that Wnt-levels had not reached the threshold 
at which Wnt-signalling becomes self-perpetuating. The role of Msi1 in repressing 
translation of certain mRNAs has been associated with the ability to maintain the stem-
cell state of cells by controlling differentiation and tumourigenesis (Okano et al. 2002). 
It is possible that the reduced expression of Msi1 observed in Apc2-/- intestinal 
epithelium is representative of a loss of maintenance of the stem-cell population, which 
could explain the reduced organoid formation efficiency.  
As discussed here, the entopic over-expression of any of the ISC markers examined 
plays no recognized role on the functionality of ISCs. Therefore, I propose that subtly 
increased Wnt-signalling as a result of Apc2 loss has resulted in increased expression of 
ISC markers, but also induced ISC death via apoptosis. Loss of a number of ISCs is 
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supportable by the intestine, and this apoptosis has masked the true increase in 
expression of ISC markers. The combined results from the organoid formation efficiency 
assay and the R-spondin dependency assay supports the hypothesis that there are fewer 
functional ISCs present within the Apc2-/- intestine, but that those which survived the 
apoptotic influence of a change in Wnt-signalling levels are more highly Wnt-activated 
than wildtype, as seen by their decreased dependency on R-spondin. 
This proposed mechanism could be tested by making a single cell suspension of 
intestinal epithelium cells then using antibodies for ISC specific surface markers to FACs 
sort out Cd44+ Cd24lo Cd166+ Grp78lo/- Ckit+ as recently described in (Wang et al. 
2013b). This would enable RNA extraction from ISCs and non-stem epithelial cells from 
both wildtype and Apc2-/- mice in order assess the levels of Wnt-signalling using qRT-
PCR. This method would also enable a discreet count of the proportion of epithelial cells 
which express these markers. Despite not being a functional assay, this could support 
the organoid formation assay. 
5.5.4 Additional loss of Apc2 results in increased survival of Apcflox/flox mice 
Interestingly, the loss of Apc2 resulted in an increased survival of the Apcflox/flox mice 
despite having no effect on the number of cells within the region of aberrant 
proliferation at day 4 post induction. Also, double mutants survived for significantly 
longer than Apcflox/flox mice. This can be attributed to the increased apoptosis which 
results from additional deletion of Apc2, and is attested by the significantly lower 
number of cells in the region of aberrant proliferation at day 5 (counted by Carl Daly, 
data not shown). This indicates that the combined deletion of the two genes increases 
Wnt-signalling to such a level that the increased apoptosis acts as a compensatory 
mechanism to control for the increased proliferation due to Apc loss. 
Another hypothesis is that as the Apc2 mutation is a constitutive knockout which results 
in elevated Wnt-signalling levels, the cells are already acclimatised to increased Wnt-
signalling. This would mean that they are better equipped to respond to the gross 
elevation of the Wnt-signalling pathway which occurs after induction of Apc loss via 
tamoxifen injection. This is supported by the observation that Apc2-/- intestinal 
epithelium expresses the Wnt-inhibitor groucho at a higher level than is seen in 
wildtype and so are more prepared to cope with a change in Wnt-signalling levels. 
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5.5.5 Additional loss of Apc2 results in attenuated the Wnt-signalling and stem cell 
phenotype in Apcflox/flox crypts 
Despite the observation that double mutants have a reduced Wnt-expression readout in 
comparison to Apcflox/flox mice, it is likely that this is actually a side effect of increased 
apoptosis. We propose that the high levels of Wnt-signalling resulting from combined 
deletion of Apc and Apc2 results in apoptosis of the most highly activated cells, thereby 
causing a detectable decrease in measured Wnt-signalling. This supports the “just-right” 
hypothesis of Wnt-signalling which proposes that levels of Wnt-signalling must reach a 
certain threshold before they drive a tumourigenic phenotype, and there is a higher 
threshold over which levels of apoptosis are so high that they counter-act the 
phenotype (Figure 5.32) (Albuquerque et al. 2002).  
 
5.32 Diagrammatic representation of the "just-right" hypothesis of neoplasia. As the levels of 
Wnt-signalling increase, the levels of proliferation and apoptosis increase as well, but the 





This would also explain the observation that loss of Apc2 resulted in reduced expression 
of ISC markers in Apcflox/flox intestinal epithelium as increased levels of Wnt-signalling 
induced apoptosis of intestinal stem cells. This is supported by the reduced efficiency of 
organoid formation of double mutant crypts. 
However, as previously discussed, the upregulation of expression of the Wnt-inhibitor 
groucho seen as a result of Apc2-/- alone, may be priming Apc2-/- cells to attenuate the 
Wnt-signalling and therefore ISC phenotype due to loss of Apc. This would explain why 
additional deletion of Apc2 reduces the Wnt-signalling levels within the intestinal 
epithelium. 
5.5.6 Loss of Apc2 does not impact tumourigenesis despite affecting the ISC 
population 
The effects on the epithelial Wnt-signalling levels of Apc2 loss alone and in conjunction 
with Apc loss would suggest that Apc2 would play some role in intestinal 
tumourigenesis. However, as previously discussed, it was observed that loss of Apc2 
was not sufficient to induce tumourigenesis, and that deletion of Apc2 on an Apc 
heterozygous background (Apcflox/+) had no effect on either survival or tumour burden. 
As Wnt-activated ISCs are the “cells of origin” of intestinal cancer (Barker et al. 2008), 
the changes on the ISC compartment as a result of Apc2 deletion could be expected to 
alter the number of tumours formed. However, despite loss of Apc2 resulting in the 
presence of fewer functional stem cells, the R-spondin dependency assay indicates that 
the stem cells remaining are more highly Wnt-activated. As it is only Wnt-activated ISCs 
which can act as the “cells of origin” of intestinal adenomas, these changes could 
effectively balance each other out, meaning that although the number of ISCs has 
changed, the number of “cells of origin” has not.  
It is also possible that in the Apcflox/+ model, the increased Wnt-signalling observed due 
to loss of Apc2 is resulting in a selective pressure for the change of location of the 
spontaneous second mutation of Apc, as described by the “just-right” hypothesis. The 
“just –right” models of Wnt-signalling in tumourigenesis recognises that in FAP patients 
who carry a germ line mutation in one copy of APC, the sporadic mutation which occurs 
and results in tumourigenesis is not a random mutation, but is dependent on the 
position and function of the germ line mutations (Clarke 2006; Clevers 2006; Polakis 
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2007). Most APC mutations result in truncated APC protein missing all the 
axin/conductin binding regions, but the mutations generally differ in the number of the 
β-catenin regulating 20-amino acid repeats which are retained. It has been shown that if 
the germ line mutation retains none of these 20-amino acid repeats then the sporadic 
point mutation will most frequently result in the retention of one or two of these 20-
amino acid repeats, whereas if the germ line mutation results in retention of one or 
more of these repeats, then the sporadic mutation will generally result in a complete 
loss of all of the repeats (Albuquerque et al. 2002). This shows how the second hit to 
APC is strongly influenced by the germ line mutation. This is most likely because only 
Wnt-levels within certain threshold boundaries drive tumourigenesis. Below the lower 
threshold Wnt-signalling levels are not adequate to drive the levels of proliferation 
required for tumourigenesis, and above the upper threshold, the apoptosis levels are so 
high that they counteract the tumourigenic phenotype (see Figure 5.24). This results in 
a selective pressure for the survival of tumours driven by mutations which facilitate the 
“just-right” levels of Wnt-signalling. 
Recently, the “just-right” hypothesis of Wnt-dependent tumourigenesis was further 
interrogated by the assessment of the phenotype following β-catenin stabilisation 
throughout the intestine. It has previously been shown that in normal tissue there is a 
gradient of Wnt-signalling levels from the proximal intestine to the distal intestine. 
Stabilisation of β-catenin resulted in a “graduated neoplastic response” ranging from 
complete transformation of proximal intestine to a neoplastic phenotype to enlarged 
crypts at the distal intestine where entopic Wnt-levels are relatively low (Leedham et al. 
2012). This supports the hypothesis that intestinal tumourigenesis is dependent on a 
fine balance of Wnt-signalling.  
Loss of Apc2 alone does not increase Wnt signalling levels high enough to reach the 
lower threshold required for tumourigenesis to occur and requires loss of Apc to do so. 
However, in the Apcflox/+ mouse, the “second hit” of Apc, according to the “just-right” 
hypothesis, is localised to enable the tumourigenic levels of Wnt-signalling to be 
achieved. When coupled with Apc2 loss, LOH mutations of Apc which result in complete 
Apc loss of function may be causing Wnt-levels to soar above the maintainable 
threshold, and apoptosis to be induced in mutated cells so that tumourigenesis does not 
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occur. This means that there could be a selective pressure for the Apc LOH mutations to 
be less severe in the absence of Apc2, and thereby preventing the manifestation of any 
phenotype due to Apc2 loss.  
This hypothesis could be tested by deep sequencing of intestinal tumours derived from 
both Apcflox/+ and Apcflox/+ Apc2-/- mice in order to determine if the absence of Apc2 has 
resulted in a change in location of the “second-hit” of Apc. 
However, as Apcflox/flox Apc2-/- mice display both reduced ISC marker expression and a 
decreased organoid formation efficiency than Apcflox/flox it can be assumed that the 
additional loss of Apc2 attenuates the expansion of the ISC compartment seen in 
Apcflox/flox mice. As ISCs are known to be the cell of origin for intestinal adenomas, it 
could be assumed that a reduced ISC population would result, purely by probability, in a 
reduced tumour burden. However, this phenotype is the result of the loss of Apc2 on an 
Apcflox/flox background, where both Apc mutations are severe. The ISC compartment of 
normal tissue within Apcflox/+ Apc2-/- mice would have to be assessed in order to make 
assumptions about the number of “cells of origin” and therefore the probability of 
transformation of cells. 
 Summary 5.6
As Apc2 is an Apc homologue, and as such can deplete cytoplasmic β-catenin levels, 
albeit less efficiently than Apc (Schneikert et al. 2013), loss of Apc2 results in a slight 
increase in Wnt-signalling levels. This increase in Wnt-signalling is not enough to reach 
the threshold and drive tumourigenesis, but does cause an increase in apoptosis within 
the ISC compartment. Cell death within the ISC compartment as a result of Apc2 loss 
appears to result in fewer ISCs which are more Wnt-activated, although this hypothesis 
requires further examination. The contradictory results between qRT-PCR for ISC 
expression markers and the efficiency at which the crypts form organoids in culture 
highlight the utility of the organoid formation efficiency assay in assessing the 
functional ISC compartment. Msi1 was the only ISC marker which followed an 
expression pattern which represented the results of the organoid formation efficiency 
assay, and so further investigation of the utility of using Msi1 expression as a surrogate 
marker of functional stem cell capacity could be useful. 
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The decreased number of ISCs as a result of Apc2 loss does not result in a decrease in 
tumour burden in an Apcflox/+ model, as the ISCs are more Wnt-activated than wildtype 
and so the actual number of Wnt-activated ISCs (cells of origin) has not altered. 
The constitutive loss of Apc2 developmentally conditions intestinal epithelial cells to 
maintain homeostasis in the presence of elevated Wnt-signalling levels. This means that 
Apc2-/- cells are more prepared to deal with the gross increase in Wnt-signalling 
resulting from Apc loss, and therefore additional deletion of Apc2 attenuates the Apc 
phenotype. 
This fine balance of Wnt-signalling required for tumourigenesis may result in a 
selection pressure for less aggressive LOH mutations in an Apcflox/+ Apc2-/- model, 
thereby explaining how loss of Apc2 in this context has no apparent effect on survival or 
tumour burden. 
 Future work 5.7
In order to corroborate the “just-right” theory of the relationship between Wnt-
signalling and tumourigenesis, the locations of the “second hit” of Apc in both Apcflox/+ 
and Apcflox/+ Apc2-/- intestinal tumours must be determined via deep sequencing. It will 
also be important to assess the ISC compartment within normal tissue of these two 
models in an attempt to determine the role of Apc2 in the maintenance of the ISC 
compartment. 
As previously discussed it will also be essential to FACs sort out the ISCs of Apc2-/- and 
wildtype mice and perform qRT-PCR to assess how Wnt-signalling levels have actually 
changed between the ISC populations of the two genotypes. This could be achieved 
using antibodies for the ISC specific cell surface markers described by Wang et al, for 
FACs sorting, which would also enable be possible to use the proportion of epithelial 
cells expressing these markers as a readout of ISC number to support the data from the 
organoid formation efficiency assay (Wang et al. 2013b). 
It would also be interesting to further explore the role of Msi1 not only as an activator of 
the Wnt-pathway via repression of Apc translation, but also as a regulator of stem cell 
state. This could be achieved through the use of siRNA to interrupt Msi1 expression 
within intestinal organoid in culture, and assess the effect on nuclear β-catenin levels as 
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well as expression of markers of cell differentiation. This experiment, alongside analysis 
of the effect of overexpression of Msi1 in culture using a pcDNA vector coupled with a 
CMV promoter could help clarify the role which Msi1 is playing in regulating the ISC 
compartment within the Apc2-/- mouse model. 
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6 General Discussion 
In order to begin developing more targeted drugs for the treatment of colorectal cancer, 
it is necessary to gain a better understanding of the genetic mutations and processes 
which occur at an early stage of colorectal tumourigenesis. Conditional homozygous 
deletion of the important tumour suppressor gene Apc enables the modelling of the 
initial stages of tumourigenesis within the intestine, and indicates that one of the 
earliest stages of tumourigenesis is a loss of differentiation and an expansion of cell 
types with an intestinal stem-like phenotype (Sansom et al. 2004). As ISCs have been 
shown to be the cell of origin of intestinal tumourigenesis (Barker et al. 2007), it is 
thought that changes within the ISC compartment may play a role in determining both 
risk of development of CRC, and potential severity of disease, and expansion of the ISC 
compartment is one of the earliest stages of tumourigenesis. 
To gain insight into the potential of using changes within the ISC compartment as a 
predictor of disease, it is necessary to develop our current methods for assessing these 
changes. Currently, the principle way of studying the ISC compartment (without 
additional genetic alterations) is through the use of gene expression analysis, either 
using qRT-PCR or in situ hybridisation. Multiple genes have been proposed as potential 
markers of the ISC population, however there is a great deal of controversy regarding 
both the specificity and the location of expression of these markers (Barker et al. 2012). 
This situation is made additionally complicated by the evidence that there may actually 
be two distinct ISC populations which play very different roles in the maintenance of 
intestinal homeostasis, with CBC being responsible for intestinal homeostasis and the 
+4 cells playing an essential role in intestinal repair following damage (Yan et al. 2012). 
A variety of assays for assessing the stem cell compartments of other adult tissues based 
on the functional properties of those stem cells have previously been proposed. In order 
to assess the stem cell compartment of mammary tissue either a cleared fat-pad assay 
or a “mammosphere” assay can be used. The cleared fat-pad assay involves the 
disassociation of mammary glands from donor mice, and then transplanting them into 
the cleared mammary fat pads of young recipient mice (DEOME et al. 1959) . As these 
mice mature and are subsequently bred, the transplanted cells produce fully 
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differentiated mammary glands. By transplanting limiting dilutions of the disassociated 
cells into recipient mice, it is possible to use this as a readout of the levels of mammary 
repopulating units (MRUs) within the mammary gland, which are proposed to be 
representative of mammary stem cells (Stingl et al. 2006). In order to enable a more 
high-throughput approach to assessing the mammary stem cell population, an in vitro 
assay was also developed. The mammosphere assay involves the culture of single 
mammary cells in non-adherent conditions which enables mammary stem cells to 
survive and proliferate, but results in the cell death of other mammary cell lineages. 
These stem cells grow into spheroids which can be passaged and so represent a self-
renewing population of mammary cells (Dontu et al. 2003), and the number of 
spheroids which form can be used as a representation of the number of stem cells 
within the mammary gland (Stingl et al. 2006). Both of these mechanisms have been 
useful, however, it is argued that mammospheres which form in culture are not derived 
from single cells as they are not clonal in nature, but are the result of cell aggregation of 
seeded cells (Liao et al. 2007). This indicates that the ability of cells to form 
mammospheres may not be directly linked to the ability of those cells to function as 
stem cells. Mammary glands grown from transplantation into cleared fat pads have 
been shown to be of clonal origin, but it could be suggested that the ability of a cell to 
grow in the artificial environment of a cleared fat pad does not represent the cells 
ability to function as a true mammary stem cell in vivo. 
The mammosphere stem cell assay was inspired by work on the central nervous system 
which showed that a sub-population of neuronal precursor cells are capable of survival, 
expansion, self-renewal and differentiation in non-adherent culture conditions in the 
form of neurospheres (Reynolds and Weiss 1992). The efficiency of neurosphere 
formation has been widely used as an assay of the neural stem cell compartment, but 
must be used with care, as like other stem cell function assays, they may represent an 
ability of neural cells to behave like stem cells in vitro in an artificial environment rather 
than representing an actual stem cell population, and it has been shown that the 
majority of neurospheres are not of clonal origin (Singec et al. 2006). 
Functional stem cell assays are therefore widely used to gain insight into the both the 
neural and mammary stem cell compartment, and classify stem cells not on their 
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expression of markers but on their actual ability to proliferate, differentiate and self-
renew. The only system which models all of these functions from cells derived from 
intestinal epithelium, is that of organoid culture (Sato et al. 2009), and so this system 
was used to develop a novel method to assess the ISC compartment. The ability to form 
these organoids represents the functional capacity of cells to function as ISCs, i.e. the 
ability to produce all of the different intestinal epithelial lineages and to self-renew.  
Here, intestinal organoid formation efficiency was used as a mechanism for assessing 
the stem cell compartment as it represented a stem cell assay most similar to the gold 
standard assays used in other tissues, discussed above. Other methods for using the 
organoid system to assess ISC capacity would be possible, such as the use of the number 
of protrusions formed per organoid, however there are difficulties associated with this 
method. Counting the number of protrusions per organoid is difficult to achieve due to 
the 3-dimensional nature of the organoids and the great variability in protrusion 
numbers between organoids of the same genotype. Problems would also arise using this 
method due to the fact that protruding crypts are formed by crypt fission, and so the 
number of crypt protrusions formed in culture may bare little relationship to the 
number of ISCs in the disassociated crypt prior to seeding, but be more representative 
of conditions favouring crypt fission. By assessing the organoid formation efficiency of 
various mouse models of CRC we have been able to determine the utility of this method 
in a variety of different settings. Organoid formation efficiency proved to aid 
understanding of changes in the ISC compartment that were not detectable by qRT PCR 
and in situ hybridisation alone, such as in the Apc2-/- mouse model, where the organoid 
formation efficiency was in direct contradiction to the expression data for ISC markers.  
 Loss of Cited-1 results in an increase in expression of ISC markers and higher 6.1
organoid formation efficiency 
Using the Cited-1-/- mouse it had previously been shown that loss of Cited-1 resulted in a 
subtle increase in Wnt signalling, one of the most important signalling pathways 
involved in maintaining the ISC compartment. Assessing the ISC compartment of this 
mouse model using traditional gene expression methods hinted that there may be some 
subtle expansion of the ISC compartment due to increased Wnt signalling levels. By 
using the organoid formation efficiency assay on disassociated intestinal crypts derived 
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from wildtype and Cited-1-/- mice it was possible to determine the potential utility of 
this method in assessing subtle changes in the ISC compartment. In this model, loss of 
Cited-1 resulted in an increased organoid formation efficiency, which supported the 
increased expression of ISC markers to indicate an expansion of the functional ISC 
compartment. This expansion of the ISC compartment was not sufficient to initiate 
intestinal tumourigenesis, indicating that an expansion of the ISC compartment alone, 
and therefore an increase in potential adenoma “cells of origin”, without a tumour 
initiating event, such as loss of Apc, has no effect on tumourigenesis. Interestingly, Cited-
1 loss in an Apc heterozygous model of tumourigenesis actually decreased 
tumourigenesis despite this expansion in the ISC compartment (Méniel et al. 2013). This 
indicates that the status of the ISC compartment alone is not an accurate predictor of 
risk of tumourigenesis in this model. 
 Loss of Pml results in an increase in expression of ISC markers but no change 6.2
in organoid formation efficiency 
Interestingly, when studying the role of Pml in the maintenance of the ISC compartment 
in both Apcflox/flox mice and Apcflox/flox Ptenflox/flox mice, the loss of Pml resulted in an 
increase in expression of ISC markers which, like that seen in the Cited-1 model, was not 
associated with an increase in intestinal tumourigenesis. Interestingly, the organoid 
formation efficiency assay showed that despite an increase in expression of the markers 
there was no change in functional capacity, which potentially explains why there was no 
change in tumourigenesis. By analysing these models in this way it was possible to 
hypothesise why an increase in expression of ISC markers did not translate into 
increased tumourigenesis, as the changes within the ISC compartment due to Pml loss 
did not result in a functional change. In this model, assessment of the functional ISC 
compartment using organoid formation efficiency proved a more accurate indicator of 
tumourigenesis than using the expression levels of ISC marker genes.  
 Loss of Apc2 results in an increase in expression of ISC markers but a lower 6.3
organoid formation efficiency 
In the mouse model of Apc2 loss, it was shown that despite an increase in expression of 
ISC markers, there was a significant decrease in organoid formation efficiency. This 
indicated that there were fewer functional ISCs which were expressing the ISC markers 
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at a higher level. It would not have been possible to determine this without the use of 
the organoid formation assay, which also enabled (through the use of the associated 
PrestoBlue R-spondin dependency assay) the generation of qRT-PCR evidence which 
showed that loss of Apc2 results in an increase in expression of Wnt-target genes. 
Despite the further work required in order to elucidate the mechanism behind the 
changes in the ISC compartment due to Apc2 loss and their effect on tumourigenesis, use 
of the organoid formation efficiency assay has enabled the separation of expression 
levels of ISC markers, and the functional capacity of the cells which they mark. Loss of 
Apc2 resulted in a decreased functional capacity of the ISC compartment, but with no 
effect on levels of tumourigenesis or tumour burden. 
The examples used within this thesis highlight the potential utility of the organoid 
formation assay in assessing the ISC compartment as an additional technique to be 
combined with ISC marker expression analysis. However, the ability of crypts to form 
organoids in culture may not be a true readout of ISC capacity within the crypt, and 
potentially we are selecting for a subpopulation of intestinal epithelial cells which does 
not represent the in vivo ISC population, but are capable of forming organoids in vitro. 
Because of this, the assay needs to be developed to produce a readout of self-renewal 
potential of the organoid forming cells via passage efficiency.  
Here, through the use of a number of different mouse models of tumourigenesis, I have 
shown that, despite their role as the cell of origin of intestinal tumourigenesis, the 
functional status of the ISC compartment is not necessarily an accurate predictor of 
disease (see Table 19). This appears to reflect the complexity of the relationship 
between number, ISC marker expression, functional capacity and Wnt-signalling levels 
of the ISCs. However, the ISC compartment can still be informative of changes in 
homeostasis within the intestine, and the ability to accurately assess this cellular 
compartment remains important. The organoid formation assay presented here enables 
a certain level of insight into the ISC compartment, but remains an expensive and time 
consuming method, whereas gene expression analysis may not be a good indicator of 
ISC functionality. The use of gene expression analysis to assess the ISC compartment 
would be a more reliable method if expression levels of that gene were shown to 
consistently represent the organoid formation efficiency of that genotype. 
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 The potential of Msi-1 as a marker of the functional ISC population 6.4
Of the ISC markers which were assessed, expression levels of Msi1 was the only one 
which consistently translated into equivalent organoid formation efficiency between 
different models (see Table 19). Loss of Cited-1 resulted in an increase in Msi1 
expression and increased organoid formation efficiency.  Loss of Pml in both Apc and 
Apc Pten deficient mice resulted in no significant change in Msi1 expression and no 
change in organoid formation efficiency. Interestingly, Msi1 was the only ISC marker 
analysed which was down regulated due to loss of Apc2, associated with decreased 
organoid formation efficiency. This may mean that Msi1 expression levels could provide 
a more accurate readout of changes within the ISC compartment. 
 Msi1 was originally proposed as a marker of the ISC population due to the location of its 
expression within the developing and adult intestine and its upregulation in tumours 
derived from Apcmin mice (Potten et al. 2003). It has been shown more recently that Msi1 
expression marks both the CBC cells and the +4 cells, the two populations of cells which 
have been identified as possible constituents of the ISC compartment (Kayahara et al. 
2003; Muñoz et al. 2012). CBC cells are thought to represent a proliferative ISC 
population responsible for maintenance of intestinal homeostasis, whereas the +4 cells 
are thought to represent a more quiescent ISC type, and are responsible for gut repair 
after injury (Takeda et al. 2011). Furthermore, FAC sorting for GFP positive cells from a 
recently developed mouse model which expresses GFP under the control of an Msi1 
promoter, demonstrates the ability to isolate two populations of intestinal epithelial 
cells which differentially express the proposed markers of CBC and the +4 cell types 
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Cited-/- compared to 
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Lgr5 5.7* 
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lower than wildtype 
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Pml-/- compared to 
Apcflox/flox Ptenflox/flox 
Lgr5 1.5* 
Olmf4 expression spread across 












Table 19. Summary of observed phenotypes, comparing gene expression analysis to organoid formation efficiency and effect on tumourigenesis. 
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Interestingly, Msi1 plays a role within the ISC compartment beyond that of a simple 
marker of locations. Msi1 encodes an RNA-binding protein, which has been described in 
Drosophila as essential for the maintenance of stem cell identity (Siddall et al. 2006). In 
mammals, Msi1 tightly regulated levels of p21 via transcriptional repression (Battelli et 
al. 2006) and Msi1 levels are inversely correlated with that of p21 in intestinal epithelial 
cells in which Msi1 is overexpressed (Rezza et al. 2010). P21 has been shown to play an 
important role in maintenance of the ISC compartment with loss of p21 enhancing ISC 
survival following radiation injury (George et al. 2009). 
As well as potentially playing a direct role maintaining the ISC compartment, Msi1 has 
been shown to be a potent regulator of both the Notch and the Wnt signalling pathways. 
Notch signalling, which is thought to be a major constituent of the ISC niche, has been 
shown to be activated by Msi1 overexpression in intestinal epithelial cultures (Rezza et 
al. 2010). Overexpression of Msi1 via infection with Msi1 encoding viral particles was 
shown to increase the number of cells expressing the Notch receptor NICD, as well as its 
target, Hes1. The importance of Notch signalling as a niche regulator has been 
supported by evidence that in order to form organoids in culture, single ISCs require the 
addition of a Notch ligand, and that organoid formation efficiency can be increased by 
the co-culture of ISCs with Paneth cells, which express Notch ligands (Sato et al. 2010). 
This could indicate why Msi1 expression levels correlate with organoid formation 
efficiency, as they could be a representation of Notch signalling levels within the crypt. 
This could indicate that organoid formation efficiency is not an accurate representation 
of the number of the ISCs within a crypt, but rather represents a readout of the status of 
the ISC niche. This issue could be addressed by assessing the Notch signalling status 
within the models presented here to determine if Notch signalling levels are a better 
indication of organoid formation efficiency than expression levels of ISC markers. The 
use of Notch inhibitors would enable subtle manipulation of the Notch signalling 
pathway within organoid culture, and could enable the interrogation of potential role of 
Notch signalling in the maintenance of the ISC compartment. 
As previously mentioned, Msi1 is a Wnt-target gene, and interestingly, it is also a 
negative regulator of Apc via transcriptional regulation (Spears and Neufeld 2011). In 
this way, an increase in Wnt signalling results in an increase in expression of Msi1, 
204 
 
which in turn binds to Apc mRNA and reduces translation, thereby resulting in a further 
increase in Wnt signalling levels. Msi1 is also able to regulate Wnt signalling indirectly, 
since Msi1 induces Frat1 expression which in turn increases β-catenin stabilisation, 
thereby increasing Wnt activation (Rezza et al. 2010). Due to the seemingly direct 
relationship between Msi1 and Wnt signalling levels, it is surprising that in our Apc2-/- 
model, Wnt signalling was increased but Msi1 expression was significantly down 
regulated. One explanation for this seemingly contradictory evidence is that perhaps 
Wnt signalling levels need to reach a certain threshold before it induces Msi1 expression 
and therefore becomes self-regulating. 
The evidence presented here supports the idea that Msi1 expression is representative of 
organoid formation efficiency, although whether this is due to an expansion of the ISC 
compartment itself or a more highly activated niche component of the intestinal 
epithelium is unclear. It is however clear that Msi1 potentially may be of great interest 
in this field and that more work into the precise nature of its role in maintenance of the 
ISC compartment is required. An Msi1 knockout mouse is available, and it has been 
shown using this model that loss of Msi1 does not result in an increase in intestinal Apc 
levels, but does result in a decreased ISC compartment (Ernlund 2011). An interesting 
experiment would be to transfect disassociated intestinal crypts with either Msi1 siRNA 
or Msi1 expressing viral particles prior to crypt seeding to assess the effect of down 
regulation or overexpression of Msi1 on organoid formation efficiency. If the Msi1 
knockout does result in a decreased ISC population without affecting Wnt-signalling 
levels, it would be interesting to breed these mice with Apcflox/+ mice, to establish if a 
decreased ISC compartment translates into decreased tumourigenesis. It would be 
predicted that with fewer “cells of origin” the LOH event would be less common and so 
tumour burden would decrease, and survival increase due to loss of Msi1. Ideally, the 
production of an Msi1 allele flanked by LoxP sites would enable a higher level of control 
of gene expression. 
The work presented here indicates that changes in the number of ISCs does not 
translate well as a predictor of disease, as ISCs are only “cells of origin” once they have 
been malignantly transformed. Because of this, the levels of Wnt signalling specifically 
within the ISCs may prove more indicative of tumourigenesis. The R-spondin 
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dependency assay, when used on organoids derived from mice wildtype for Apc, may 
prove more useful in this instance. By assessing the dependency of organoids on R-
spondin, we may be able to assess the levels of Wnt signalling within the ISC 
compartment in order to gain further understanding into the genetic pathways involved 
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